var images_info;if (!images_info) images_info =[]; images_info["99"]={"99012":{"type":"graphic_picture","displayName":"Familial Mediterranean fever","title":"Familial Mediterranean fever","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Familial Mediterranean fever</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99012_Familial_mediterranean_fvr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous edematous plaque involving the lower left leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99012 Version 2.0</div></div></div>"},"99020":{"type":"graphic_picture","displayName":"Neutrophilic eccrine hidradenitis on palm","title":"Neutrophilic eccrine hidradenitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neutrophilic eccrine hidradenitis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/99020_Ntrphlceccrnhdrdntsplm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules on the palm of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99020 Version 3.0</div></div></div>"},"99025":{"type":"graphic_table","displayName":"Pharmacotherapy anxiety disorders in children and adolescents","title":"Pharmacotherapy for anxiety disorders in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacotherapy for anxiety disorders in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Initial daily dose</td> <td class=\"subtitle1\">Suggested dose titration based upon response</td> <td class=\"subtitle1\">Maintenance daily dose range</td> <td class=\"subtitle1\">Selected characteristics*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Selective serotonin reuptake inhibitors (SSRIs)*</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td> <p>Children: 5 to 10 mg</p> Adolescents: 10 mg</td> <td>After 7 days increase daily dose to 20 mg; then after 4 and 8 weeks increase daily dose by 20 mg, if needed</td> <td>10 to 80 mg</td> <td> <ul> <li>Prolonged half-life. </li> <li>Metabolized by and inhibits CYP2D6.</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluvoxamine</td> <td>25 to 50 mg at bedtime</td> <td>Increase daily dose by 25 mg (child) or 25 to 50 mg (adolescent) after a minimum of 7 days, if needed</td> <td>50 to 300 mg</td> <td> <ul> <li>Girls generally require lower maintenance doses than boys.</li> <li>Give with meals and bedtime in divided doses to minimize side effects.</li> <li>Metabolized by CYP1A2 and 2D6.</li> <li>Inhibits CYP1A2 and 2C19.</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sertraline</td> <td>12.5 to 25 mg</td> <td>Increase daily dose by 12.5 mg (child) or 25 to 50 mg (adolescent) after a minimum of 7 days, if needed</td> <td>50 to 200 mg</td> <td> <ul> <li>Diarrhea more frequent than other SSRIs.</li> <li>Metabolized by CYP2D6.</li> <li>Inhibits CYP2D6 with larger doses.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Paroxetine</td> <td>5 to 10 mg</td> <td>Increase daily dose by 5 mg (child) or 10 mg (adolescent) after a minimum of 7 days, if needed</td> <td>10 to 60 mg</td> <td> <ul> <li>Short half-life.</li> <li>Mild anticholinergic side effects.</li> <li>Metabolized by and inhibits CYP2D6.</li> <li>Weight gain.</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Serotonin norepinephrine reuptake inhibitor (SNRI)*</td> </tr> <tr> <td class=\"indent1\">Venlafaxine extended-release (ER)</td> <td>37.5 mg</td> <td>Increase daily dose by 37.5 mg (child) or 75 mg (adolescent) after a minimum of 7 days, if needed</td> <td>75 to 225 mg</td> <td> <ul> <li>Dose-related increase in diastolic blood pressure and/or heart rate may be seen.</li> <li>Some children may experience weight loss.</li> <li>Metabolized by CYPs 2D6 and 3A4.</li> <li>Prolongation of Qt interval.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Duloxetine</td> <td>30 mg</td> <td>Increase daily dose by 30 mg after a minimum of 14 days, if needed</td> <td> <p>30 to 60 mg</p> <p>Some patients may benefit from a higher daily dose, increased by 30 mg increments every 2 to 4 weeks, to maximum of 120 mg per day</p> </td> <td> <ul> <li> <p>Some children may experience dose-related gastrointestinal-related adverse effects (eg, nausea and abdominal pain), and weight loss. Palpitations and increased pulse were observed more frequently than with placebo in a pediatric GAD trial.</p> </li> <li> <p>Use with strong inhibitors (eg, fluvoxamine) or inducers (eg, carbamazepine, rifampin) of CYP1A2 should in general be avoided.</p> </li> <li>Strong CYP2D6 inhibitors (eg, fluoxetine, paroxetine, tipranavir) can increase duloxetine concentrations by up to 60%. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tricyclic antidepressants (TCA)</td> </tr> <tr> <td class=\"indent1\">Clomipramine</td> <td>Children &#8805;10 years old and adolescents: 25 mg</td> <td>Increase daily dose by 25 mg after a minimum of 7 days, if needed; give in divided doses with meals and bedtime</td> <td>25 to 250 mg (2 to 6<sup>&#182;</sup> mg/kg per day); doses &#62;2.5 mg/kg per day should be used cautiously<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">Applies to clomipramine and imipramine: <ul class=\"decimal_heading\"> <li>Cardiovascular screening including ECG recommended prior to initiating treatment.<sup>&#182;</sup> </li> <li>Anticholinergic side effects may limit usefulness in children.</li> <li>Drowsiness, irritability and vomiting may be seen.</li> <li>Give in divided doses with meals and at bedtime to minimize side effects.</li> <li>Metabolized by CYPs 1A2, 2C19 and 3A4.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Imipramine</td> <td>10 to 25 mg</td> <td>Increase daily dose by 25 mg after a minimum of 7 days, if needed; give in divided doses with meals and bedtime</td> <td>10 to 300 mg (2 to 6<sup>&#182;</sup> mg/kg per day); doses &#62;2.5 mg/kg per day should be used cautiously<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Clonazepam</td> <td>0.25 to 0.5 mg</td> <td>&nbsp;</td> <td>1 to 6 mg</td> <td rowspan=\"2\">Applies to clonazepam and lorazepam: <ul class=\"decimal_heading\"> <li>Drowsiness, irritability and oppositional behavior may be seen </li> <li>Subject to abuse, addiction and diversion </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td>0.25 to 0.5 mg</td> <td>&nbsp;</td> <td>0.25 to 8 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Clinicians should be aware of the potential for activating side effects of antidepressants in younger children and regulatory warnings of potential for an increased risk of suicidality in children. With the exception of duloxetine, antidepressants are not approved by the US Food &amp; Drug Administration for treatment of anxiety disorders in children. Recommended doses are those shown to have been effective in randomized controlled trials of children with various anxiety disorders and clinical experience. All doses shown are for oral administration. Obsessive-compulsive disorder (OCD) is reviewed separately in UpToDate.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; GI: gastrointestinal; GAD: generalized anxiety disorder.<br />* Common generally mild adverse effects of SSRIs and SNRIs seen in children treated for anxiety disorders may include headache, anorexia, vomiting, sleep disturbance and somnolence.<br />¶ Dose- related ECG changes have been reported in children and close monitoring is necessary with larger doses. According to the product information approved in the United States, doses &gt;2.5 mg/kg per day are not recommended in children.</div><div class=\"graphic_reference\">Courtesy of authors with additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014; 14 Suppl 1:S1.</li>&#xD;&#xA;    <li>Rynn M, Puliafico A, Heleniak C, et al. Advances in pharmacotherapy for pediatric anxiety disorders. Depress Anxiety 2011; 28:76.</li>&#xD;&#xA;    <li>Martin A, Scahill L, Kratochvil C. Pediatric Psychopharmacology, Oxford University Press, New York 2010. p.480.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99025 Version 3.0</div></div></div>"},"99027":{"type":"graphic_picture","displayName":"Neutrophilic eccrine hidradenitis on face","title":"Neutrophilic eccrine hidradenitis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Neutrophilic eccrine hidradenitis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/99027_Ntrphlceccrnhdrdntsfc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99027 Version 3.0</div></div></div>"},"99029":{"type":"graphic_figure","displayName":"MM survival by age","title":"Estimated overall survival (OS) in multiple myeloma (MM) by age and year of diagnosis","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Estimated overall survival (OS)&nbsp;in multiple myeloma (MM) by age and year of diagnosis</div><div class=\"cntnt\"><img style=\"width:751px; height:587px;\" src=\"images/HEME/99029_MM_survival_comparisons_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) OS&nbsp;comparison between patients diagnosed during January 2001-December 2005 and those diagnosed during January 2006-December 2010.<br />(B) Trends in the one- and five-year OS estimates between January 2001 and December 2010 with patients grouped by the year of diagnosis. The dotted lines represent the 95% CIs.<br />(C) OS comparison between patients diagnosed during 2001-2005 and those diagnosed during 2006-2010 limited to patients of 65 years of age or younger.<br />(D) OS comparison between patients diagnosed during 2001-2005 and those diagnosed during 2006-2010 limited to patients older than 65 years of age.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Leukemia. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28:1122. Copyright &copy; 2014. <a href=\"http://www.nature.com/leu\" spellcheck=\"true\" target=\"_blank\">www.nature.com/leu</a>.</div><div id=\"graphicVersion\">Graphic 99029 Version 1.0</div></div></div>"},"99030":{"type":"graphic_figure","displayName":"MM survival by ISS and FISH","title":"Estimated overall survival (OS) in multiple myeloma (MM) by International Staging System (ISS) score","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Estimated overall survival (OS) in multiple myeloma (MM)&nbsp;by International Staging System (ISS) score</div><div class=\"cntnt\"><img style=\"width:757px; height:585px;\" src=\"images/HEME/99030_MM_survival_comparisons_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Survival according to the ISS among patients diagnosed during 2001&ndash;2005.<br />(B) Survival according to the ISS among patients diagnosed later.<br />(C) Survival according to the FISH-based risk status among patients diagnosed during 2001&ndash;2005.<br />(D) Survival according to the FISH-based risk status among patients diagnosed later.</div><div class=\"graphic_footnotes\">ISS: International Staging System; FISH: fluorescence in situ hybridization.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Leukemia. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28:1122. Copyright &copy; 2014. <a href=\"http://www.nature.com/leu\" spellcheck=\"true\" target=\"_blank\">www.nature.com/leu</a>.</div><div id=\"graphicVersion\">Graphic 99030 Version 2.0</div></div></div>"},"99037":{"type":"graphic_table","displayName":"NCI CTCAE v5 weight loss","title":"NCI CTCAE v5.0 weight loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 weight loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Weight loss</td> <td>5 to &#60;10% from baseline; intervention not indicated</td> <td>10 to &#60;20% from baseline; nutritional support indicated</td> <td>&#8805;20% from baseline; tube feeding or TPN indicated</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Weight loss is characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; TPN: total parenteral nutrition.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 99037 Version 4.0</div></div></div>"},"99038":{"type":"graphic_algorithm","displayName":"AIH induction therapy algorithm","title":"Approach to induction therapy for adults with autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 680px\" class=\"figure\"><div class=\"ttl\">Approach to induction therapy for adults with autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:660px; height:627px;\" src=\"images/GAST/99038_AIHinductiontherapyalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to the topic on the treatment of autoimmune hepatitis for additional discussion of the indications for treatment and for details on the treatment of special populations including patients with fulminant hepatitis, children, women who are pregnant, patients with cirrhosis, patients with hepatitis C virus, and patients with variants of autoimmune hepatitis.<br />¶ Asymptomatic patient with aminotransferase levels &lt;10 times the upper limit of normal.<br />Δ Refer to topic on the treatment of autoimmune hepatitis for detailed instruction on drug administration. Oral prednisolone is an alternative to prednisone. Budesonide may also be an alternative to prednisone, particularly for patients at increased risk for glucocorticoid side effects. Oral mercaptopurine is an alternative to azathioprine.<br /><FONT class=lozenge>◊</FONT> Eg, brittle diabetes, osteoporosis, emotional lability, history of psychosis, poorly controlled hypertension.<br />§ In Europe, initial therapy is often with prednisone/prednisolone and oral azathioprine. If this treatment is chosen, go to Box A.<br />¥ Refer to the UpToDate topic on the treatment of patients with autoimmune hepatitis for details.</div><div id=\"graphicVersion\">Graphic 99038 Version 7.0</div></div></div>"},"99046":{"type":"graphic_picture","displayName":"Retinoblastoma pathology","title":"Retinoblastoma pathology","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Retinoblastoma pathology</div><div class=\"cntnt\"><img style=\"width:510px; height:338px;\" src=\"images/PEDS/99046_Retinoblastoma_pathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathology of well-differentiated retinoblastoma showing Flexner-Wintersteiner rosettes. The tumor cells that form the Flexner-Wintersteiner rosette surround a central lumen containing small cytoplasmic extensions of the encircling cells; the central lumen is devoid of fiber-rich neuropil.</div><div id=\"graphicVersion\">Graphic 99046 Version 1.0</div></div></div>"},"99049":{"type":"graphic_picture","displayName":"Familial Mediterranean fever 2","title":"Familial Mediterranean fever","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Familial Mediterranean fever</div><div class=\"cntnt\"><img style=\"width:710px; height:440px;\" src=\"images/DERM/99049_Familil_mediterranean_fvr_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a picture of the knee of a 41-year-old Sephardic Jewish man who periodically has episodes of fever, abdominal pains, and a tender, warm, erythematous, erysipelas-like patch.</div><div class=\"graphic_reference\">Courtesy of Samuel L Moschella, MD, FAAD, FACP.</div><div id=\"graphicVersion\">Graphic 99049 Version 2.0</div></div></div>"},"99055":{"type":"graphic_picture","displayName":"Palmoplantar eccrine hidradenitis","title":"Palmoplantar eccrine hidradenitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Palmoplantar eccrine hidradenitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99055_Palmoplantar_eccrin_hdrdnts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tender, erythematous papules and nodules on the palm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99055 Version 2.0</div></div></div>"},"99056":{"type":"graphic_picture","displayName":"Palmoplantar eccrine hidradenitis on foot","title":"Palmoplantar eccrine hidradenitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Palmoplantar eccrine hidradenitis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/99056_Plmplntr_eccrn_hdrdnts_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tender, erythematous papules and nodules on the sole of the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99056 Version 2.0</div></div></div>"},"99080":{"type":"graphic_picture","displayName":"Neutrophilic urticarial dermatosis","title":"Neutrophilic urticarial dermatosis","html":"<div class=\"graphic\"><div style=\"width: 810px\" class=\"figure\"><div class=\"ttl\">Neutrophilic urticarial dermatosis</div><div class=\"cntnt\"><img style=\"width:790px; height:544px;\" src=\"images/DERM/99080_Neutrophilicurticarldrmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pale erythematous macules on the flank.</div><div class=\"graphic_reference\">Reproduced with permission from: Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: A variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88:26. DOI: <a href=\"http://journals.lww.com/md-journal/pages/articleviewer.aspx?year=2009&amp;issue=01000&amp;article=00002&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/MD.0b013e3181943f5e</a>. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 99080 Version 2.0</div></div></div>"},"99089":{"type":"graphic_table","displayName":"Post-2015 global TB strategy","title":"The post-2015 global tuberculosis strategy at a glance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The post-2015 global tuberculosis strategy at a glance</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Vision</strong></td> <td>A TB-free world <ul class=\"decimal_heading\"> <li>Zero deaths, disease, and suffering due to TB </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Goal</strong></td> <td>End the global tuberculosis epidemic</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Milestones for 2025</strong></td> <td> <ul class=\"decimal_heading\"> <li>75 percent reduction in TB deaths (compared with 2015) </li> <li>50 percent reduction in TB incidence rate (less than 55 TB cases per 100,000 population) </li> <li>No affected families facing catastrophic costs due to TB </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Targets for 2035</strong></td> <td> <ul class=\"decimal_heading\"> <li>95 percent reduction in TB deaths (compared with 2015) </li> <li>90 percent reduction in TB incidence rate (less than 10 TB cases per 100,000 population) </li> <li>No affected families facing catastrophic costs due to TB </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Principles</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <ol> <li>Government stewardship and accountability, with monitoring and evaluation </li> <li>Strong coalition with civil society organizations and communities </li> <li>Protection and promotion of human rights, ethics, and equity </li> <li>Adaptation of the strategy and targets at country level, with global collaboration </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pillars and components</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">1. Integrated, patient-centered care and prevention</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">A. Early diagnosis of TB including universal drug-susceptibility testing; and systematic screening of contacts and high-risk groups<br /> B. Treatment of all people with TB including drug-resistant TB; and patient support<br /> C. Collaborative TB/HIV activities, and management of comorbidities<br /> D. Preventive treatment of persons at high risk; and vaccination against TB</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">2. Bold policies and supportive systems</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">A. Political commitment with adequate resources for TB care and prevention<br /> B. Engagement of communities, civil society organizations, and public and private care providers<br /> C. Universal health coverage policy, and regulatory frameworks for case notification, vital registration, quality and rational use of medicines, and infection control<br /> D. Social protection, poverty alleviation, and actions on other determinants of TB</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">3. Intensified research and innovation</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">A. Discovery, development, and rapid uptake of new tools, interventions, and strategies<br /> B. Research to optimize implementation and impact, and promote innovations</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Global Tuberculosis Report 2014. Geneva, World Health Organization, 2014. Copyright &copy; 2014 World Health Organization. Available at: <a href=\"http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1\" target=\"_blank\">http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1</a>. (Accessed on January 13, 2015).</div><div id=\"graphicVersion\">Graphic 99089 Version 1.0</div></div></div>"},"99092":{"type":"graphic_diagnosticimage","displayName":"Dermal sinus tract in occipital region","title":"Dermal sinus tract in occipital region","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Dermal sinus tract in occipital region</div><div class=\"cntnt\"><img style=\"width:728px; height:327px;\" src=\"images/NEURO/99092_Derml_sinus_tract_occipital.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A three-year-old boy presented after two months of morning headache and intermittent vomiting. He was febrile and somnolent with dysconjugate gaze. Blood work showed a leukocytosis with 29,800 leukocytes/microL. Cranial computed tomography (A) revealed a bony tract in the midline occipital skull, suggesting the presence of a dermal sinus tract. Closer direct inspection of the skin revealed a dimple that was the sinus tract opening. Magnetic resonance imaging (B) revealed a large cystic enhancing posterior fossa mass with hydrocephalus. A ventriculostomy was placed, with cloudy cerebrospinal fluid (7575 leukocytes). Bacterial culture isolated <EM>Cutibacterium</EM> (formerly <EM>Propionibacterium</EM>) <EM>acnes</EM>. The patient underwent posterior fossa craniotomy with complete resection of the dermal sinus tract which led directly into the infected ruptured dermoid cyst.<br />(A) Sagittal noncontrast computed tomography with defect in occipital bone (arrow).<br />(B) Sagittal T<SUB>2</SUB> magnetic resonance imaging demonstrating the tract at the skin (arrowhead) and cystic lesion (infected dermoid cyst [arrow] associated with dermal sinus tract).</div><div class=\"graphic_reference\">Reproduced from: Lam S, Barry J, Dauser RC. Dermal sinus tract: clinical presentation and imaging findings. Pediatr Neurol 2014; 51:747. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99092 Version 2.0</div></div></div>"},"99099":{"type":"graphic_table","displayName":"Causes of an elevated alkaline phosphatase","title":"Causes of an elevated alkaline phosphatase","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of an elevated alkaline phosphatase</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"20\"><strong>Marked elevation<br /> (&#8805;4 times the upper limit of normal)</strong>*</td> <td class=\"subtitle2_left\">Extrahepatic biliary obstruction<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Choledocholithiasis (most common) <ul class=\"decimal_heading\"> <li>Uncomplicated </li> <li>Complicated (biliary pancreatitis, acute cholangitis) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Malignant obstruction <ul class=\"decimal_heading\"> <li>Pancreas </li> <li>Gallbladder </li> <li>Ampulla of Vater </li> <li>Bile duct </li> <li>Metastasis to perihilar lymph nodes</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Biliary strictures <ul class=\"decimal_heading\"> <li>Primary sclerosing cholangitis with extrahepatic bile duct stricture </li> <li>Complications after invasive procedures </li> <li>Chronic pancreatitis with stricturing of distal bile duct </li> <li>Biliary anastomotic stricture following liver transplantation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Infections <ul class=\"decimal_heading\"> <li>AIDS cholangiopathy </li> <li><em>Ascaris lumbricoides</em> </li> <li>Liver flukes </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Intrahepatic cholestasis</td> </tr> <tr> <td class=\"indent1\">Drug and toxins associated with cholestasis<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Primary biliary cholangitis<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Primary sclerosing cholangitis<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Intrahepatic cholestasis of pregnancy</td> </tr> <tr> <td class=\"indent1\">Benign postoperative cholestasis</td> </tr> <tr> <td class=\"indent1\">Total parenteral nutrition</td> </tr> <tr> <td class=\"indent1\">Infiltrative diseases<sup>&#916;</sup> <ul class=\"decimal_heading\"> <li>Amyloidosis </li> <li>Lymphoma </li> <li>Sarcoidosis </li> <li>Tuberculosis </li> <li>Hepatic abscess </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Metastatic carcinoma to the liver<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Liver allograft rejection</td> </tr> <tr> <td class=\"indent1\">Ischemic cholangiopathy</td> </tr> <tr> <td class=\"indent1\">Alcoholic hepatitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sickle cell disease (hepatic crisis)</td> </tr> <tr> <td class=\"subtitle2_left\">Nonhepatic causes<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Transient hyperphosphatemia of infancy and childhood</td> </tr> <tr> <td rowspan=\"8\"><strong>Moderate elevation<br /> (&#60;4 times upper limit normal)</strong></td> <td class=\"subtitle2_left\">Hepatic causes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nonspecific, seen with all types of liver disease including: <ul class=\"decimal_heading\"> <li>Hepatitis: viral, chronic, alcoholic </li> <li>Cirrhosis </li> <li>Infiltrative diseases of the liver </li> <li>Hypoperfusion states: sepsis, heart failure </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Nonhepatic causes<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Physiologic (children and adolescents)</td> </tr> <tr> <td class=\"indent1\">Third trimester of pregnancy</td> </tr> <tr> <td class=\"indent1\">Influx of intestinal alkaline phosphatase after eating a fatty meal (individuals with blood type O or B)</td> </tr> <tr> <td class=\"indent1\">High bone turnover <ul class=\"decimal_heading\"> <li>Growth </li> <li>Healing fractures </li> <li>Osteomalacia </li> <li>Paget disease of bone </li> <li>Osteogenic sarcoma, bone metastasis </li> <li>Hyperparathyroidism </li> <li>Hyperthyroidism </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Extrahepatic disease <ul class=\"decimal_heading\"> <li>Myeloid metaplasia </li> <li>Peritonitis </li> <li>Diabetes mellitus </li> <li>Subacute thyroiditis </li> <li>Gastric ulcer (uncomplicated) </li> <li>Extrahepatic tumors <ul> <li>Osteosarcoma </li> <li>Lung </li> <li>Gastric </li> <li>Head and neck </li> <li>Renal cell </li> <li>Ovarian </li> <li>Uterine </li> <li>Hodgkin lymphoma </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The alkaline phosphatase value may vary and be &#60;4 times the upper limit of normal at times (eg, early in the disease process).<br />&#182; May cause an isolated elevation in hepatic alkaline phosphatase if partial obstruction.<br />&#916; May cause an isolated elevation in hepatic alkaline phosphatase.<br /><span class=\"lozenge\">&#9674;</span> Alkaline phosphatase may be derived from several sites including the liver, bone, third trimester placenta, intestine, and kidneys. An elevation in alkaline phosphatase with a normal gamma-glutamyl transpeptidase or 5'-nucleotidase suggests a nonhepatic source of alkaline phosphatase.</div><div id=\"graphicVersion\">Graphic 99099 Version 6.0</div></div></div>"},"99102":{"type":"graphic_table","displayName":"Quality of death and dying in children","title":"Elements of care associated with quality of death and dying in the pediatric intensive care setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elements of care associated with quality of death and dying in the pediatric intensive care setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pain and symptom management</td> </tr> <tr> <td class=\"indent1\">The child's pain is treated</td> </tr> <tr> <td class=\"indent1\">Other troubling symptoms are treated</td> </tr> <tr> <td class=\"indent1\">Clinical staff respond quickly to concerns about the child's symptoms</td> </tr> <tr> <td class=\"subtitle1_single\">Communication</td> </tr> <tr> <td class=\"indent1\">Clinical staff provide information in a way that can easily be understood</td> </tr> <tr> <td class=\"indent1\">Clinical staff prepare caregivers/family members for what might happen to the child</td> </tr> <tr> <td class=\"indent1\">Clinical staff inquire about and respect caregivers'/family members' wishes and decisions</td> </tr> <tr> <td class=\"indent1\">Clinical staff create an atmosphere in which caregivers/family members feel comfortable asking questions about their child</td> </tr> <tr> <td class=\"subtitle1_single\">Support of decisions to withdraw life-sustaining treatments</td> </tr> <tr> <td class=\"indent1\">Caregivers/family members have opportunities to discuss options about the child's care with the healthcare team</td> </tr> <tr> <td class=\"indent1\">Conflicts between caregivers/family members and clinical staff about the best way to care for the child are avoided</td> </tr> <tr> <td class=\"subtitle1_single\">Privacy</td> </tr> <tr> <td class=\"indent1\">Caregivers/family are given privacy with the child near the end of the child's life</td> </tr> <tr> <td class=\"subtitle1_single\">Physical and instrumental needs of family</td> </tr> <tr> <td class=\"indent1\">Caregivers/family members are able to easily meet their basic physical needs (accessible bathroom, showers, affordable meals, places to stay, parking, etc)</td> </tr> <tr> <td class=\"subtitle1_single\">Emotional needs/support of family</td> </tr> <tr> <td class=\"indent1\">Clinical staff demonstrate that they cared about the child as an individual</td> </tr> <tr> <td class=\"indent1\">Clinical staff support the caregivers/family emotionally</td> </tr> <tr> <td class=\"indent1\">Caregivers/family are given opportunities to be near their child</td> </tr> <tr> <td class=\"subtitle1_single\">Fulfilling the parental role</td> </tr> <tr> <td class=\"indent1\">Clinical staff help caregivers/family find ways to touch, hold, and/or connect with the child</td> </tr> <tr> <td class=\"subtitle1_single\">Spirituality and religious/cultural issues</td> </tr> <tr> <td class=\"indent1\">Hospital clergy and chaplains are available</td> </tr> <tr> <td class=\"indent1\">Staff inquires about and respects the family's spiritual and/or religious needs</td> </tr> <tr> <td class=\"subtitle1_single\">Continuity/coordination of care</td> </tr> <tr> <td class=\"indent1\">Nurses and doctors pass information about the child onto the next shift or rotation</td> </tr> <tr> <td class=\"subtitle1_single\">Grief and bereavement</td> </tr> <tr> <td class=\"indent1\">Clinical staff help caregivers/family create memories (such as handprints, lockets of hair, photographs) of the child</td> </tr> <tr> <td class=\"indent1\">Upon the child's death, the caregivers/family are allowed to stay with the child for as long as they wish</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Sellers DE, Dawson R, Cohen-Bearak A, et al. Measuring the quality of dying and death in the pediatric intensive care setting: The clinician PICU-QODD. J Pain Symptom Manage 2015; 49:66. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99102 Version 1.0</div></div></div>"},"99120":{"type":"graphic_diagnosticimage","displayName":"Radiograph pathological fracture blastic prostate metastasis","title":"Pathological fracture in advanced blastic metastatic prostate carcinoma","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Pathological fracture in advanced blastic metastatic prostate carcinoma</div><div class=\"cntnt\"><img style=\"width:680px; height:534px;\" src=\"images/RADIOL/99120_Rdg_pthl_frct_blst_prst_mts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P radiograph (A) of the left humerus shows a pathological fracture through the middle of the shaft (arrow). Extensive blastic metastases are seen in entire visualized skeleton (arrowheads). Image B is a magnified view and shows the region of the transverse fracture (arrow), blastic metastases (arrowheads), and callus formation (dashed arrow), indicating healing.</div><div class=\"graphic_footnotes\">A-P: anterioposterior.</div><div id=\"graphicVersion\">Graphic 99120 Version 1.0</div></div></div>"},"99121":{"type":"graphic_diagnosticimage","displayName":"US posterior scapular spine in sagittal plane","title":"US posterior scapular spine in sagittal plane","html":"<div class=\"graphic\"><div style=\"width: 729px\" class=\"figure\"><div class=\"ttl\">US posterior scapular spine in sagittal plane</div><div class=\"cntnt\"><img style=\"width:709px; height:448px;\" src=\"images/EM/99121_Pstr_scplr_spn_sgttl_pln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image over the posterior scapula in the sagittal plane.</div><div class=\"graphic_footnotes\">Trap: trapezius; SS: supraspinatus muscle; Spine: scapular spine; IS: infraspinatus muscle; TMin: teres minor muscle; Arrow: osseous ridge separating the infraspinatus and teres minor muscles.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99121 Version 2.0</div></div></div>"},"99125":{"type":"graphic_diagnosticimage","displayName":"Radiograph axillary view of shoulder","title":"Axillary view of normal shoulder on radiograph","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Axillary view of normal shoulder on radiograph</div><div class=\"cntnt\"><img style=\"width:562px; height:525px;\" src=\"images/RADIOL/99125_Radiograph_axillary_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axillary view of a normal shoulder shows the components of the shoulder including the glenoid (g), humeral head (h), coracoid process (c), clavicle (cl), lesser tuberosity (lt), acromion (a), and greater tuberosity (gt).</div><div id=\"graphicVersion\">Graphic 99125 Version 1.0</div></div></div>"},"99128":{"type":"graphic_figure","displayName":"Shoulder ligaments anterior view","title":"Shoulder ligaments anterior view","html":"<div class=\"graphic\"><div style=\"width: 827px\" class=\"figure\"><div class=\"ttl\">Shoulder ligaments anterior view</div><div class=\"cntnt\"><img style=\"width:807px; height:481px;\" src=\"images/EM/99128_Shoulderlgmntantrrview.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99128 Version 4.0</div></div></div>"},"99129":{"type":"graphic_diagnosticimage","displayName":"Radiograph using Zanca view grade for III AC separation","title":"Pre- and postoperative radiography for Grade III AC separation using Zanca view","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Pre- and postoperative radiography for Grade III AC separation using Zanca view</div><div class=\"cntnt\"><img style=\"width:724px; height:248px;\" src=\"images/RADIOL/99129_Rdgrp_znc_vw_grd_III_AC_spr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A is a Zanca view of the left AC joint showing a grade III AC separation (arrow). Image B is a postoperative radiograph using the Zanca view to demonstrate the AC joint (arrow) following left coracoclavicular ligament reconstruction with semitendinosis allograft, fibertape repair, and focal resection of the osteoarthritic distal clavicle.</div><div class=\"graphic_footnotes\">AC: acromioclavicular.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 99129 Version 1.0</div></div></div>"},"99162":{"type":"graphic_table","displayName":"Studies of sexual function following prolapse repair","title":"Studies of sexual function following prolapse repair","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies of sexual function following prolapse repair</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"6\">Sexual function following prolapse repair (without transvaginal mesh use for prolapse)*</td> </tr> <tr> <td class=\"subtitle2\">Author</td> <td class=\"subtitle2\">Type of repair</td> <td class=\"subtitle2\">Follow-up</td> <td class=\"subtitle2\">Number of subjects</td> <td class=\"subtitle2\">Validated questionnaire(s)</td> <td class=\"subtitle2\">Sexual function</td> </tr> <tr> <td>Handa, et al. 2007</td> <td>Apical, abdominal sacrocolpopexy +/&ndash; Burch procedure</td> <td>12 months</td> <td>224; 148 completed PISQ-12</td> <td>PISQ-12</td> <td>Improved overall</td> </tr> <tr> <td>Sarlos, et al. 2008</td> <td>Apical, laparoscopic sacrocolpopexy +/&ndash; incontinence procedures</td> <td>3 to 24 months</td> <td>47</td> <td>QOL - Kings' Health Questionnaire</td> <td> <p>Improved overall</p> Scores not given 83% \"equal or better\"</td> </tr> <tr> <td>Geller, et al. 2011</td> <td>Apical, robotic sacrocolpopexy +/&ndash; incontinence procedures</td> <td>12 months</td> <td>25</td> <td>PISQ-12</td> <td>Unchanged overall</td> </tr> <tr> <td>Price, et al. 2011</td> <td>Apical, laparoscopic sacrocolpopexy +/&ndash; other prolapse and/or incontinence procedures</td> <td>6 to 36 months</td> <td>48</td> <td>International consultation on incontinence questionnaire for vaginal symptoms; sexual symptoms score</td> <td>Improved overall</td> </tr> <tr> <td>Komesu, et al. 2007</td> <td>Posterior repair +/&ndash; other prolapse and incontinence procedures</td> <td>3 to 6 months</td> <td>73</td> <td>PISQ</td> <td>Improved overall</td> </tr> <tr> <td>Paraiso, et al. 2006</td> <td>Posterior repair +/&ndash; other prolapse and incontinence procedures</td> <td>12 months</td> <td>35<sup>&#182;</sup></td> <td>PISQ</td> <td>Improved overall</td> </tr> <tr> <td>Azar, et al. 2008</td> <td>Anterior and/or posterior repair</td> <td>3 to 4 months</td> <td>60</td> <td>FSFI</td> <td>Improved overall</td> </tr> <tr> <td>Pauls, et al. 2007</td> <td>Combination of repairs for prolapse +/or incontinence</td> <td>&nbsp;</td> <td>48</td> <td>FSFI</td> <td> <p>No change overall</p> <p>52% improved</p> <p>46% worsened</p> 2% no change</td> </tr> <tr> <td>Rogers, et al. 2006</td> <td>Combination of repairs for prolapse +/or incontinence</td> <td>3 to 6 months</td> <td>75</td> <td>PISQ</td> <td> <p>Improved overall</p> <p>68% improved</p> 32% worsened</td> </tr> <tr> <td>Thakar, et al. 2008</td> <td>Combination of repairs for prolapse +/or incontinence</td> <td>4 months</td> <td>35</td> <td>PISQ</td> <td>Improved overall</td> </tr> <tr> <td>Helstr&#246;m, et al. 2005</td> <td>Manchester technique for prolapse +/or intravaginal slingplasty for incontinence</td> <td>12 months</td> <td>45</td> <td>McCoy inventory for sexual behavior</td> <td>Worsened overall</td> </tr> <tr> <td>Roovers, et al. 2006</td> <td>Combination of repairs for prolapse +/&ndash; incontinence</td> <td>12 months</td> <td>43</td> <td>Questionnaire for screening sexual dysfunction (modified) - individual items analyzed without an overall score</td> <td>Improved overall</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Does not include transvaginal mesh prolapse repair.</div><div class=\"graphic_footnotes\">* Only sexually active patients who underwent repair without transvaginal mesh for prolapse with baseline and postoperative questionnaire data recorded are included in the table.<br />¶ Sexually active patients who underwent graft augmented repair were excluded from the table.</div><div id=\"graphicVersion\">Graphic 99162 Version 1.0</div></div></div>"},"99165":{"type":"graphic_figure","displayName":"Anatomy of suprascapular nerve and surrounding structures","title":"Anatomy of suprascapular nerve and surrounding structures","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Anatomy of suprascapular nerve and surrounding structures</div><div class=\"cntnt\"><img style=\"width:493px; height:504px;\" src=\"images/EM/99165_Antmsprscplrnrvsrndstrc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the suprascapular nerve crosses deep to the superior transverse scapular ligament at the superior scapular (or suprascapular)&nbsp;notch (superior yellow circle), while the vessels cross superior to the ligament. After traversing the suprascapular fossa, the neurovascular structures course through the spinoglenoid notch (inferior yellow circle)&nbsp;and head medially along the inferior border of the scapular spine.</div><div class=\"graphic_reference\">Reproduced with permission from: Strauss EJ, Alaia MJ, Kwon YW. Suprascapular and axillary nerve injuries. In: Disorders of the Shoulder, 3rd ed, Iannotti JP, Williams GR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99165 Version 4.0</div></div></div>"},"99169":{"type":"graphic_diagnosticimage","displayName":"US image of reflection pulley and biceps brachii tendon","title":"US image of reflection pulley and biceps brachii tendon","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">US&nbsp;image of reflection pulley and biceps brachii tendon</div><div class=\"cntnt\"><img style=\"width:479px; height:410px;\" src=\"images/EM/99169_US_pulley_biceps_brachii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior instability of the long head of the biceps brachii tendon (star) is prevented in part by the reflection pulley (arrows).</div><div class=\"graphic_footnotes\">Left: posterior; Right: anterior; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99169 Version 2.0</div></div></div>"},"99170":{"type":"graphic_diagnosticimage","displayName":"US short axis view of subscapularis tendon","title":"US short axis view of subscapularis tendon","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">US short axis view of subscapularis tendon</div><div class=\"cntnt\"><img style=\"width:526px; height:415px;\" src=\"images/EM/99170_Short_axis_subscapularis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis view of the subscapularis tendon (outlined by the black line) over its insertion on the lesser tuberosity of the humerus (Lesser Tuberosity). Note the heterogeneous appearance of the tendon due to the multiple hyperechoic tendon slips (arrows) interspersed with hypoechoic muscle.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99170 Version 2.0</div></div></div>"},"99171":{"type":"graphic_diagnosticimage","displayName":"Sagittal ultrasound image greater tuberosity","title":"Sagittal ultrasound image greater tuberosity","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Sagittal ultrasound image greater tuberosity</div><div class=\"cntnt\"><img style=\"width:494px; height:370px;\" src=\"images/EM/99171_Sagittal_US_great_tubersty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal image over the greater tuberosity demonstrating the superior (small white arrows) and middle facets (large white arrows). The anterior 1.5 cm of supraspinatus tendon (SS) inserts on the superior facet, while the posterior 0.5 to 1 cm of the SS overlaps with the infraspinatus (IS) tendon (SS-IS Overlap) insertion on the middle facet.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle.<br />Left: posterior; Right: anterior; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99171 Version 2.0</div></div></div>"},"99176":{"type":"graphic_table","displayName":"Structures to image for sonographic examination of shoulder","title":"Structures to image for sonographic musculoskeletal examination of shoulder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Structures to image for sonographic musculoskeletal examination of shoulder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Biceps tendon and muscle (including dynamic examination of tendon stability) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Subscapularis muscle and tendon (including dynamic evaluation for subcoracoid impingement) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Acromioclavicular joint </li> </ul> </td> </tr> <tr> <td> <ul> <li>Infraspinatus tendon and muscle </li> </ul> </td> </tr> <tr> <td> <ul> <li>Teres minor tendon and muscle </li> </ul> </td> </tr> <tr> <td> <ul> <li>Posterior glenohumeral joint (including dynamic imaging as indicated) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Spinoglenoid notch </li> </ul> </td> </tr> <tr> <td> <ul> <li>Supraspinatus tendon and muscle </li> </ul> </td> </tr> <tr> <td> <ul> <li>Subacromial-subdeltoid bursa (including dynamic evaluation for subacromial impingement) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO.</div><div id=\"graphicVersion\">Graphic 99176 Version 2.0</div></div></div>"},"99177":{"type":"graphic_picture","displayName":"Seated patient position for ultrasound examination of shoulder","title":"Seated patient position for ultrasound examination of shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seated patient position for ultrasound examination of shoulder</div><div class=\"cntnt\"><img style=\"width:348px; height:544px;\" src=\"images/EM/99177_Seated_position_US_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Location of the patient and sonologist when performing an ultrasound evaluation of the shoulder with the patient in a seated position.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99177 Version 2.0</div></div></div>"},"99179":{"type":"graphic_picture","displayName":"Start position for ultrasound examination of biceps brachii","title":"Start position for ultrasound examination of biceps brachii","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Start position for ultrasound examination of biceps brachii</div><div class=\"cntnt\"><img style=\"width:347px; height:644px;\" src=\"images/EM/99179_Position_US_biceps_brachii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The best position to begin sonographic examination of the biceps brachii has the patient in a supine position with their forearm supinated to bring the long head of the biceps brachii tendon anteriorly.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99179 Version 2.0</div></div></div>"},"99186":{"type":"graphic_table","displayName":"Clinical and laboratory manifestations of Ebola virus disease","title":"Clinical and laboratory manifestations of Ebola virus disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory manifestations of Ebola virus disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage&nbsp;of illness</td> <td class=\"subtitle1\">Time post-symptom onset</td> <td class=\"subtitle1\">Clinical</td> <td class=\"subtitle1\">Laboratory</td> </tr> <tr> <td>Early febrile</td> <td>Days 1-3</td> <td>Fever, malaise, fatigue, body aches</td> <td>Leukopenia, lymphopenia, thrombocytopenia, elevated AST and ALT</td> </tr> <tr> <td>Gastrointestinal</td> <td>Days 3-10</td> <td> <p>Primary: Epigastric and abdominal pain, nausea, vomiting, diarrhea</p> <p>&nbsp;</p> Associated: Persistent fever, asthenia, headache, conjunctival injection, chest pain, dysphagia, odynophagia, arthralgias, myalgias, hiccups, delirium, and rash</td> <td> <p>Persistently elevated AST/ALT and thrombocytopenia</p> <p>&nbsp;</p> <p>Elevated BUN and creatinine</p> <p>&nbsp;</p> <p>Hypokalemia, hypomagnesemia, hyponatremia, hypoalbuminemia</p> <p>&nbsp;</p> <p>Elevated PT/PTT/INR/fibrin-split products</p> <p>&nbsp;</p> Leukocytosis (elevated neutrophils and band cells)</td> </tr> <tr> <td>Shock</td> <td>Days 7-12</td> <td>Diminished consciousness or coma, thready pulse, oliguria, anuria, tachypnea</td> <td> <p>In addition to findings during&nbsp;gastrointestinal stage:</p> <p>&nbsp;</p> <p>Elevated lactate</p> <p>&nbsp;</p> Decreased bicarbonate</td> </tr> <tr> <td>Other complications</td> <td>Day 10 and after</td> <td>Gastrointestinal hemorrhage, respiratory failure associated with aggressive fluid resuscitation or lung injury, secondary infections, neurocognitive abnormalities, seizures, syndrome consistent with menigoencephalitis</td> <td> <p>Findings may overlap with prior stages of illness</p> <p>&nbsp;</p> <p>Decreased hemoglobin and hematocrit observed with gastrointestinal bleeding</p> <p>&nbsp;</p> <p>Hypoxemia observed with respiratory failure</p> </td> </tr> <tr> <td>Recovery</td> <td>Days 7-12&nbsp;</td> <td>Resolution of gastrointestinal symptoms, increased oral intake, increased energy</td> <td>Resolution of laboratory abnormalities</td> </tr> <tr> <td>Convalescence</td> <td>Up to&nbsp;12 months</td> <td>Arthralgias, myalgias, abdominal pain, fatigue, persistent neurocognitive abnormalities, uveitis, meningitis, hearing loss</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; AST: aspartate aminotransferase; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; BUN +blood urea nitrogen.</div><div class=\"graphic_reference\">Courtesy of: Daniel S. Chertow, MD, MPH.</div><div id=\"graphicVersion\">Graphic 99186 Version 3.0</div></div></div>"},"99194":{"type":"graphic_picture","displayName":"US probe position for biceps brachii examination","title":"US probe position for biceps brachii examination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US probe position for biceps brachii examination</div><div class=\"cntnt\"><img style=\"width:429px; height:590px;\" src=\"images/EM/99194_US_probe_biceps_brachii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) transducer position over the anterior proximal arm in preparation of evaluating the long head of the biceps brachii tendon in short-axis. The black rectangle depicts the US transducer head. The arrow demonstrates how the US transducer is glided proximally and curves medially during the long head of the biceps brachii tendon evaluation.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99194 Version 2.0</div></div></div>"},"99195":{"type":"graphic_diagnosticimage","displayName":"US long head biceps brachii at musculotendinous junction","title":"US long head biceps brachii at musculotendinous junction","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">US long head biceps brachii at musculotendinous junction</div><div class=\"cntnt\"><img style=\"width:569px; height:594px;\" src=\"images/EM/99195_US_biceps_brachii_mscltndns.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Black circle: long head of the biceps brachii; Arrows: pectoralis major tendon; RT BT SAX: right biceps tendon short-axis; Humerus: humerus bone; Deltoid: deltoid muscle.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99195 Version 2.0</div></div></div>"},"99196":{"type":"graphic_algorithm","displayName":"AIH maintenance and discontinuation algorithm","title":"Approach to maintenance therapy and treatment withdrawal in adults with autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Approach to maintenance therapy and treatment withdrawal in adults with autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:729px; height:931px;\" src=\"images/GAST/99196_AIHmaintendiscontinuation.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to the topic on the treatment of autoimmune hepatitis for additional discussion of the treatment of special populations including patients with fulminant hepatitis, children, women who are pregnant, patients with cirrhosis, patients with hepatitis C virus, and patients with variants of autoimmune hepatitis.<br />¶ Refer to the topic on the treatment of autoimmune hepatitis for detailed instruction on drug administration and tapering. Oral prednisolone is an alternative to prednisone, and oral mercaptopurine is an alternative to azathioprine.<br />Δ Relapse may be heralded by the development of fatigue, arthralgias, and anorexia, accompanied by a rise in serum aminotransferase levels and/or an increase in serum gamma globulin levels. A rise in serum aminotransferases to more than three times the upper limit of normal or a rise in serum gamma globulins to more than 2 g/dL correlates strongly with the presence of histologic deterioration.<br /><FONT class=lozenge>◊</FONT> A liver biopsy may help predict which patients are likely to have successful drug withdrawal, but it has not been shown to affect long-term patient outcomes and is not required prior to withdrawing treatment. However, our preference is to obtain a biopsy prior to withdrawing treatment and to continue treatment if there is significant interface hepatitis or other histologic evidence of active disease.</div><div id=\"graphicVersion\">Graphic 99196 Version 5.0</div></div></div>"},"99197":{"type":"graphic_diagnosticimage","displayName":"US long head biceps brachii at intertubercular groove","title":"US long head biceps brachii at intertubercular groove","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">US long head biceps brachii at intertubercular groove</div><div class=\"cntnt\"><img style=\"width:720px; height:441px;\" src=\"images/EM/99197_US_brachii_intertubercular.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; LAT: lateral; GT: greater tuberosity; Arrows: transverse humeral ligament; Black oval: long head of the biceps brachii tendon; LT: lesser tuberosity; SSC: subscapularis tendon.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99197 Version 2.0</div></div></div>"},"99198":{"type":"graphic_diagnosticimage","displayName":"US long head biceps brachii intraarticular","title":"US long head biceps brachii intraarticular","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">US long head biceps brachii intraarticular</div><div class=\"cntnt\"><img style=\"width:531px; height:395px;\" src=\"images/EM/99198_US_biceps_brachii_intrrtclr.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; SS: supraspinatus tendon (anisotropic); White oval: long head of the biceps brachii tendon; SScap: subscapularis tendon; Humerus: humerus bone. <br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99198 Version 2.0</div></div></div>"},"99199":{"type":"graphic_picture","displayName":"Probe position for long-axis of biceps brachii","title":"Probe position for long-axis sonographic examination of biceps brachii","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Probe position for long-axis sonographic examination of biceps brachii</div><div class=\"cntnt\"><img style=\"width:431px; height:516px;\" src=\"images/EM/99199_Prb_lng_axis_biceps_brachii.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Black rectangle: depiction of ultrasound transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99199 Version 2.0</div></div></div>"},"99200":{"type":"graphic_diagnosticimage","displayName":"US long-axis view biceps brachii","title":"US long-axis view biceps brachii","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">US long-axis view biceps brachii</div><div class=\"cntnt\"><img style=\"width:647px; height:519px;\" src=\"images/EM/99200_US_long_axis_biceps_brachii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A long axis ultrasound (US) image of the long head of the biceps brachii tendon is shown above.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Black and white arrows: long head of the biceps brachii tendon; Humerus: humerus bone. <br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99200 Version 3.0</div></div></div>"},"99201":{"type":"graphic_picture","displayName":"Probe position for subscapularis tendon long-axis","title":"Probe position for subscapularis tendon long-axis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Probe position for subscapularis tendon long-axis</div><div class=\"cntnt\"><img style=\"width:428px; height:504px;\" src=\"images/EM/99201_Probe_subscapularis_tendon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound transducer position to evaluate the subscapularis tendon in the long-axis.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the ultrasound transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99201 Version 2.0</div></div></div>"},"99203":{"type":"graphic_diagnosticimage","displayName":"US subscapularis tendon in long-axis","title":"US subscapularis tendon in long-axis","html":"<div class=\"graphic\"><div style=\"width: 673px\" class=\"figure\"><div class=\"ttl\">US subscapularis tendon in long-axis</div><div class=\"cntnt\"><img style=\"width:653px; height:594px;\" src=\"images/EM/99203_US_subscapularis_long_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A long-axis&nbsp;view of the subscapularis tendon obtained with ultrasound&nbsp;(US) is shown above.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Arrows: subscapularis tendon; LT: lesser tuberosity; White oval: long head of the biceps brachii tendon;&nbsp; humerus: humerus bone.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99203 Version 2.0</div></div></div>"},"99205":{"type":"graphic_diagnosticimage","displayName":"US anteromedial shoulder","title":"US anteromedial shoulder","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">US anteromedial shoulder</div><div class=\"cntnt\"><img style=\"width:776px; height:532px;\" src=\"images/EM/99205_US_anteromedial_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image over the anteromedial shoulder obtained while evaluating for subcoracoid bursopathy and impingement.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; SSCAP: subscapularis tendon; Star: region of subcoracoid bursa; Humerus: humerus bone.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99205 Version 2.0</div></div></div>"},"99206":{"type":"graphic_movie","displayName":"Dynamic assessment of subcoracoid impingement","title":"Dynamic assessment of subcoracoid impingement","html":"<div class=\"graphic normal\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Dynamic assessment of subcoracoid impingement</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99206_Dynmcsubcoracodimpingvid.mp4\" style=\"width:576px;height:416px\"></div><img style=\"width:576px; height:391px;\" src=\"images/EM/99206_Dynmcsubcoracodimpingimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic ultrasound (US) evaluation for subcoracoid bursopathy and impingement.</div><div class=\"graphic_footnotes\">C: coracoid process; SSCAP: subscapularis tendon; Humerus: humerus bone; Deltoid: deltoid muscle.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99206 Version 2.0</div></div></div>"},"99209":{"type":"graphic_picture","displayName":"Probe position to examine subscapularis tendon in short-axis","title":"Probe position to examine subscapularis tendon in short-axis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Probe position to examine subscapularis tendon in short-axis</div><div class=\"cntnt\"><img style=\"width:427px; height:505px;\" src=\"images/EM/99209_Prb_subscapularis_shrt_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound transducer position to evaluate the subscapularis tendon in the short-axis.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the ultrasound transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99209 Version 2.0</div></div></div>"},"99211":{"type":"graphic_picture","displayName":"Probe position to examine acromioclavicular joint","title":"Probe position to examine acromioclavicular joint","html":"<div class=\"graphic\"><div style=\"width: 729px\" class=\"figure\"><div class=\"ttl\">Probe position to examine acromioclavicular joint</div><div class=\"cntnt\"><img style=\"width:709px; height:572px;\" src=\"images/EM/99211_Probe_acromioclavicular.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Black rectangle: depiction of the ultrasound transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99211 Version 2.0</div></div></div>"},"99212":{"type":"graphic_diagnosticimage","displayName":"US acromioclavicular joint","title":"US acromioclavicular joint","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">US acromioclavicular joint</div><div class=\"cntnt\"><img style=\"width:750px; height:321px;\" src=\"images/EM/99212_US_acromioclavicular_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound (US)&nbsp;image shows the region of the acromioclavicular joint.</div><div class=\"graphic_footnotes\">Arrowheads: superior acromioclavicular ligament and joint capsule; Star: intra-articular fibrocartilaginous disc; Clavicle: clavicle bone; Acromion: acromion bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99212 Version 2.0</div></div></div>"},"99221":{"type":"graphic_picture","displayName":"Probe start position posterior shoulder examination","title":"Probe start position posterior shoulder examination","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Probe start position posterior shoulder examination</div><div class=\"cntnt\"><img style=\"width:594px; height:419px;\" src=\"images/EM/99221_Probe_start_post_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The position of the ultrasound (US) transducer to begin the evaluation of the posterior shoulder is shown above. The transducer starts over the scapular spine, and is glided caudally to image the infraspinatus muscle in a short-axis view.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the US transducer head; arrow: direction US transducer is glided to identify the infraspinatus muscle.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99221 Version 3.0</div></div></div>"},"99222":{"type":"graphic_picture","displayName":"Resisted external derotation test","title":"Resisted external derotation test","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Resisted external derotation test</div><div class=\"cntnt\"><img style=\"width:588px; height:409px;\" src=\"images/RHEUM/99222_Resisted_external_drttn_tst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Resisted external derotation test. With the patient supine, the hip and knee on the affected side are both flexed 90 degrees, and then the hip is externally rotated. From this position, the patient is asked to rotate the thigh back to a neutral position while the examiner opposes this motion.</div><div class=\"graphic_reference\">Test illustrated in photo originally described in: Lequesne M, Mathieu P, Vuillemin-Bodaghi V, et al. Gluteal tendinopathy in refractory greater trochanter pain syndrome: diagnostic value of two clinical tests. Arthritis Rheum 2008; 59:241.</div><div id=\"graphicVersion\">Graphic 99222 Version 1.0</div></div></div>"},"99223":{"type":"graphic_diagnosticimage","displayName":"US infraspinatus muscle and tendon","title":"US infraspinatus muscle and tendon","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">US infraspinatus muscle and tendon</div><div class=\"cntnt\"><img style=\"width:532px; height:598px;\" src=\"images/EM/99223_Infraspinatus_muscle_tendon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of the infraspinatus muscle (outlined by white line) in short-axis.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; IS Ten: infraspinatus tendon; Scapula: scapular bone. <br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99223 Version 2.0</div></div></div>"},"99224":{"type":"graphic_picture","displayName":"Probe position to examine infraspinatus mid portion to insertion","title":"Probe position to examine infraspinatus mid portion to insertion","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Probe position to examine infraspinatus mid portion to insertion</div><div class=\"cntnt\"><img style=\"width:710px; height:473px;\" src=\"images/EM/99224_Prb_pst_exm_infrspnt_md_prt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;transducer position beginning over the mid-portion of the infraspinatus muscle in short-axis and gliding laterally to the infraspinatus tendon insertion on the middle facet of the greater tuberosity of the humeral head.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99224 Version 3.0</div></div></div>"},"99225":{"type":"graphic_movie","displayName":"US examination of infraspinatus in short-axis","title":"US examination of infraspinatus in short-axis","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">US examination of infraspinatus in short-axis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99225_USinfraspinatusshortvid.mp4\" style=\"width:480px;height:448px\"></div><img style=\"width:540px; height:487px;\" src=\"images/EM/99225_USinfraspinatusshortimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic ultrasound (US) image of the infraspinatus muscle and tendon in short-axis. The transducer is being glided from medial to lateral, ending at the infraspinatus tendon insertion on the middle facet of the greater tuberosity of the humeral head.</div><div class=\"graphic_footnotes\">D: deltoid; IS: infraspinatus; CEPH: cephalad; HH: head of the humerus bone.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99225 Version 2.0</div></div></div>"},"99233":{"type":"graphic_diagnosticimage","displayName":"US infraspinatus insertion short axis view","title":"US infraspinatus insertion short axis view","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">US infraspinatus insertion short axis view</div><div class=\"cntnt\"><img style=\"width:629px; height:541px;\" src=\"images/EM/99233_US_infrspnts_insrt_shrt_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of the infraspinatus tendon (infraspinatus) in short-axis at its insertion on the middle facet of the greater tuberosity of the humeral head (humerus).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99233 Version 2.0</div></div></div>"},"99234":{"type":"graphic_diagnosticimage","displayName":"US infraspinatus long axis view","title":"US infraspinatus long axis view","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">US infraspinatus long axis view</div><div class=\"cntnt\"><img style=\"width:776px; height:441px;\" src=\"images/EM/99234_US_infraspinatus_lng_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of the infraspinatus muscle (IM) and tendon (IT) in long-axis from the mid-scapular region to its insertion on the middle facet of the greater tuberosity of the humeral head (GT).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; G: glenoid; Humeral head: head of the humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99234 Version 2.0</div></div></div>"},"99235":{"type":"graphic_picture","displayName":"US probe position from infraspinatus to teres minor","title":"US probe position from infraspinatus to teres minor","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">US probe position from infraspinatus to teres minor</div><div class=\"cntnt\"><img style=\"width:710px; height:475px;\" src=\"images/EM/99235_US_prb_pst_infrspnt_trs_mnr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;transducer position moving caudally from a position over the infraspinatus muscle in short-axis to a position over the teres minor muscle in short-axis.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99235 Version 3.0</div></div></div>"},"99236":{"type":"graphic_diagnosticimage","displayName":"US teres minor midportion short axis view","title":"US teres minor midportion short axis view","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">US teres minor midportion short axis view</div><div class=\"cntnt\"><img style=\"width:539px; height:544px;\" src=\"images/EM/99236_US_trs_mnr_mdpr_shrt_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of the mid-portion of the teres minor muscle (TMin, outlined by white line) in short axis.</div><div class=\"graphic_footnotes\">IS: infraspinatus; Scapula: scapular bone.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99236 Version 2.0</div></div></div>"},"99238":{"type":"graphic_picture","displayName":"Probe position to examine teres minor midportion to insertion","title":"Probe position to examine teres minor midportion to insertion","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Probe position to examine teres minor midportion to insertion</div><div class=\"cntnt\"><img style=\"width:706px; height:456px;\" src=\"images/EM/99238_Prb_pst_xm_trs_mnr_mdpr_ins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;transducer position beginning over the mid-portion of the teres minor muscle in short-axis and gliding laterally to the teres minor tendon insertion on the inferior facet of the greater tuberosity of the humeral head.</div><div class=\"graphic_footnotes\">Rectangle: Depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99238 Version 3.0</div></div></div>"},"99262":{"type":"graphic_diagnosticimage","displayName":"US teres minor tendon short axis view","title":"US teres minor tendon short axis view","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">US teres minor tendon short axis view</div><div class=\"cntnt\"><img style=\"width:537px; height:539px;\" src=\"images/EM/99262_US_trs_mnr_tndn_shrt_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of the teres minor tendon (star) in short-axis over the inferior facet of the greater tuberosity of the humeral head (IF).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Triceps: triceps muscle.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99262 Version 2.0</div></div></div>"},"99263":{"type":"graphic_diagnosticimage","displayName":"US teres minor muscle and tendon long axis view","title":"US teres minor muscle and tendon long axis view","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">US teres minor muscle and tendon long axis view</div><div class=\"cntnt\"><img style=\"width:714px; height:370px;\" src=\"images/EM/99263_US_tr_mnr_msl_td_lng_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of the teres minor muscle (Tmin M) and tendon (star) in long-axis from the mid-scapular region to its insertion on the inferior facet of the greater tuberosity of the humeral head (GT).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humeral head: head of the humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99263 Version 2.0</div></div></div>"},"99264":{"type":"graphic_picture","displayName":"Probe position to examine posterior glenohumeral joint","title":"Probe position to examine posterior glenohumeral joint","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Probe position to examine posterior glenohumeral joint</div><div class=\"cntnt\"><img style=\"width:720px; height:458px;\" src=\"images/EM/99264_Prob_posterior_glenohumeral.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Black rectangle: depiction of the ultrasound transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99264 Version 3.0</div></div></div>"},"99265":{"type":"graphic_movie","displayName":"Dynamic ultrasound assessment of posterior glenohumeral joint","title":"Dynamic ultrasound assessment of posterior glenohumeral joint","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Dynamic ultrasound assessment of posterior glenohumeral joint</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99265_USpostglenohumeralvid.mp4\" style=\"width:528px;height:496px\"></div><img style=\"width:524px; height:498px;\" src=\"images/EM/99265_USpostglenohumeralimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic ultrasound (US) image of the posterior glenohumeral joint while the shoulder is internally and externally rotated.</div><div class=\"graphic_footnotes\">D: deltoid; IS: infraspinatus muscle and tendon; MED: medial; Asterisk: glenoid labrum; GL: glenoid bone; HH: head of the humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99265 Version 2.0</div></div></div>"},"99266":{"type":"graphic_diagnosticimage","displayName":"US posterior glenohumeral joint","title":"US posterior glenohumeral joint","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">US posterior glenohumeral joint</div><div class=\"cntnt\"><img style=\"width:648px; height:554px;\" src=\"images/EM/99266_US_pstrr_glenohumeral_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of posterior glenohumeral joint.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; IS: infraspinatus; White star: glenoid labrum; Glenoid: glenoid of the scapula; Arrows: articular cartilage of the humeral head (anechoic structure); Humeral head: head of the humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99266 Version 2.0</div></div></div>"},"99267":{"type":"graphic_picture","displayName":"Probe position post glenohumeral joint to spinoglenoid notch","title":"Probe position post glenohumeral joint to spinoglenoid notch","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Probe position post glenohumeral joint to spinoglenoid notch</div><div class=\"cntnt\"><img style=\"width:720px; height:470px;\" src=\"images/EM/99267_Glenohumrl_jt_spnglend_ntch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound (US) transducer should be glided slightly medial from its position over the posterior glenohumeral joint to image the spinoglenoid notch.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99267 Version 3.0</div></div></div>"},"99270":{"type":"graphic_diagnosticimage","displayName":"US spinoglenoid notch","title":"US spinoglenoid notch","html":"<div class=\"graphic\"><div style=\"width: 673px\" class=\"figure\"><div class=\"ttl\">US spinoglenoid notch</div><div class=\"cntnt\"><img style=\"width:653px; height:621px;\" src=\"images/EM/99270_US_spinoglenoid_notch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of the spinoglenoid notch (large arrow).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; IS: infraspinatus muscle; Small arrows: inferior transverse scapular ligament; Scapula: scapula bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99270 Version 2.0</div></div></div>"},"99277":{"type":"graphic_picture","displayName":"Probe position spinoglenoid notch to suprascapular notch","title":"Probe position spinoglenoid notch to suprascapular notch","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Probe position spinoglenoid notch to suprascapular notch</div><div class=\"cntnt\"><img style=\"width:720px; height:471px;\" src=\"images/EM/99277_Spinoglenoid_suprascapular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound (US) transducer should be glided cephalad from its position over the spinoglenoid notch to image the suprascapular notch.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99277 Version 3.0</div></div></div>"},"99278":{"type":"graphic_diagnosticimage","displayName":"US suprascapular notch","title":"US suprascapular notch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US suprascapular notch</div><div class=\"cntnt\"><img style=\"width:421px; height:421px;\" src=\"images/EM/99278_US_suprascapular_notch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of the suprascapular notch (large arrow).</div><div class=\"graphic_footnotes\">Trapezius: trapezius muscle; SS: supraspinatus muscle; Small arrows: superior transverse scapular ligament;&nbsp;Scapula: scapula bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99278 Version 2.0</div></div></div>"},"99279":{"type":"graphic_picture","displayName":"Modified Crass position for ultrasound of supraspinatus tendon","title":"Modified Crass position for ultrasound of supraspinatus tendon","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Modified Crass position for ultrasound of supraspinatus tendon</div><div class=\"cntnt\"><img style=\"width:722px; height:435px;\" src=\"images/EM/99279_Modified_Crass_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Modified Crass patient position for evaluating the supraspinatus tendon.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99279 Version 3.0</div></div></div>"},"99280":{"type":"graphic_picture","displayName":"Crass position for ultrasound of supraspinatus tendon","title":"Crass position for ultrasound of supraspinatus tendon","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Crass position for ultrasound of supraspinatus tendon</div><div class=\"cntnt\"><img style=\"width:713px; height:531px;\" src=\"images/EM/99280_Crss_pst_US_sprspnt_tndn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crass patient position for evaluating the supraspinatus tendon.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff,&nbsp;DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99280 Version 3.0</div></div></div>"},"99281":{"type":"graphic_picture","displayName":"Probe placement to examine anterior glenohumeral joint","title":"Probe placement to examine anterior glenohumeral joint","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Probe placement to examine anterior glenohumeral joint</div><div class=\"cntnt\"><img style=\"width:714px; height:422px;\" src=\"images/EM/99281_Prb_plc_exm_ant_glnhmrl_jnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To begin the supraspinatus examination, the ultrasound (US) transducer is first placed over the intertubercular groove where the long head of the biceps brachii tendon is seen in short-axis. The transducer should then be glided posteriorly over the greater tuberosity.</div><div class=\"graphic_footnotes\">Rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99281 Version 3.0</div></div></div>"},"99282":{"type":"graphic_picture","displayName":"Probe placement to examine supraspinatus insertion","title":"Probe placement to examine supraspinatus insertion","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Probe placement to examine supraspinatus insertion</div><div class=\"cntnt\"><img style=\"width:715px; height:434px;\" src=\"images/EM/99282_Prb_plcmnt_exm_sprsp_insr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound (US) transducer is glided cephalad over the lateral margin of the superior facet of the greater tuberosity of the humeral head to identify the insertion of the supraspinatus tendon in short-axis.</div><div class=\"graphic_footnotes\">Black rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99282 Version 2.0</div></div></div>"},"99283":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus insertion short axis view","title":"US supraspinatus insertion short axis view","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">US supraspinatus insertion short axis view</div><div class=\"cntnt\"><img style=\"width:651px; height:461px;\" src=\"images/EM/99283_US_sprspnt_insr_shrt_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis ultrasound (US) image of the supraspinatus tendon (SS) insertion on the superior facet of the greater tuberosity of the humeral head (GT).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humeral head: head of the humerus bone; Star: biceps tendon.<br />Left: posterior; Right: anterior; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99283 Version 2.0</div></div></div>"},"99284":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus midportion short axis view","title":"US supraspinatus midportion short axis view","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">US supraspinatus midportion short axis view</div><div class=\"cntnt\"><img style=\"width:632px; height:507px;\" src=\"images/EM/99284_US_sprspnt_mdpr_shrt_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis ultrasound (US) image of the anterior margin of the mid (intra-articular) portion of the supraspinatus tendon (SS). The astute sonologist will recognize that this image is intra-articular due to the presence of the anechoic articular cartilage on the surface of the humeral head.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humeral head; head of the humerus bone; Star: biceps tendon.<br />Left: posterior; Right: anterior; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99284 Version 2.0</div></div></div>"},"99285":{"type":"graphic_picture","displayName":"Probe placement supraspinatus long axis view","title":"Probe placement supraspinatus long axis view","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Probe placement supraspinatus long axis view</div><div class=\"cntnt\"><img style=\"width:711px; height:428px;\" src=\"images/EM/99285_Prb_plc_sprspnt_lng_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To image the supraspinatus tendon in long-axis, the ultrasound (US) transducer is first placed in long-axis over the long head of the biceps brachii tendon as it enters the proximal aspect of the intertubercular groove. The US transducer is glided posteriorly to image the supraspinatus tendon insertion on the superior (anterior fibers) and middle (posterior fibers, overlap region with the infraspinatus) facets of the greater tuberosity.</div><div class=\"graphic_footnotes\">Rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99285 Version 3.0</div></div></div>"},"99286":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus long axis view","title":"US supraspinatus long axis view","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">US supraspinatus long axis view</div><div class=\"cntnt\"><img style=\"width:712px; height:479px;\" src=\"images/EM/99286_US_supraspinatus_lng_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-axis ultrasound (US) image of the supraspinatus (SS) insertion on the superior facet of the greater tuberosity (GT).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; SA-SD Bursa: subacromial-subdeltoid bursa and peri-bursal fat;&nbsp;Humeral head: head of the humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99286 Version 2.0</div></div></div>"},"99287":{"type":"graphic_diagnosticimage","displayName":"US subacromial subdeltoid bursa","title":"US subacromial subdeltoid bursa","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">US subacromial subdeltoid bursa</div><div class=\"cntnt\"><img style=\"width:678px; height:520px;\" src=\"images/EM/99287_US_sbcrml_sbdltd_brs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of the subacromial-subdeltoid bursa (small arrows [hypoechoic line]).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Large arrows: peri-bursal fat (hyperechoic, granular appearance); SS: supraspinatus; GT: superior facet of the greater tuberosity; Humeral head: head of the humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99287 Version 2.0</div></div></div>"},"99288":{"type":"graphic_diagnosticimage","displayName":"US subacromial subdeltoid bursa tear drop sign","title":"US subacromial subdeltoid bursa tear drop sign","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">US subacromial subdeltoid bursa tear drop sign</div><div class=\"cntnt\"><img style=\"width:535px; height:412px;\" src=\"images/EM/99288_US_sbcrml_sbdlt_brs_drp_sgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of fluid within the subacromial-subdeltoid bursa (star) extending distal to the insertion of the supraspinatus (SS) on the greater tuberosity (GT). This finding is commonly referred to as the \"tear drop sign\".</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humerus: humerus bone.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99288 Version 2.0</div></div></div>"},"99311":{"type":"graphic_picture","displayName":"Probe placement to assess subacromial impingement","title":"Probe placement to assess subacromial impingement","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Probe placement to assess subacromial impingement</div><div class=\"cntnt\"><img style=\"width:561px; height:564px;\" src=\"images/EM/99311_Prb_plc_ass_sbcrml_imp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Position of the ultrasound (US) transducer during dynamic assessment for subacromial impingement.</div><div class=\"graphic_footnotes\">Rectangle: depiction of the US transducer head.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99311 Version 3.0</div></div></div>"},"99312":{"type":"graphic_movie","displayName":"Dynamic ultrasound assessment of subacromial impingement","title":"Dynamic ultrasound assessment of subacromial impingement","html":"<div class=\"graphic normal\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Dynamic ultrasound assessment of subacromial impingement</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99312_USsubacromialimpingevid.mp4\" style=\"width:544px;height:448px\"></div><img style=\"width:576px; height:451px;\" src=\"images/EM/99312_USsubacromialimpingeimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic ultrasound (US) evaluation for subacromial impingement.</div><div class=\"graphic_footnotes\">D: deltoid muscle; A: acromion bone; Hypoechoic line between the arrows: subacromial-subdeltoid bursa; SS: supraspinatus tendon; MED: medial; GT: greater tuberosity of humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99312 Version 2.0</div></div></div>"},"99313":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus tendinopathy long axis view","title":"US supraspinatus tendinopathy long axis view","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">US supraspinatus tendinopathy long axis view</div><div class=\"cntnt\"><img style=\"width:626px; height:390px;\" src=\"images/EM/99313_US_sprspnt_tndnpthy_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-axis ultrasound (US) image of a tendinopathic supraspinatus tendon (SS). Note the thickened (8 mm), hypoechoic, and heterogeneous appearance of the tendon.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humerus: humerus bone; +: electronic calipers; + length: distance between calipers.<br /> Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99313 Version 2.0</div></div></div>"},"99314":{"type":"graphic_movie","displayName":"Probe movement to assess supraspinatus","title":"Probe movement to assess supraspinatus","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Probe movement to assess supraspinatus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99314_Probeassesssupraspntsvid.mp4\" style=\"width:560px;height:368px\"></div><img style=\"width:576px; height:369px;\" src=\"images/EM/99314_Probeassesssupraspntsimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic ultrasound (US) image demonstrating repositioning of the US transducer from over the long head of the biceps brachii tendon in the intertubercular groove to a position over the greater tuberosity in preparation for evaluating the supraspinatus tendon. Notice that the long head of the biceps brachii tendon is always on the screen, allowing its use as a soft-tissue landmark.</div><div class=\"graphic_footnotes\">D: deltoid; GT: greater tuberosity of humerus bone; Asterisk: long head of the biceps brachii; LT: lesser tuberosity of humerus bone; HH: head of humeral bone.<br />Left: posterior; Right: anterior; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99314 Version 2.0</div></div></div>"},"99316":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus calcific tendinopathy long axis view","title":"US supraspinatus calcific tendinopathy long axis view","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">US supraspinatus calcific tendinopathy long axis view</div><div class=\"cntnt\"><img style=\"width:595px; height:441px;\" src=\"images/EM/99316_USsprspntclcfctndnpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-axis US image of a calcific tendinopathy of the SS.</div><div class=\"graphic_footnotes\">US: ultrasound; Deltoid: deltoid muscle; +: electronic calipers; Ca++: calcium deposit; SS: supraspinatus tendon;&nbsp;Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99316 Version 3.0</div></div></div>"},"99317":{"type":"graphic_movie","displayName":"Infraspinatus atrophy","title":"Infraspinatus atrophy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infraspinatus atrophy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99317_Infraspinatusatrophyvid.mp4\" style=\"width:428px;height:444px\"></div><img style=\"width:419px; height:417px;\" src=\"images/EM/99317_Infraspinatusatrophyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of infraspinatus atrophy due to suprascapular nerve compression from a spinoglenoid notch cyst. The video begins with a short-axis image over the teres minor muscle. The US transducer is then glided cephalad over the infraspinatus muscle. The infraspinatus muscle is hyperechoic, granular, and small (atrophic) compared to the teres minor.</div><div class=\"graphic_footnotes\">D: deltoid muscle; CEPH: cephalad; IS: infraspinatus muscle; TMin: teres minor muscle: Scapula: infraspinatus fossa of the scapula.<br />Left: cephalad; Right: caudad; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99317 Version 2.0</div></div></div>"},"99318":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus partial tear at insertion long axis view","title":"US supraspinatus partial tear at insertion long axis view","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">US supraspinatus partial tear at insertion long axis view</div><div class=\"cntnt\"><img style=\"width:746px; height:567px;\" src=\"images/EM/99318_US_supraspints_partial_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-axis ultrasound (US) image of an articular surface partial thickness tear (thick arrow) of the supraspinatus tendon (SS) at its insertion on the greater tuberosity (GT). Due to its far distal location, this particular tear is referred to as a \"rim-rent tear\". There is also a cortical irregularity on the greater tuberosity (arrow), suggesting this is a chronic tear.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99318 Version 3.0</div></div></div>"},"99319":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus full thickness tear long axis view","title":"US supraspinatus full thickness tear long axis view","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">US supraspinatus full thickness tear long axis view</div><div class=\"cntnt\"><img style=\"width:666px; height:412px;\" src=\"images/EM/99319_US_sprspnt_fll_thck_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis ultrasound (US) image of a full thickness supraspinatus tear. Bursal tissue (star) lying on the articular cartilage can mimic the appearance of tendon tissue leading to the misdiagnosis of an intact rotator cuff. The presence of a cartilage interface sign (arrows) and significant erosion of the greater tuberosity (GT) assists with the diagnosis of a full thickness rotator cuff tear.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99319 Version 2.0</div></div></div>"},"99320":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus partial tear bursal surface long axis view","title":"US supraspinatus partial tear bursal surface long axis view","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">US supraspinatus partial tear bursal surface long axis view</div><div class=\"cntnt\"><img style=\"width:630px; height:511px;\" src=\"images/EM/99320_Supraspinatus_partial_bursl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis ultrasound (US) image of a partial thickness bursal surface supraspinatus (SS) tear (arrows). Hypertrophic bursal tissue (star) is lying in the region of the tear. Note the loss of the normal convexity of the superficial surface of the supraspinatus.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; GT: greater tuberosity; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99320 Version 2.0</div></div></div>"},"99321":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus partial intrasubstance tear long axis view","title":"US supraspinatus partial intrasubstance tear long axis view","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">US supraspinatus partial intrasubstance tear long axis view</div><div class=\"cntnt\"><img style=\"width:630px; height:466px;\" src=\"images/EM/99321_US_sprs_prtl_intr_tr_lng_ax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis ultrasound (US) image of a partial thickness intra-substance supraspinatus (SS) tear (arrow).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; GT: greater tuberosity; +: electronic calipers; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99321 Version 2.0</div></div></div>"},"99322":{"type":"graphic_diagnosticimage","displayName":"US supraspinatus full thickness tear with medial retraction","title":"US supraspinatus full thickness tear with medial retraction","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US supraspinatus full thickness tear with medial retraction</div><div class=\"cntnt\"><img style=\"width:715px; height:332px;\" src=\"images/EM/99322_US_sprspn_fll_thck_tr_mdl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis ultrasound (US) image of a full thickness supraspinatus (SS) tear (double headed arrow) with medial retraction of 1.87 cm.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; GT: greater tuberosity; Humerus: humerus bone;&nbsp; +: electronic calipers; Star: cortical defect of the greater tuberosity.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99322 Version 2.0</div></div></div>"},"99323":{"type":"graphic_table","displayName":"Nonopioid analgesic and NSAIDs table: IV agents","title":"Parenterally available nonopioid analgesic and nonsteroidal antiinflammatory drugs (NSAIDs): Usual dosing for adults with acute pain or inflammation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenterally available nonopioid analgesic and nonsteroidal antiinflammatory drugs (NSAIDs): Usual dosing for adults with acute pain or inflammation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"18%\"></colgroup><colgroup width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Usual analgesic dose (intravenous)</td> <td class=\"subtitle1\">Maximum dose per day (mg)</td> <td class=\"subtitle1\">Selected characteristics and role in therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Para-aminophenol derivative</td> </tr> <tr> <td class=\"indent1\">Acetaminophen<br /> (paracetamol, APAP)</td> <td> <p>Weight &#8805;50 kg: 650 mg IV every 4 hours or 1000 mg IV every 6 hours</p> Weight &#60;50 kg: 12.5 mg/kg IV every 4 hours or 15 mg/kg IV every 6 hours</td> <td> <p>Weight &#8805;50 kg: 4000 mg IV</p> Weight &#60;50 kg: 75 mg/kg per day up to 3750 mg IV</td> <td> <ul> <li>Short-term treatment of mild to moderate acute pain and febrile conditions when oral administration is not available and as an adjunct to opioid analgesics for treatment of moderate to severe acute pain when a rapid onset is needed (eg, postoperatively). </li> <li>Also an option for use prior to or during surgery (ie, preemptive analgesia strategy). </li> <li>Onset 5 to 10&nbsp;minutes. </li> <li>Minimal alteration of platelet functioning. </li> <li>Less risk of GI bleeding, renal, and cardiovascular toxicity than nonselective NSAIDs. </li> <li>Lacks antiinflammatory activity. </li> <li>Patients should be well hydrated. </li> <li>Infusion requires 15 minutes and administration in 100 mL volume per 1000 mg dose. </li> <li>Avoid or use a lower total daily dose (maximum 2000 mg per day) in older adults, patients at risk for hepatotoxicity (eg, regular alcohol use, malnourished) or with significant renal or hepatic impairment. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Nonselective NSAIDs*</td> </tr> <tr> <td class=\"indent1\">Ketorolac</td> <td> <p>Age &#60;65 years and weight &#8805;50 kg: 15 to 30 mg IV every 6 hours</p> Age &#8805;65 years or weight &#60;50 kg: 15 mg IV every 6 hours</td> <td> <p>Age &#60;65 years and weight &#8805;50 kg: 120 mg IV per day for up to five days</p> Age &#8805;65 years or weight &#60;50 kg: 60 mg per day IV for up to five days</td> <td> <ul> <li>A frequently used option for short-term treatment of acute pain when oral NSAID administration is not available, and as an adjunct to other analgesics for the treatment of moderate to severe pain when rapid onset is required (eg, postoperatively). </li> <li>Onset ~30 minutes. </li> <li>Duration of platelet dysfunction ~24 hours. </li> <li>Administered as IV bolus over 15 seconds in minimal fluid volume. </li> <li>Risk of gastropathy and renal failure is related to dose and duration of use. </li> <li>Patients should be well hydrated and without significant kidney disease (CrCl &#62;60 mL/minute). </li> <li>Avoid use in patients with a history of ischemic heart disease, stroke, or heart failure. </li> <li>According to the US label, NSAID use is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. However, safe use of ketorolac in selected patients undergoing cardiovascular surgery has been described. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> <td>400 to 800 mg IV every 6 hours</td> <td>3200 mg IV</td> <td> <ul> <li>Short-term treatment of mild to moderate acute pain when oral administration is not available and as an adjunct to other analgesics for treatment of moderate to severe postoperative pain. </li> <li>Onset ~30 minutes. </li> <li>Duration of platelet dysfunction ~8 hours. </li> <li>Patients should be well hydrated and without significant kidney disease (CrCl &#62;60 mL/minute). </li> <li>Infusion requires 30 minutes and administration in 100 mL volume per 400 mg dose or 200 mL per 800 mg dose. </li> <li>Avoid use in patients with a history of ischemic heart disease, stroke, or heart failure. </li> <li>According to the US label, NSAID use is contraindicated for the treatment of perioperative pain in the setting of CABG surgery. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diclofenac<br /> </td> <td>37.5 mg IV every 6 hours</td> <td>150 mg IV</td> <td> <ul> <li>Short-term treatment of mild to moderate acute pain when oral administration is not available and, potentially, as an adjunct to other analgesics for treatment of moderate to severe postoperative pain. </li> <li>Onset of US available product ~15 to 30 minutes. </li> <li>Duration of platelet dysfunction ~8 hours. </li> <li>Patients should be well hydrated and without significant kidney disease (CrCl &#62;60 mL/minute). </li> <li>US preparation (Dyloject) is administered as an IV bolus over 15 seconds in minimal fluid volume. </li> <li>Another IV diclofenac preparation (Volatarol) that is available in many countries other than US&nbsp;is administered over&nbsp;&#8805;30 minutes&nbsp;in &#8805;100 mL volume and&nbsp;should not be given by IV bolus. </li> <li>Avoid use in patients with a history of ischemic heart disease, stroke, or heart failure. </li> <li>According to the US label, use is contraindicated for the treatment of perioperative pain in the setting of CABG surgery; and in perioperative period (any surgery) in patients with&nbsp;significant renal impairment and at risk for volume depletion. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Selective COX-2 inhibitor</td> </tr> <tr> <td class=\"indent1\">Parecoxib<br /> (not available in United States)</td> <td>20 to 40 mg IV every 6 to 12 hours</td> <td> <p>Age &#60;65 years: 80 mg IV</p> Age &#8805;65 years and body weight &#60;50 kg: 40 mg IV</td> <td> <ul> <li>For short-term or single-dose treatment of postoperative pain. </li> <li>Also a potential&nbsp;option for use prior to or during surgery (ie, preemptive analgesia strategy). </li> <li>Onset &#60;15 minutes. </li> <li>Minimal or no alteration of platelet functioning. </li> <li>Administered as rapid IV bolus in minimal fluid volume. </li> <li>Patients should be well hydrated and without significant kidney disease (CrCl &#62;60 mL/minute). </li> <li>Increased risks of adverse cardiovascular thromboembolic events and surgical wound complications have been observed in CABG postoperative safety studies. </li> <li>Parecoxib is a prodrug of valedcoxib;&nbsp;chronic use of valdecoxib has been associated with an increased risk of serious cardiovascular thrombotic events, myocardial infarction,&nbsp;and stroke relative to some nonselective NSAIDs. </li> <li>Use is contraindicated in patients who are at increased risk for cardiovascular thrombotic events, during the perioperative period of coronary artery bypass graft (CABG) surgery, and/or with a history of sulfonamide hypersensitivity. </li> <li>Dose reduction needed for older adults and weight &#60;50 kg. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Use of parenteral nonopioid analgesics as opioid-sparing agents in multimodal postoperative pain management is discussed in the UpToDate topic review of perioperative pain management. A calculator to determine creatinine clearance (CrCl) is available separately in UpToDate. For additional information, refer to Lexicomp individual drug monographs included with UpToDate and local product information.</div><div class=\"graphic_footnotes\">CABG: coronary artery bypass graft; COX-2: cyclooxygenase isoform 2; CrCl:&nbsp;creatinine clearance;&nbsp;IV: intravenous; NSAID: nonsteroidal antiinflammatory drug.<br />* Nonselective NSAIDs inhibit platelet functioning and are contraindicated as preemptive analgesics before major surgery and intraoperatively prior to establishment of hemostasis. Use of parenteral NSAIDs should not exceed five days. In some countries, a maximum duration of use of ≤2 days or a single dose is recommended. Safety concerns are addressed in the UpToDate topic review of nonselective NSAIDs overview of adverse effects.<br /></div><div id=\"graphicVersion\">Graphic 99323 Version 10.0</div></div></div>"},"99325":{"type":"graphic_table","displayName":"IWCLL response criteria for CLL","title":"International Workshop Group on CLL (IWCLL) response criteria for CLL<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Workshop Group on CLL (IWCLL) response criteria for CLL<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Complete remission (CR)</td> </tr> <tr> <td class=\"indent1\">Requires <strong>all</strong> of the following criteria assessed at least two months after completion of therapy: <ul class=\"decimal_heading\"> <li>Absolute lymphocyte count &#60;4000/microL (4 x 10<sup>9</sup>/L). </li> <li>No lymph nodes &#62;1.5 cm in diameter. </li> <li>No hepatomegaly or splenomegaly. </li> <li>No constitutional symptoms attributable to CLL.* </li> <li>Bone marrow recovery as demonstrated by ANC &#62;1500/microL (1.5 x 10<sup>9</sup>/L), platelet count &#62;100,000/microL (100 x 10<sup>9</sup>/L), and hemoglobin concentration &#62;11 g/dL (110 g/L) in the absence of transfusion or growth factor support. </li> <li>Bone marrow free of clonal CLL cells by conventional flow cytometry and/or immunohistochemistry and without nodular lymphoid aggregates. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">CR with incomplete bone marrow recovery (CRi)</td> </tr> <tr> <td class=\"indent1\">Fulfills all requirements for CR except has persistent neutropenia, anemia, or thrombocytopenia thought to be unrelated to the disease and likely related to drug toxicity. These patients must have a normal bone marrow aspirate and biopsy with no evidence of clonal infiltrates.</td> </tr> <tr> <td class=\"subtitle1_single\">Partial remission (PR)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">At least <strong>two</strong> of these criteria must be documented for a minimal duration of two months after the completion of therapy: <ul class=\"decimal_heading\"> <li>A decrease in the peripheral absolute lymphocyte count by at least 50% from the level prior to therapy. </li> <li>A reduction in previously enlarged nodes by at least 50% with no increase in the size of any single lymph node and no new enlarged lymph nodes. An increase of &#60;25% in a lymph node &#60;2 cm is not considered significant. </li> <li>If enlarged prior to therapy, the liver and spleen should be reduced in size by at least 50%. </li> </ul> <br /> One of the following hematologic parameters must be met in addition to&nbsp;two of the above criteria in order to qualify for a PR: <ul class=\"decimal_heading\"> <li>ANC &#8805;1500/microL (1.5 x 10<sup>9</sup>/L) or greater than 50% improvement over baseline (if this value was abnormally low at baseline) without granulocyte colony-stimulating factor support. </li> <li>Platelet count &#8805;100,000/microL (100 x 10<sup>9</sup>/L) or at least 50% improvement over baseline (if this value was abnormally low at baseline). </li> <li>Hemoglobin concentration &#8805;11 g/dL (110 g/L) or 50% improvement over baseline (if this value was abnormally low at baseline) without red blood cell transfusions or erythropoietin support. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Nodular PR</td> </tr> <tr> <td class=\"indent1\">Persistent bone marrow nodules on bone marrow biopsy in patients achieving a CR or PR. Lymphoid aggregates should be evaluated with immunohistochemistry to determine whether they are comprised of CLL cells, lymphocytes other than CLL cells, or T cells.</td> </tr> <tr> <td class=\"subtitle1_single\">Progressive disease (PD)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">At least <strong>one</strong> of these criteria must be documented: <ul class=\"decimal_heading\"> <li>The appearance of a newly enlarged lymph node (&#62;1.5 cm), splenomegaly, or hepatomegaly. </li> <li>An increase of 50% or more in size of a previously involved site (eg, lymph nodes, spleen, or liver).<sup>&#916;</sup> </li> <li>An increase of 50% or more in the total circulating lymphocyte count with absolute lymphocyte count of 5000/microL (5 x 10<sup>9</sup>/L) or greater. </li> <li>Richter's transformation documented by lymph node biopsy. </li> <li>Development of neutropenia, anemia, or thrombocytopenia attributable to CLL.<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Stable disease</td> </tr> <tr> <td class=\"indent1\">Patients who do not meet the criteria for a complete remission, partial remission, or progressive disease, have stable disease. Stable disease is therapeutically equivalent to a nonresponse (ie, refractory disease).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CLL: chronic lymphocytic leukemia; ANC: absolute neutrophil count.<br />* These include ≥10% unintentional weight loss within the previous six months, fatigue that interferes with work or usual activities, fevers greater than 100.5°F (&gt;38°C) for ≥2 weeks, or night sweats for &gt;1 month.<br />¶ Since the publication of the IWCLL response criteria, \"nodal response\" has been used to describe a reduction in lymphadenopathy in the setting of persistent lymphocytosis, particularly in patients treated with B cell receptor and adhesion-related kinase inhibitors (eg, ibrutinib, idelalisib). For patients receiving a drug associated with tumor mobilization, investigators should reserve the label PD for cases that demonstrate other definitive signs of PD (eg, anemia, thrombocytopenia, lymphadenopathy, hepatosplenomegaly). Lymphocytosis alone should not interfere with the identification of a partial response.<br />∆ A lymph node that was 1 to 1.5 cm previously must increase by 50% or more to a size greater than 1.5 to 2 cm in the longest axis.<br /><FONT class=lozenge>◊</FONT> Cytopenias cannot be used to determine disease progression during active therapy since they may be due to administered cytotoxic agents. Cytopenias that occur at least three months after the completion of therapy and are accompanied by an infiltrate of clonal CLL cells on bone marrow biopsy can be used to define disease progression. Specific values that define progression include a decrease in hemoglobin level by more than 2 g/dL (20 g/L) or to less than 10 g/dL (100 g/L) or a decrease in platelet count by more than 50% or to less than 100,000/microL (100 x 10<SUP>9</SUP>/L).</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446. </li>&#xD;&#xA;    <li>Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30:2820.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99325 Version 2.0</div></div></div>"},"99326":{"type":"graphic_table","displayName":"Sensitivity and specificity of tests to diagnose CHD","title":"Sensitivity and specificity of various noninvasive tests to diagnose the presence of coronary heart disease (CHD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of various noninvasive tests to diagnose the presence of coronary heart disease (CHD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Diagnosis of coronary artery disease</td> </tr> <tr> <td class=\"subtitle2\">Sensitivity (%)</td> <td class=\"subtitle2\">Specificity (%)</td> </tr> <tr> <td>Exercise ECG</td> <td class=\"centered\">45 to 61</td> <td class=\"centered\">70 to 90</td> </tr> <tr> <td>Exercise stress echocardiography</td> <td class=\"centered\">70 to 85</td> <td class=\"centered\">77 to 89</td> </tr> <tr> <td>Exercise stress SPECT</td> <td class=\"centered\">73 to 92</td> <td class=\"centered\">63 to 88</td> </tr> <tr> <td>Pharmacologic stress echocardiography</td> <td class=\"centered\">72 to 90</td> <td class=\"centered\">79 to 95</td> </tr> <tr> <td>Pharmacologic stress SPECT</td> <td class=\"centered\">88 to 91</td> <td class=\"centered\">75 to 90</td> </tr> <tr> <td>Coronary CTA</td> <td class=\"centered\">93 to 99</td> <td class=\"centered\">64 to 90</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTA: computed tomography angiogram; ECG: electrocardiogram; SPECT: single photon emission computed tomography.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.</li>&#xD;&#xA;    <li>Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34:2949.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99326 Version 1.0</div></div></div>"},"99327":{"type":"graphic_table","displayName":"Findings that raise suspicion for monogenic IBD","title":"Findings that raise suspicion for monogenic inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Findings that raise suspicion for monogenic inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Key findings</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Very early age of onset of IBD-like immunopathology</td> <td>Likelihood increases with very early onset, particularly in those younger than two years of age at diagnosis</td> </tr> <tr> <td>Family history</td> <td>In particular consanguinity, predominance of affected males in families, or multiple family members affected</td> </tr> <tr> <td>Atypical endoscopic or histological findings</td> <td>For example, extreme epithelial apoptosis or loss of germinal centers</td> </tr> <tr> <td>Resistance to conventional therapies</td> <td>Such as exclusive enteral nutrition, corticosteroids, and/or biological therapy</td> </tr> <tr> <td>Skin lesions, nail dystrophy, or hair abnormalities</td> <td>For example, epidermolysis bullosa, eczema, folliculitis, pyoderma or abscesses, woolen hair, or trichorrhexis nodosa</td> </tr> <tr> <td>Severe or very early onset perianal disease</td> <td>Fistulas and abscesses</td> </tr> <tr> <td>Lymphoid organ abnormalities</td> <td>For example, lymph node abscesses, splenomegaly</td> </tr> <tr> <td>Recurrent or atypical infections</td> <td>Intestinal and nonintestinal</td> </tr> <tr> <td>Hemophagocytic lymphohistiocytosis</td> <td>Induced by viral infections, such as Epstein-Barr virus or cytomegalovirus or macrophage activation syndrome</td> </tr> <tr> <td>Associated autoimmunity</td> <td>For example, arthritis, serositis, sclerosing cholangitis, anemia, and endocrine dysfunction, such as thyroiditis, type 1 diabetes mellitus</td> </tr> <tr> <td>Early development of tumors</td> <td>For example, non-Hodgkin lymphoma, skin tumors, hamartoma, thyroid tumors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease.</div><div class=\"graphic_reference\">Reproduced from: Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014; 147:998. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99327 Version 5.0</div></div></div>"},"99328":{"type":"graphic_algorithm","displayName":"Diagnosis of very early onset IBD","title":"Diagnosis of very early onset inflammatory bowel disease (IBD)","html":"<div class=\"graphic\"><div style=\"width: 815px\" class=\"figure\"><div class=\"ttl\">Diagnosis of very early onset inflammatory bowel disease (IBD)</div><div class=\"cntnt\"><img style=\"width:795px; height:465px;\" src=\"images/GAST/99328_DiagnosisvryerlyonstIBD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>I. Initial evaluation.</strong> Patient and family history, physical examination, endoscopic investigations, imaging, and limited biochemistry and microbiology/virology tests are required to establish the diagnosis of IBD, assess disease localization and behavior, and determine inflammatory activity. If there is doubt, those tests can contribute to exclude the much more frequent GI infections and non-IBD immune responses toward dietary antigens. Cow's milk protein allergy can present with enteropathy and colitis, and celiac disease can mimic autoimmune enteropathies. Fecal calprotectin can be helpful but may be increased even in healthy infants.<br /><strong>II. Functional screening &#8594; Genetic confirmation strategy.</strong> The diagnostic strategy to investigate a monogenic cause of IBD like intestinal inflammation is largely based on restricted functional screening followed by genetic confirmation. A restricted set of laboratory tests is needed to propose candidate genes of the most common genetic defects for subsequent limited sequencing.<br /><strong>III. Genetic screening &#8594; Functional confirmation strategy.</strong> As a complementary approach, genetic screening for IBD-causative rare variants using next-generation sequencing might be followed by limited functional confirmatory studies. The complexity of problems in these children requires interdisciplinary support, including pediatric gastroenterologists, immunologists, geneticists, and infectious disease specialists.</div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; GI: gastrointestinal; CBC: complete blood count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; CMV: cytomegalovirus; <em>C. difficile</em>: <em>Clostridium difficile</em>; TB: tuberculosis; HIV: human immunodeficiency virus; CMPA: cow's milk protein allergy; NK cells: natural killer cells; CGD: chronic granulomatous disease; CVID: common variable immunodeficiency; Ig: immunoglobulin; SCID: severe combined immunodeficiency; XIAP: X-linked inhibitor of apoptosis protein; IPEX: immunodysregulation polyendocrinopathy enteropathy X-linked syndrome; XLP2: X-linked lymphoproliferative disease; IL10: interleukin 10; LPS: lipopolysaccharide; PBMC: peripheral blood mononuclear cell.<br />* These additional steps are appropriate for patients with IBD-like symptoms developing before 2 years of age, with excessive autoimmunity, or severe perianal disease.</div><div class=\"graphic_reference\">Original figure modified for this publication. From: Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014; 147:990. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99328 Version 6.0</div></div></div>"},"99342":{"type":"graphic_figure","displayName":"Effects of dose increase, prolonged infusion on beta-lactam","title":"Effects of dose increase and prolonged infusion on beta-lactam exposure","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Effects of dose increase and prolonged infusion on beta-lactam exposure</div><div class=\"cntnt\"><img style=\"width:781px; height:599px;\" src=\"images/ID/99342_Effc_incrs_prln_inf_bt_lctm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect on fT &gt; MIC of (a) doubling the antibiotic dose, (b) shortening the dosing interval, (c) prolonging the infusion time from 0.5 h to 3 h and (d) a combination of increasing the dose and prolonging the infusion time. fT &gt; MIC, percentage of the dosing interval that free drug concentrations remain above the MIC; q8h, every 8 h; MIC, minimum inhibitory concentration; q6h, every 6 h.</div><div class=\"graphic_reference\">Reproduced from: MacVanea S, Kutia J, Nicolaua D. Prolonging -lactam infusion: A review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents 2013; 107. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99342 Version 1.0</div></div></div>"},"99343":{"type":"graphic_diagnosticimage","displayName":"US pathologic subacromial subdeltoid bursa","title":"US pathologic subacromial subdeltoid bursa","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">US pathologic subacromial subdeltoid bursa</div><div class=\"cntnt\"><img style=\"width:708px; height:456px;\" src=\"images/EM/99343_US_pthlgc_sbcrml_sbdltd_brs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of subacromial-subdeltoid bursopathy (arrows). Note the thickened, hypoechoic appearance of the bursal tissue. There is also an associated partial thickness tear of the supraspinatus (SS).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; GT: greater tuberosity; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99343 Version 2.0</div></div></div>"},"99344":{"type":"graphic_diagnosticimage","displayName":"US subcoracoid bursa with fluid","title":"US subcoracoid bursa with fluid","html":"<div class=\"graphic\"><div style=\"width: 677px\" class=\"figure\"><div class=\"ttl\">US subcoracoid bursa with fluid</div><div class=\"cntnt\"><img style=\"width:657px; height:445px;\" src=\"images/EM/99344_US_subcoracoid_bursa_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of fluid within the subcoracoid bursa (star) between the coracoid process (Coracoid) and subscapularis tendon (SSCAP).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99344 Version 2.0</div></div></div>"},"99345":{"type":"graphic_movie","displayName":"US dynamic subacromial impingement with fluid","title":"US dynamic subacromial impingement with fluid","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">US dynamic subacromial impingement with fluid</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99345_USsubacromialimpfludvid.mp4\" style=\"width:512px;height:448px\"></div><img style=\"width:565px; height:461px;\" src=\"images/EM/99345_USsubacromialimpfludimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of a dynamic subacromial impingement test. Fluid can be seen being milked from under the acromion into the subacromial-subdeltoid bursa during shoulder abduction.</div><div class=\"graphic_footnotes\">A: acromion; D: deltoid muscle; Asterisk: fluid within the subacromial-subdeltoid bursa; SS: supraspinatus; MED: medial; GT: greater tuberosity of the humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99345 Version 2.0</div></div></div>"},"99346":{"type":"graphic_movie","displayName":"Ascending aortic dissection","title":"Ascending aortic dissection","html":"<div class=\"graphic normal\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Ascending aortic dissection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/99346_Ascaodissectionvid.mp4\" style=\"width:636px;height:448px\"></div><img style=\"width:645px; height:441px;\" src=\"images/SURG/99346_Ascaodissectionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">2D transthoracic echocardiogram in the parasternal long axis orientation. Note the dilated aortic root and posterior linear echodensity/dissection flap.</div><div id=\"graphicVersion\">Graphic 99346 Version 2.0</div></div></div>"},"99347":{"type":"graphic_movie","displayName":"Abdominal aortic dissection","title":"Abdominal aortic dissection","html":"<div class=\"graphic normal\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic dissection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/99347_Abdominalaodissectionvid.mp4\" style=\"width:636px;height:448px\"></div><img style=\"width:645px; height:438px;\" src=\"images/SURG/99347_Abdominalaodissectionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal view 2D transthoracic echocardiogram demonstrating the abdominal aorta with a linear dissection flap (left panel). The addition of color flow Doppler (right panel) demonstrates pulsatile flow traversing along the linear echodensity/dissection flap.</div><div id=\"graphicVersion\">Graphic 99347 Version 2.0</div></div></div>"},"99348":{"type":"graphic_figure","displayName":"Rigid abduction orthosis","title":"Rigid abduction orthosis","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Rigid abduction orthosis</div><div class=\"cntnt\"><img style=\"width:531px; height:353px;\" src=\"images/PEDS/99348_Rigid_abduction_orthosis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99348 Version 1.0</div></div></div>"},"99349":{"type":"graphic_movie","displayName":"US long head of the biceps tendinopathy","title":"US long head of the biceps tendinopathy","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">US long head of the biceps tendinopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99349_USinfraspinatusatrophvid.mp4\" style=\"width:480px;height:416px\"></div><img style=\"width:548px; height:448px;\" src=\"images/EM/99349_USinfraspinatusatrophimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Power-Doppler ultrasound (US) of the long head of the biceps brachii tendon (bicipital tendon) demonstrating enlargement, hypoechogenicity, and heterogeneity consistent with tendinopathy. In addition, there is thickening of the tendon sheath with associated hyperemia indicative of tenosynovitis.</div><div class=\"graphic_footnotes\">D: deltoid muscle; BT: long head of the biceps brachii tendon; MED: medial; H: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99349 Version 3.0</div></div></div>"},"99350":{"type":"graphic_diagnosticimage","displayName":"US biceps brachii tendon longitudinal tear short axis view","title":"US biceps brachii tendon longitudinal tear short axis view","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">US biceps brachii tendon longitudinal tear short axis view</div><div class=\"cntnt\"><img style=\"width:558px; height:466px;\" src=\"images/EM/99350_US_bcp_brch_tnd_lngtd_tr_sh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis ultrasound (US) image of the long head of the biceps brachii tendon (star) with a longitudinal tear (arrow) and excessive intra-tendon sheath fluid.</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; MED: medial; R BT SAX: right biceps tendon short-axis.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99350 Version 2.0</div></div></div>"},"99351":{"type":"graphic_diagnosticimage","displayName":"US biceps brachii tendon with increased intra-sheath fluid","title":"US biceps brachii tendon with increased intra-sheath fluid","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">US biceps brachii tendon with increased intra-sheath fluid</div><div class=\"cntnt\"><img style=\"width:560px; height:468px;\" src=\"images/EM/99351_US_bcp_brc_tnd_int_shth_fld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis ultrasound (US) image of a normal appearing long head of the biceps brachii tendon (BT) with excessive intra-tendon sheath fluid (star) due to intra-articular glenohumeral joint pathology.</div><div class=\"graphic_footnotes\">Deltoid: Deltoid muscle; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99351 Version 2.0</div></div></div>"},"99353":{"type":"graphic_movie","displayName":"US subacromial-subdeltoid bursal fluid","title":"US subacromial-subdeltoid bursal fluid","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">US subacromial-subdeltoid bursal fluid</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99353_USsubacromialsubdeltdvid.mp4\" style=\"width:480px;height:416px\"></div><img style=\"width:540px; height:440px;\" src=\"images/EM/99353_USsubacromialsubdeltdimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic ultrasound (US) examination revealing fluid within the subacromial-subdeltoid bursa mimicking fluid within the bicipital tendon sheath. The fluid displaces medially and laterally, superficially and away from the bicipital tendon with compression indicating that the fluid is not contained within the bicipital tendon sheath.</div><div class=\"graphic_footnotes\">D: deltoid muscle; MED: medial; SA: fluid within the subacromial-subdeltoid bursa; BT: long head of the biceps brachii tendon; H: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99353 Version 2.0</div></div></div>"},"99355":{"type":"graphic_diagnosticimage","displayName":"US high grade biceps tendinopathy","title":"US high grade biceps tendinopathy","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">US high grade biceps tendinopathy</div><div class=\"cntnt\"><img style=\"width:552px; height:459px;\" src=\"images/EM/99355_US_hgh_grd_bcp_tndnpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis ultrasound (US) image high grade bicipital tendinopathy (star) with a focal hypoechoic/anechoic region suggestive of an intra-substance tear (arrow).</div><div class=\"graphic_footnotes\">Deltoid: Deltoid muscle; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99355 Version 2.0</div></div></div>"},"99357":{"type":"graphic_algorithm","displayName":"Patient with undifferentiated shock (initial approach)","title":"Approach to the patient with undifferentiated hypotension or shock: Initial approach","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with undifferentiated hypotension or shock: Initial approach</div><div class=\"cntnt\"><img style=\"width:538px; height:530px;\" src=\"images/PULM/99357_Patient_undif_hypoten_shock.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shaded boxes indicate the points in the process at which no further action needs to be taken, a diagnosis has been made, or continued resuscitation is required.</div><div class=\"graphic_footnotes\">IV: intravascular; ACLS: advanced cardiac life support; MI: myocardial infarction; PE: pulmonary embolus.<br />* The first priority is to stabilize the airway with oxygen and/or mechanical ventilation. Although most patients are intubated, not every patient requires mechanical ventilation (eg, those with a tension pneumothorax).<br />&para; Aggressive fluids and blood products may be required for those with hemorrhage.</div><div id=\"graphicVersion\">Graphic 99357 Version 2.0</div></div></div>"},"99359":{"type":"graphic_diagnosticimage","displayName":"US biceps tendon empty groove sign","title":"US biceps tendon empty groove sign","html":"<div class=\"graphic\"><div style=\"width: 725px\" class=\"figure\"><div class=\"ttl\">US biceps tendon empty groove sign</div><div class=\"cntnt\"><img style=\"width:705px; height:549px;\" src=\"images/EM/99359_US_bcp_tndn_empty_grv_sgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis ultrasound (US) image of the intertubercular groove demonstrating an \"empty groove sign\" (star) suggesting the bicipital tendon has either dislocated or had a full thickness tear.</div><div class=\"graphic_footnotes\">Deltoid: Deltoid muscle; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99359 Version 2.0</div></div></div>"},"99360":{"type":"graphic_table","displayName":"Types of EDS PI","title":"Type of Ehlers-Danlos syndrome (EDS) and common features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Type of Ehlers-Danlos syndrome (EDS) and common features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Classic (EDS I, EDS II)</td> </tr> <tr> <td>Skin</td> <td> <p>Velvety or \"doughy\" texture</p> <p>Stretchy</p> <p>Fragile, easily injured, slow to heal</p> Wide scars from past cuts or injuries</td> </tr> <tr> <td>Joints</td> <td>Loose, flexible</td> </tr> <tr> <td>Other</td> <td> <p>Fatigue</p> <p>Hernias (weak spots in organ walls that can cause a lump or bulge)</p> <p>Heart problems</p> <p>Soft lumps on the elbows or knees</p> <p>Small bumps on the sides of the feet</p> Pregnancy-related problems</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Hypermobility (EDS III)</td> </tr> <tr> <td>Skin</td> <td> <p>Soft, smooth, mildly stretchy</p> Not usually fragile</td> </tr> <tr> <td>Joints</td> <td> <p>Loose, flexible (including the spine)</p> <p>Frequent dislocations (popping out of place)</p> Chronic pain in the joints</td> </tr> <tr> <td>Other</td> <td> <p>Heart problems</p> <p>Digestive problems</p> <p>Fatigue</p> Dizziness upon standing</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Vascular (EDS IV)</td> </tr> <tr> <td>Skin</td> <td>Thin, bruises easily</td> </tr> <tr> <td>Joints</td> <td> <p>Large joints (elbows, knees) usually normal</p> Small joints (fingers, toes) might be somewhat loose or flexible</td> </tr> <tr> <td>Other</td> <td> <p>A tear in a blood vessel or organ wall&nbsp;&ndash; this can cause internal bleeding and be <strong>life threatening</strong></p> Pregnancy-related problems</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There are 6 main types of Ehlers-Danlos syndrome (EDS). This table lists the 3 most common, and some of the features often seen in each. Not every person will have the exact same symptoms. The other 3 main types of EDS are called \"kyphoscoliosis EDS,\" \"arthrochalasia EDS,\" and \"dermatosparaxis EDS.\" These are less common than the types listed above. In addition, there are also a few other forms of EDS. But these are extremely rare.</div><div id=\"graphicVersion\">Graphic 99360 Version 2.0</div></div></div>"},"99361":{"type":"graphic_movie","displayName":"US ruptured long head biceps tendon","title":"US ruptured long head biceps tendon","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US ruptured long head biceps tendon</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99361_USbicepstendonruptrdvid.mp4\" style=\"width:384px;height:432px\"></div><img style=\"width:415px; height:449px;\" src=\"images/EM/99361_USbicepstendonruptrdimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic ultrasound (US) examination of a patient with a ruptured long head of the biceps brachii. In this particular video, the US transducer is being glided in a cephalad to caudad direction beginning at the level of the pectoralis major tendon. The short head of the biceps brachii muscle can be seen forming superficially and medially (left side of the screen) at the beginning of the video. As the video progresses, the atrophic, hyperechoic long head of the biceps brachii muscle can be seen just lateral (right side of the screen) to the short head.</div><div class=\"graphic_footnotes\">SBT: short head of the biceps brachii muscle; LBT: long head of the biceps brachii; H: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99361 Version 2.0</div></div></div>"},"99362":{"type":"graphic_diagnosticimage","displayName":"US biceps tendon medial dislocation and empty groove sign","title":"US biceps tendon medial dislocation and empty groove sign","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">US biceps tendon medial dislocation and empty groove sign</div><div class=\"cntnt\"><img style=\"width:505px; height:413px;\" src=\"images/EM/99362_US_bcp_tnd_mdl_dslc_emp_grv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis ultrasound (US) image of the intertubercular groove demonstrating an \"empty groove sign\" (large arrow) due to medial dislocation of the bicipital tendon (star).</div><div class=\"graphic_footnotes\">Deltoid: Deltoid muscle; Humerus: Humerus bone.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99362 Version 2.0</div></div></div>"},"99363":{"type":"graphic_diagnosticimage","displayName":"US biceps tendon medial subluxation","title":"US biceps tendon medial subluxation","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">US biceps tendon medial subluxation</div><div class=\"cntnt\"><img style=\"width:585px; height:474px;\" src=\"images/EM/99363_US_bcp_tndn_mdl_sblxtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis ultrasound (US) image of the intertubercular groove demonstrating medial subluxation of the bicipital tendon (star).</div><div class=\"graphic_footnotes\">Deltoid: Deltoid muscle; Humerus: Humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99363 Version 2.0</div></div></div>"},"99372":{"type":"graphic_diagnosticimage","displayName":"US acromioclavicular joint osteoarthritis","title":"US acromioclavicular joint osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">US acromioclavicular joint osteoarthritis</div><div class=\"cntnt\"><img style=\"width:638px; height:447px;\" src=\"images/EM/99372_US_acrmclvclr_jnt_ostrthrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of an acromioclavicular joint with osteoarthritis.</div><div class=\"graphic_footnotes\">Arrows: osteophytes; Star: hypertrophic capsule and superior acromioclavicular ligament; Acromion: acromion bone; Clavicle: clavicle bone.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99372 Version 2.0</div></div></div>"},"99403":{"type":"graphic_diagnosticimage","displayName":"US acromioclavicular periarticular cyst","title":"US acromioclavicular periarticular cyst","html":"<div class=\"graphic\"><div style=\"width: 691px\" class=\"figure\"><div class=\"ttl\">US acromioclavicular periarticular cyst</div><div class=\"cntnt\"><img style=\"width:671px; height:516px;\" src=\"images/EM/99403_US_acrmclvclr_prrtclr_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of a peri-articular cyst (outline) extending from the acromioclavicular joint into the surrounding soft tissues.</div><div class=\"graphic_footnotes\">Clavicle: clavicle bone; acromion: acromion bone. <br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99403 Version 2.0</div></div></div>"},"99405":{"type":"graphic_diagnosticimage","displayName":"US acromioclavicular joint sprain","title":"US acromioclavicular joint sprain","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">US acromioclavicular joint sprain</div><div class=\"cntnt\"><img style=\"width:703px; height:324px;\" src=\"images/EM/99405_US_acromioclaviclr_jnt_sprn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of a sprained left (LT) and normal right (RT) acromioclavicular joint. Note the thickening and hypoechogenicity of the left superior acromioclavicular ligament and capsule (star) and the widening of the acromioclavicular joint relative to the right acromioclavicular joint.</div><div class=\"graphic_footnotes\">A: acromion bone; C: clavicle bone; ACJ: acromioclavicular joint. <br />Left image: Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.<br />Right image: Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99405 Version 2.0</div></div></div>"},"99409":{"type":"graphic_movie","displayName":"US dynamic assessment acromioclavicular joint","title":"US dynamic assessment acromioclavicular joint","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">US dynamic assessment acromioclavicular joint</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/99409_USacromioclavclrjointvid.mp4\" style=\"width:608px;height:332px\"></div><img style=\"width:576px; height:295px;\" src=\"images/EM/99409_USacromioclavclrjointimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of dynamic testing for acromioclavicular joint instability. The joint can be seen widening with horizontal shoulder abduction and narrowing with horizontal shoulder adduction. With horizontal shoulder adduction, the acromion also depresses relative to the clavicle.</div><div class=\"graphic_footnotes\">Asterisk: superior acromioclavicular ligament and joint capsule; A: acromion bone; JT: acromioclavicular joint; C: clavicle bone; LAT: lateral.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99409 Version 2.0</div></div></div>"},"99423":{"type":"graphic_diagnosticimage","displayName":"US posterior glenohumeral joint with osteoarthritis","title":"US posterior glenohumeral joint with osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">US posterior glenohumeral joint with osteoarthritis</div><div class=\"cntnt\"><img style=\"width:505px; height:583px;\" src=\"images/EM/99423_US_pstr_glnhmrl_jnt_ostrthr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of an osteoarthritic posterior glenohumeral joint demonstrating synovial hypertrophy (star), labral irregularities (GL), and hypertrophic osseous changes (arrows).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; IS: infraspinatus muscle; Glenoid: glenoid rim of the scapula bone; Humerus: humerus bone.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99423 Version 2.0</div></div></div>"},"99427":{"type":"graphic_diagnosticimage","displayName":"US glenoid labrum tear","title":"US glenoid labrum tear","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">US glenoid labrum tear</div><div class=\"cntnt\"><img style=\"width:483px; height:611px;\" src=\"images/EM/99427_US_glenoid_labrum_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of a labral tear (arrow) in the posterior glenoid labrum (GL).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; IS: infraspinatus muscle; Humeral head: head of the humerus bone; Glenoid: glenoid rim of the scapula bone. <br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99427 Version 2.0</div></div></div>"},"99431":{"type":"graphic_diagnosticimage","displayName":"US spinoglenoid notch cyst","title":"US spinoglenoid notch cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US spinoglenoid notch cyst</div><div class=\"cntnt\"><img style=\"width:436px; height:545px;\" src=\"images/EM/99431_US_spinoglenoid_notch_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US) image of a spinoglenoid notch cyst (star, outlined by line).</div><div class=\"graphic_footnotes\">Deltoid: deltoid muscle; IS: infraspinatus; White arrows: spinoglenoid notch; +: electronic calipers;&nbsp;Scapula: scapula bone.<br />Left: lateral; Right: medial; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99431 Version 2.0</div></div></div>"},"99432":{"type":"graphic_algorithm","displayName":"Algorithm for pediatric RLS","title":"Algorithm for the diagnosis and management of pediatric restless legs syndrome","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis and management of pediatric restless legs syndrome</div><div class=\"cntnt\"><img style=\"width:664px; height:765px;\" src=\"images/PEDS/99432_AlgopediatricRLSWEDedt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dotted arrows: Proceed only after assessment of severity, risks, and benefits by provider, family, and patient. Refer to UpToDate topic text for further details.</div><div class=\"graphic_footnotes\">RLS: restless legs syndrome; ADHD: attention deficit hyperactivity disorder.<br />* Serum ferritin is an acute-phase reactant and is not accurate within four weeks of a febrile illness or in the setting of chronic inflammation. At the initial evaluation, we typically also check hemoglobin, total iron binding capacity (TIBC) and percent iron saturation, for a more complete profile of the child's iron status. For guidance on interpreting these tests, refer to UpToDate topic review on iron deficiency in children and adolescents.<br />&para; For adults with RLS, oral iron therapy is recommended if serum ferritin is &lt;75 mcg/L. For children with RLS, oral iron is recommended if serum ferritin is &lt;50 mcg/L, and may be considered if it is in the 50 to 75 mcg/L range. If ferritin is &gt;100 mcg/L, oral iron typically is not effective, due to hepcidin-induced limitation of iron absorption. Ferritin &gt;100 also may reflect acute or chronic inflammation.<br />&Delta; Refer to UpToDate topic text for details about selection and dosing of medications, and for other considerations for children &lt;6 years of age, and for those with comorbid ADHD, anxiety, or depression.</div><div class=\"graphic_reference\">Modified with permission from the Restless Legs Syndrome Foundation (<a href=\"http://www.rls.org/\" target=\"_blank\">www.rls.org</a>). Copyright &copy; 2015.</div><div id=\"graphicVersion\">Graphic 99432 Version 4.0</div></div></div>"},"99433":{"type":"graphic_diagnosticimage","displayName":"US pectoralis major complete tear","title":"US pectoralis major complete tear","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">US pectoralis major complete tear</div><div class=\"cntnt\"><img style=\"width:720px; height:290px;\" src=\"images/EM/99433_US_pectoralis_major_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound (US)&nbsp;image of a complete tear of the pectoralis major muscle at the musculotendinous junction. The muscle fibers (left white arrow) have retracted medially away from the tendon (right white arrow) and are separated by a subacute hematoma (star).</div><div class=\"graphic_footnotes\">Pectoralis major: pectoralis major muscle (left) and tendon (right); Deltoid: deltoid muscle; Humerus: humerus bone.<br />Left: medial; Right: lateral; Bottom of screen: deep; Top of screen: superficial.</div><div class=\"graphic_reference\">Courtesy of Jonathan Finnoff, DO. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99433 Version 2.0</div></div></div>"},"99434":{"type":"graphic_table","displayName":"Dosing for prolonged infusions of beta-lactams","title":"Dosing for prolonged infusions of beta-lactams<sup>[1-8]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing for prolonged infusions of beta-lactams<sup>[1-8]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Creatinine clearance</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Dosing interval</td> <td class=\"subtitle1\">Infusion time</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Piperacillin-tazobactam</strong>*</td> <td>&#62;20 mL/minute</td> <td>3.375 or 4.5 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr> <td>&#8804;20 mL/minute or intermittent HD or PD</td> <td>3.375 or 4.5 g</td> <td>Every 12 hours</td> <td>4 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup></td> <td>3.375 or 4.5 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Cefepime</strong><sup>&#916;</sup></td> <td>&#8805;50 mL/minute</td> <td>2 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr> <td>30 to 49 mL/minute</td> <td>2 g</td> <td>Every 12 hours</td> <td>4 hours</td> </tr> <tr> <td>15 to 29 mL/minute</td> <td>1 g</td> <td>Every 12 hours</td> <td>4 hours</td> </tr> <tr> <td>&#60;15 mL/minute or intermittent HD</td> <td>1 g</td> <td>Every 24 hours</td> <td>4 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup></td> <td>2 g</td> <td>Every 12 hours</td> <td>4 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Imipenem</strong><sup>&#9674;</sup></td> <td>&#62;70</td> <td>500 mg or 1 g</td> <td>Every 6 hours</td> <td>3 hours</td> </tr> <tr> <td>41 to 70</td> <td>500 mg or 750 mg</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>21 to 40</td> <td>250 or 500 mg</td> <td>Every 6 hours</td> <td>3 hours</td> </tr> <tr> <td>6 to 20 or intermittent HD or PD</td> <td>250 or 500 mg</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup></td> <td>500 mg</td> <td>Every 6 hours</td> <td>3 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Meropenem</strong><sup>&#167;</sup></td> <td>&#8805;50 mL/minute</td> <td>1 or 2 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>25 to 49 mL/minute</td> <td>1 or 2 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td>10 to 24 mL/minute</td> <td>500 mg or 1 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td>&#60;10 mL/minute or intermittent HD</td> <td>500 mg or 1 g</td> <td>Every 24 hours, given after HD</td> <td>3 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup></td> <td>1 or 2 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Ceftazidime-avibactam</strong></td> <td>&#62;50 mL/minute</td> <td>2.5 g</td> <td>Every 8 hours</td> <td>2 hours</td> </tr> <tr> <td>31 to 50 mL/minute</td> <td>1.25 g</td> <td>Every 8 hours</td> <td>2 hours</td> </tr> <tr> <td>16 to 30 mL/minute</td> <td>0.94 g</td> <td>Every 12 hours</td> <td>2 hours</td> </tr> <tr> <td>6 to 15 mL/minute</td> <td>0.94 g</td> <td>Every 24 hours</td> <td>2 hours</td> </tr> <tr> <td>&#60;5 mL/minute or intermittent HD</td> <td>0.94 g</td> <td>Every 48 hours, given after HD</td> <td>2 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup></td> <td>1.25 g</td> <td>Every 8 hours</td> <td>2 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Ceftolozane-tazobactam</strong></td> <td>&#62;50 mL</td> <td>1500 or 3000 mg</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>30 to 50 mL/minute</td> <td>750 or 1500 mg</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>15 to 29 mL/minute</td> <td>375 or 750 mg</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>&#60;15 mL/minute or intermittent HD</td> <td>150 or 375 mg</td> <td>Every 8 hours (start after loading dose)</td> <td>3 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CRRT<sup>&#182;</sup></td> <td>750 or 1500 mg</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Estimated glomerular filtration rate</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Dosing interval</td> <td class=\"subtitle1\">Infusion time</td> </tr> <tr> <td rowspan=\"5\"><strong>Meropenem-vaborbactam</strong></td> <td>&#8805;50 mL/minute</td> <td>4 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>30 to 49 mL/minute</td> <td>2 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>15 to 29 mL/minute</td> <td>2 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td>&#60;15 mL/minute or intermittent HD</td> <td>1 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td>CRRT<sup>&#182;</sup></td> <td>2 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The dosing recommendations reflect the opinion of UpToDate authors for adult patients with adequate intravenous access. The dosing strategies outlined may not be appropriate for all practice settings; they are based on pharmacodynamic models that use MIC distribution assumptions that may not match local patterns. Indications for use of extended infusions of beta-lactams are discussed in the dedicated topic on this issue. Separate calculators for estimation of creatinine clearance or glomerular filtration rate in conventional or International System of Units are available within UpToDate.</div><div class=\"graphic_footnotes\">HD: hemodialysis; PD: peritoneal dialysis; CRRT: continuous renal replacement therapy; CVVHDF: continuous venovenous hemodiafiltration; MIC: minimum inhibitory concentration.<br />* The higher dose of piperacillin-tazobactam (4.5 g) is used in certain situations, such as expected augmented drug clearance (as with critical illness or cystic fibrosis) or in cases of infections with pathogens that have high, but still susceptible, MICs to piperacillin-tazobactam when alternative agents are not appropriate. This higher dose can also be used for empiric treatment in communities or institutions where the <EM>P. aeruginosa</EM> MICs to piperacillin-tazobactam range higher than 32. Some studies have also used a dose of 4.5 g every six hours infused over three hours.<br />¶ The recommendations for CRRT dosing are based off of CVVHDF with a flow rate of 1 liter per hour and minimal residual renal function.<br />Δ Some studies have also used a 3-hour infusion time for cefepime.<br /><FONT class=lozenge>◊</FONT> Imipenem is dosed by both weight and renal function. Dosing above is based on patient weight &gt;70 kg.<br />§ The higher dose of meropenem is used in patients with infections of the central nervous system or other life-threatening infections such as necrotizing fasciitis.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320.</li>&#xD;&#xA;    <li>Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013; 57:2907.</li>&#xD;&#xA;    <li>Hershberger E, Moukasassi MS, Steenbergen J, et al. CXA-101/Tazobactam (CXA/TAZ) probability of target attainment using population pharmacokinetic analysis. Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan Italy May 2011.</li>&#xD;&#xA;    <li>Avycaz [Prescribing Information]. Cincinnati, OH: Forrest Pharmaceuticals, Inc.; 2015.</li>&#xD;&#xA;    <li>Hughes DW, Frei CR, Maxwell PR, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53:2014.</li>&#xD;&#xA;    <li>Cheatham SC, Shea KM, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2011; 37:46.</li>&#xD;&#xA;    <li>Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010; 54:460.</li>&#xD;&#xA;    <li>Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010; 32:766.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99434 Version 5.0</div></div></div>"},"99435":{"type":"graphic_table","displayName":"Therapies for acute angioedema in AAE","title":"Treatment of acute episodes of angioedema in acquired angioedema (also known as acquired C1 inhibitor deficiency)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of acute episodes of angioedema in acquired angioedema (also known as acquired C1 inhibitor deficiency)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Availability</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Precautions</td> </tr> <tr class=\"divider_bottom\"> <td> <p>C1 inhibitor concentrate (plasma-derived)</p> (Berinert, Berinert P, Cinryze)</td> <td>In United States: <ul class=\"decimal_heading\"> <li>Berinert </li> <li>Cinryze </li> </ul> Other countries: <ul class=\"decimal_heading\"> <li>Berinert P </li> <li>Cinryze </li> </ul> </td> <td>20 units per kg body weight given&nbsp;intravenously over 10 minutes. Symptoms usually stabilize in 30 minutes. Second dose uncommonly needed but may be given 30 minutes to&nbsp;2 hours after first dose.</td> <td>Do not shake solution, because protein will denature. Cinryze is not FDA-approved for acute attacks but has efficacy.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Recombinant C1 inhibitor</p> Conestat alfa (Ruconest, Rhucin)</td> <td>Europe, United States, some other countries.</td> <td>50 units per kg body weight for patients &#60;84 kg. 4200 units (two vials) for those &#8805;84 kg. Second dose rarely needed.</td> <td>Patients should be screened for rabbit allergy prior to receiving with rabbit-specific IgE immunoassay and should not receive drug if positive.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Bradykinin B<sub>2</sub>-receptor antagonist</p> Icatibant (Firazyr)</td> <td> <p>United States and many other countries.</p> Approved in the United States for individuals over the age of 18 years.</td> <td>30 mg slow subcutaneous infusion (because of volume) in abdominal area. Second dose needed in about 10% of patients and can be given&nbsp;6 hours after first dose. Maximum of&nbsp;three doses in 25 hours.</td> <td>Caution in patients with unstable angina. Mild injection site reactions are common.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kallikrein inhibitor</p> Ecallantide (Kalbitor)</td> <td> <p>United States only.</p> Approved in the United States for individuals over the age of 16 years.</td> <td>30 mg (three doses of 10 mg each) given at&nbsp;three separate sites subcutaneously in abdomen, upper arm, or thigh and away from site of angioedema.</td> <td>Rare allergy reaction reported usually in &#60;1 hour. Should be administered by a clinician or nurse in a medical facility equipped to treat anaphylaxis.</td> </tr> <tr> <td>Plasma</td> <td> <ul> <li>Solvent detergent-treated plasma (S/D plasma) (preferred) </li> <li>Fresh frozen plasma (FFP) </li> </ul> </td> <td>2 units initially. Can be repeated every&nbsp;2 to&nbsp;4 hours, if needed.</td> <td>Monitor for volume overload in patients with underlying conditions predisposing to volume overload. Theoretical risk of transmission of blood-borne pathogens.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The use of the therapies&nbsp;in the table&nbsp;for acquired angioedema (ie, acquired C1 inhibitor deficiency)&nbsp;is extrapolated from hereditary angioedema. Evidence supporting the use of the agents in the acquired forms of the disease&nbsp;is limited to case reports and clinical experience. Plasma-derived C1 inhibitor concentrate&nbsp;is the agent with which there is the most clinical experience. &nbsp;</div><div class=\"graphic_footnotes\">FDA: US Food and Drug Administration; IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 99435 Version 9.0</div></div></div>"},"99437":{"type":"graphic_picture","displayName":"Plaque psoriasis on back","title":"Chronic plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Chronic plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99437_Plaque_psoriasis_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple large plaques with silver scale on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99437 Version 1.0</div></div></div>"},"99438":{"type":"graphic_picture","displayName":"Inverse psoriasis axilla","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99438_Inverse_psoriasis_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shiny, erythematous, well-demarcated plaques in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99438 Version 1.0</div></div></div>"},"99439":{"type":"graphic_picture","displayName":"Inverse psoriasis axilla 2","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99439_Inverse_psoriasis_axilla_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated erythematous plaque in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99439 Version 2.0</div></div></div>"},"99440":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis extremity","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/99440_Erythrodermic_psrss_extrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema and scale on the skin of a patient with erythrodermic psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99440 Version 2.0</div></div></div>"},"99441":{"type":"graphic_picture","displayName":"Diaper psoriasis","title":"Psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99441_Diaper_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques in the diaper area in an infant with psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99441 Version 1.0</div></div></div>"},"99442":{"type":"graphic_picture","displayName":"Diaper psoriasis with maceration","title":"Psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99442_Diaper_psoriasis_maceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and maceration in the diaper area of an infant with psoriasis. Note involvement of the inguinal fold.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99442 Version 1.0</div></div></div>"},"99443":{"type":"graphic_picture","displayName":"Scalp psoriasis in child","title":"Psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99443_Scalp_psoriasis_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly erythematous plaque on the scalp of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\">www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99443 Version 2.0</div></div></div>"},"99445":{"type":"graphic_picture","displayName":"Psoriasis at umbilicus","title":"Psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99445_Psoriasis_umbilicus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly plaque at the umbilicus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99445 Version 2.0</div></div></div>"},"99446":{"type":"graphic_picture","displayName":"Psoriasis in ear","title":"Psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/99446_Psoriasis_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and scaly plaque involving the ear.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99446 Version 2.0</div></div></div>"},"99447":{"type":"graphic_picture","displayName":"Glucocorticoid injection in greater trochanteric pain syndrome","title":"Glucocorticoid injection in greater trochanteric pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Glucocorticoid injection in greater trochanteric pain syndrome</div><div class=\"cntnt\"><img style=\"width:598px; height:868px;\" src=\"images/RHEUM/99447_Gluccr_injct_grt_trchn_pn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glucocorticoid injection for greater trochanteric pain syndrome.<br />(A) The shaded area indicates the&nbsp;superoposterior facet (posterior&nbsp;corner) of the greater trochanter.<br />(B) After preparation of the injection site with iodine or chlorhexidine, the needle is directed towards the superoposterior facet of the greater trochanter. From there, the needle is moved back and forth while small volumes are injected in a radial manner around the base of a cone approximately 2.5 cm in diameter. We use a glucocorticoid dose of 40 mg of methylprednisolone or equivalent mixed with 5 mL of 1% lidocaine. We prefer using a 22-gauge, 1.5-inch needle.</div><div class=\"graphic_reference\">Courtesy of Juan Canoso, MD.</div><div id=\"graphicVersion\">Graphic 99447 Version 2.0</div></div></div>"},"99481":{"type":"graphic_picture","displayName":"Palmoplantar psoriasis","title":"Palmoplantar psoriasis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Palmoplantar psoriasis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/99481_Palmoplantar_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly plaques with fissures on the palms and soles.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99481 Version 2.0</div></div></div>"},"99490":{"type":"graphic_figure","displayName":"Sigmoid resection for cancer","title":"Sigmoid resection for tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sigmoid resection for tumor</div><div class=\"cntnt\"><img style=\"width:426px; height:528px;\" src=\"images/SURG/99490_Sigmoidectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sigmoid resection for cancer removes the sigmoid colon, including the associated mesentery, with the inferior mesenteric vessels&nbsp;ligated close to their origin to optimally resect lymphovascular tissue.</div><div id=\"graphicVersion\">Graphic 99490 Version 1.0</div></div></div>"},"99491":{"type":"graphic_algorithm","displayName":"Evaluation of anemia in the adult","title":"Evaluation of anemia in the adult according to the mean corpuscular volume","html":"<div class=\"graphic\"><div style=\"width: 1090px\" class=\"figure\"><div class=\"ttl\">Evaluation of anemia in the adult according to the mean corpuscular volume</div><div class=\"cntnt\"><img style=\"width:1070px; height:463px;\" src=\"images/HEME/99491_Evaluation_anemia_adult.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count; MCV: mean corpuscular volume; RBCs: red blood cells; Fe: iron; TIBC: total iron-binding capacity (transferrin); LDH: lactate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 99491 Version 1.0</div></div></div>"},"99495":{"type":"graphic_picture","displayName":"Penile tourniquet","title":"Penile tourniquet caused by balloon remnants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penile tourniquet caused by balloon remnants</div><div class=\"cntnt\"><img style=\"width:296px; height:724px;\" src=\"images/EM/99495_Penile_tourniquet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Swollen circumcised penis with balloon remnant tightly wound around the shaft in a seven year old boy.<br />(B) Balloon remnant after removal.<br />(C) Residual edema of the penile shaft after removal.</div><div class=\"graphic_reference\">Courtesy of Gary R Fleisher, MD.</div><div id=\"graphicVersion\">Graphic 99495 Version 2.0</div></div></div>"},"99496":{"type":"graphic_figure","displayName":"Immunoglobulin levels in the fetus and infant in the first year","title":"Immunoglobulin (IgG, IgM, IgA) levels in the fetus and infant in the first year of life","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin (IgG, IgM, IgA) levels in the fetus and infant in the first year of life</div><div class=\"cntnt\"><img style=\"width:621px; height:497px;\" src=\"images/ALLRG/99496_Immnglblninfnt1styred1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The IgG of the fetus and newborn infant is solely of maternal origin. Maternal IgG disappears by nine months of age, by which time endogenous synthesis of IgG is well established. IgM and IgA in the neonate are entirely endogenously synthesized because maternal IgM and IgA do not cross the placenta.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgM: immunoglobulin M; IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Modified with permission from: Schneider LC, TePas EC, Umetsu DT. Allergy and Immunology. In: Pediatrics for Medical Students, 3rd ed, Bernstein D, Shelov SP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 99496 Version 6.0</div></div></div>"},"99497":{"type":"graphic_diagnosticimage","displayName":"Histopathology of Alzheimer disease","title":"Photomicrograph of human brain with Alzheimer disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph of human brain with Alzheimer disease</div><div class=\"cntnt\"><img style=\"width:259px; height:189px;\" src=\"images/NEURO/99497_Phtmcrgr_hmn_brn_Alzhmr_dss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of human brain with Alzheimer disease following Beilchowsky stain. The stain highlights an extracellular neuritic plaque (upper right) and an&nbsp;intraneuronal neurofibrillary tangle (lower left).</div><div id=\"graphicVersion\">Graphic 99497 Version 3.0</div></div></div>"},"99498":{"type":"graphic_table","displayName":"Clinical characteristics of primary immunodeficiencies","title":"Clinical characteristics of primary immunodeficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics of primary immunodeficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">B cell defects</td> </tr> <tr> <td class=\"indent1\">Recurrent pyogenic infections with extracellular encapsulated organisms, such as <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em> type b, and group A <em>Streptococcus</em>.</td> </tr> <tr> <td class=\"indent1\">Otitis, sinusitis, recurrent pneumonia, bronchiectasis, and conjunctivitis.</td> </tr> <tr> <td class=\"indent1\">Few problems with fungal or viral infections (except enterovirus and poliomyelitis).</td> </tr> <tr> <td class=\"indent1\">Diarrhea common, especially secondary to infection with <em>Giardia lamblia</em>.</td> </tr> <tr> <td class=\"indent1\">Minimal growth retardation.</td> </tr> <tr> <td class=\"indent1\">Compatible with survival to adulthood or for several years after onset unless complications occur.</td> </tr> <tr> <td class=\"subtitle1_single\">Complement defects</td> </tr> <tr> <td class=\"indent1\">Recurrent bacterial infections with extracellular encapsulated organisms, such as <em>S. pneumoniae</em> and <em>H. influenzae</em>.</td> </tr> <tr> <td class=\"indent1\">Susceptibility to recurrent infections with <em>Neisseria meningitides</em>.</td> </tr> <tr> <td class=\"indent1\">Increased incidence of autoimmune disease.</td> </tr> <tr> <td class=\"indent1\">Severe or recurrent skin and respiratory tract infection.</td> </tr> <tr> <td class=\"subtitle1_single\">T cell defects</td> </tr> <tr> <td class=\"indent1\">Recurrent infections with less virulent or opportunistic organisms, such as fungi, <em>Candida </em>sp mycobacteria, viruses, and protozoa as well as bacteria.</td> </tr> <tr> <td class=\"indent1\">Growth retardation, malabsorption, diarrhea, and failure to thrive common.</td> </tr> <tr> <td class=\"indent1\">Anergy.</td> </tr> <tr> <td class=\"indent1\">Susceptible to graft-versus-host disease from nonirradiated blood or from maternal engraftment.</td> </tr> <tr> <td class=\"indent1\">Fatal reactions may occur from live virus or Bacille Calmette-Gu&#233;rin vaccination.</td> </tr> <tr> <td class=\"indent1\">High incidence of malignancy.</td> </tr> <tr> <td class=\"indent1\">Poor survival beyond infancy or early childhood.</td> </tr> <tr> <td class=\"subtitle1_single\">Neutrophil defects</td> </tr> <tr> <td class=\"indent1\">Recurrent dermatologic infections with bacteria such as <em>Staphylococcus</em> spp, <em>Pseudomonas </em>spp, and <em>Escherichia coli</em>, and fungi such as <em>Aspergillus</em>.</td> </tr> <tr> <td class=\"indent1\"> <p>Subcutaneous, lymph node, lung, and liver abscesses.</p> Pulmonary infections common, including abscess and pneumatocele formation, contributing to chronic disease.</td> </tr> <tr> <td class=\"indent1\">Bone and joint infection common.</td> </tr> <tr> <td class=\"indent1\">Delayed separation of umbilical cord.</td> </tr> <tr> <td class=\"indent1\"> <p>Absence of pus at site(s) of infection.</p> Poor wound healing.</td> </tr> <tr> <td class=\"subtitle1_single\">Innate TLR signaling defects (eg, MyD88 and IRAK4 deficiencies)</td> </tr> <tr> <td class=\"indent1\">Early life infection with <em>Staphylococcus</em> spp, <em>Streptococcus</em> spp, and <em>Pseudomonas aeruginosa</em>.</td> </tr> <tr> <td class=\"indent1\">Impaired/delayed systemic response (fever, acute phase response [increased CRP]) to infection.</td> </tr> <tr> <td class=\"indent1\">Affects newborns, infants, and young children; lack of invasive infections after the teenage years.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TLR: Toll-like receptor; MyD88: myeloid differentiation primary response protein 88; IRAK4: interleukin-1 receptor associated kinase 4; CRP: C-reactive protein.</div><div class=\"graphic_reference\">Original figure modified for this publication. TePas EC, Umetsu DT. Immunology and Allergy. In: Nelson Essentials of Pediatrics, 4th ed, Behrman RE, Kliegman RM, WB Saunders Company, Philadelphia, 2002. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99498 Version 2.0</div></div></div>"},"99499":{"type":"graphic_table","displayName":"Clinical features of Parkinson disease dementia","title":"Clinical features of Parkinson disease dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical&nbsp;features of Parkinson disease dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cognitive features</td> <td class=\"subtitle1\">Behavioral features</td> </tr> <tr> <td> <p>Impaired attention</p> <p>Executive dysfunction</p> <p>Visuospatial dysfunction</p> Impaired verbal memory</td> <td> <p>Apathy</p> <p>Changes in mood, including depression or anxiety</p> <p>Visual hallucinations</p> <p>Paranoid delusions</p> <p>Excessive daytime sleepiness</p> Sleep disturbances, including fragmentation, nightmares, and REM sleep behavior disorder</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REM: Rapid eye movement.</div><div id=\"graphicVersion\">Graphic 99499 Version 1.0</div></div></div>"},"99506":{"type":"graphic_diagnosticimage","displayName":"Lateral radiograph avulsion fracture of the styloid of fibula","title":"Arcuate sign- avulsion fracture of the fibula on lateral radiograph","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Arcuate sign- avulsion fracture of the fibula on lateral radiograph</div><div class=\"cntnt\"><img style=\"width:723px; height:428px;\" src=\"images/RADIOL/99506_Lat_rd_avlsn_frctr_styld_fb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral radiograph of the knee (A) shows an avulsion fracture (arrow) of the styloid of the proximal fibula. Image B is a magnified view showing the avulsed fragment (arrow) and the irregular cortex of the donor site (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 99506 Version 1.0</div></div></div>"},"99507":{"type":"graphic_diagnosticimage","displayName":"MRI of complete LCL tear of the knee","title":"Complete LCL tear of the knee on MRI","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Complete LCL tear of the knee on MRI</div><div class=\"cntnt\"><img style=\"width:730px; height:334px;\" src=\"images/RADIOL/99507_MRI_complete_LCL_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal view of the right knee using proton density fat saturated sequence (PD FS, A) shows a complete tear of the lateral collateral ligament (arrowhead). Image B is a sagittal view using the same sequence, and shows the torn LCL with bulbous enlargement and redundancy of the distal portion of the ligament (arrowhead). Image C is a T1 weighted image in sagittal projection and shows the low intensity distal torn ligament (arrowhead) and the fibular head (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; PD FS: proton density fat saturated sequence; LCL: lateral collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 99507 Version 2.0</div></div></div>"},"99508":{"type":"graphic_algorithm","displayName":"Algorithm for follow-up of monochorionic twins","title":"Suggested algorithm for follow-up of monochorionic twins","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Suggested algorithm for follow-up of monochorionic twins</div><div class=\"cntnt\"><img style=\"width:594px; height:566px;\" src=\"images/OBGYN/99508_Algo_fllw_up_monochornc_twn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm illustrates the authors' approach for monitoring and timing delivery of monochorionic diamniotic twin pregnancies.</div><div class=\"graphic_footnotes\">* Routine use of MCA-PSV in the third trimester is controversial. Twin-twin transfusion syndrome, twin anemia polycythemia sequence, and selective fetal growth restriction are managed differently (refer to separate topic reviews on each disorder).</div><div id=\"graphicVersion\">Graphic 99508 Version 3.0</div></div></div>"},"99509":{"type":"graphic_diagnosticimage","displayName":"Type I endoleak after EVAR on CT scan","title":"Type I endoleak after EVAR on CT scan","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Type I endoleak after EVAR on CT scan</div><div class=\"cntnt\"><img style=\"width:723px; height:350px;\" src=\"images/RADIOL/99509_CT_typ_1_endvsclr_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the mid-abdomen (panel A) shows a large endovascular leak (arrowhead) originating from the posterior aspect of the endograft. Panel B is a coronal reconstruction of the CT scan and shows the leak originating between the covered stent (arrowhead) and fenestrated stent at the region of overlap (arrow).</div><div class=\"graphic_footnotes\">EVAR: endovascular aneurysm repair; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 99509 Version 4.0</div></div></div>"},"99511":{"type":"graphic_diagnosticimage","displayName":"Radiograph of thumb printing of the colon","title":"Thumb printing of the colon on radiograph","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Thumb printing of the colon on radiograph</div><div class=\"cntnt\"><img style=\"width:722px; height:427px;\" src=\"images/RADIOL/99511_Rdgrph_thmb_prntng_cln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-P view of the abdomen shows thumb printing of the transverse colon (arrows). Image B is a magnified view and highlights the thumb printing (arrows).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 99511 Version 1.0</div></div></div>"},"99514":{"type":"graphic_table","displayName":"Classification of HE variants","title":"Clinical classification of hereditary elliptocytosis variants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of hereditary elliptocytosis variants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Common hereditary elliptocytosis&nbsp;(HE)</td> <td class=\"subtitle1\" rowspan=\"2\">Hereditary pyropoikilocytosis (HPP)</td> <td class=\"subtitle1\" rowspan=\"2\">Spherocytic elliptocytosis</td> <td class=\"subtitle1\" rowspan=\"2\">Southeast Asian ovalocytosis (SAO)</td> </tr> <tr> <td class=\"subtitle2\">Heterozygous</td> <td class=\"subtitle2\">Homozygous or compound heterozygous (hemolytic HE)</td> </tr> <tr> <td><strong>Anemia</strong></td> <td>None to minimal</td> <td>Moderate to severe</td> <td>Severe</td> <td>Mild to moderate</td> <td>None</td> </tr> <tr> <td><strong>Hemolysis</strong></td> <td>None to mild; may have transient hemolysis during early infancy</td> <td>Moderate to severe</td> <td>Severe</td> <td>Mild to moderate</td> <td>None to mild; may have transient hemolysis during early infancy</td> </tr> <tr> <td><strong>Splenomegaly</strong></td> <td>Absent</td> <td>Present</td> <td>Present</td> <td>Present</td> <td>Absent</td> </tr> <tr> <td><strong>Peripheral smear and mean corpuscular volume (MCV)</strong></td> <td>Elliptocytes; MCV normal; may have transient poikilocytosis during early infancy</td> <td>Elliptocytes, red blood cell (RBC) fragments, and microelliptocytes; MCV low</td> <td>RBC budding and fragments, microspherocytes, and microelliptocytes; MCV very low (30 to 50 fL)</td> <td>Spherocytic elliptocytes; no fragments; MCV low</td> <td>Rounded ovalocytes and stomatocytic elliptocytes (with one or two transverse bars); MCV normal</td> </tr> <tr> <td><strong>Osmotic fragility</strong></td> <td>Normal</td> <td>Increased</td> <td>Increased</td> <td>Increased</td> <td>Normal to decreased</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for details of the evaluation and management of HE.</div><div class=\"graphic_reference\">Modified with permission from: Gallagher PG, Glader B. Hereditary spherocytes, hereditary elliptocytosis, and other disorders associated with abnormalities of the erythrocyte membrane. In: Wintrobe's Clinical Hematology, 13th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99514 Version 5.0</div></div></div>"},"99516":{"type":"graphic_table","displayName":"Hemodynamics in shock","title":"Hemodynamic profiles of shock on pulmonary artery catheter in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic profiles of shock on pulmonary artery catheter in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Physiologic variable</td> <td class=\"subtitle1\">Preload</td> <td class=\"subtitle1\">Pump function</td> <td class=\"subtitle1\">Afterload</td> <td class=\"subtitle1\">Tissue perfusion</td> </tr> <tr> <td class=\"subtitle2\">Clinical measurement</td> <td class=\"subtitle2\">Pulmonary capillary wedge pressure</td> <td class=\"subtitle2\">Cardiac output*</td> <td class=\"subtitle2\">Systemic vascular resistance</td> <td class=\"subtitle2\">Mixed venous oxyhemoglobin saturation<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Hypovolemic</td> <td class=\"centered\">&#8596; (early) or &#8595; (late)</td> <td class=\"centered\">&#8596; (early) or&nbsp;&#8595; (late)</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#62;65% (early) or &#60;65% (late)</td> </tr> <tr> <td class=\"indent2\">Cardiogenic</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#60;65%</td> </tr> <tr> <td class=\"indent2\">Distributive</td> <td class=\"centered\">&#8596; (early) or &#8595; (late)</td> <td class=\"centered\">&#8593; or &#8595; (occasionally)</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#62;65%</td> </tr> <tr> <td class=\"indent2\" colspan=\"5\">Obstructive</td> </tr> <tr> <td class=\"indent3\">PE, PH, tension pneumothorax</td> <td class=\"centered\">&#8596; (early) or &#8595; (late)</td> <td class=\"centered\">&#8596; (early) or &#8595; (late)</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#62;65%</td> </tr> <tr> <td class=\"indent3\">Pericardial tamponade<sup>&#916;</sup></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#60;65%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PE: pulmonary embolus; PH: pulmonary hypertension; PAC: pulmonary artery catheter.<br />* Cardiac output is generally measured using the cardiac index.<br />¶ Mixed venous oxyhemoglobin saturation cutoff measured on PAC is 65%, but on triple lumen catheter is 70%.<br />Δ Equalization of right atrial, right ventricular end-diastolic and pulmonary artery wedge pressures is classic in pericardial tamponade and distinguishes it from primary cardiogenic shock.<br /></div><div id=\"graphicVersion\">Graphic 99516 Version 3.0</div></div></div>"},"99517":{"type":"graphic_table","displayName":"Comparing response categories of WHO, RECIST, EASL, and mRECIST","title":"Comparing response assessment categories of WHO, RECIST, modified RECIST for HCC and EASL classifications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparing response assessment categories of WHO, RECIST, modified RECIST for HCC and EASL classifications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameters</td> <td class=\"subtitle1\">Baseline measurements</td> <td class=\"subtitle1\">Complete response (CR)</td> <td class=\"subtitle1\">Partial response (PR)</td> <td class=\"subtitle1\">Stable disease (SD)</td> <td class=\"subtitle1\">Progressive disease (PD)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Conventional criteria</td> </tr> <tr> <td class=\"indent1\">WHO</td> <td> <p>Measurable, bidimensional (product of LD and greatest perpendicular diameter)</p> Non-measurable/evaluable (eg, lymphangitic pulmonary metastases, abdominal masses)</td> <td>Measurable and non-measurable disease: Disappearance of all lesions, confirmed at &#8805;4 weeks</td> <td> <p>Measurable disease: &#8805;50% decrease in the sum of the area (longest diameters multiplied by longest perpendicular diameters), confirmed at &#8805;4 weeks</p> Non-measurable: Estimated &#8805;50% decrease confirmed at &#8805;4 weeks</td> <td>Neither PR nor PD (no change)</td> <td> <p>Measurable disease: &#8805;25% increase in the sum of the area of existent lesions, or new lesions</p> Non-measurable disease: Estimated increase &#8805;25%, or new lesions</td> </tr> <tr> <td class=\"indent1\">RECIST 1.0</td> <td> <p>Measurable, unidimensional (LD only, size with conventional techniques &#8805;20 mm, with spiral CT &#8805;10 mm)</p> <p>Target lesions: Up to 10; no more than 5 per organ</p> Non-measurable: All other lesions, including small lesions; evaluable is not recommended</td> <td>Target lesions: Disappearance of all lesions, confirmed at &#8805;4 weeks</td> <td>Target lesions: &#8805;30% decrease in the sum of the longest diameters, confirmed at &#8805;4 weeks</td> <td>Neither PR nor PD</td> <td>Target lesions: &#8805;20% increase in the sum of the longest diameters over the smallest sum observed, or new lesions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">RECIST 1.1</td> <td> <p>Measurable, unidimensional (LD only, size with conventional techniques &#8805;20 mm, with spiral CT &#8805;10 mm). For nodes, target = short axis &#177;15 mm; non-target 10 to 15 mm nodes; normal &#60;10 mm.</p> Non-measurable: All other lesions, including small lesions; evaluable is not recommended</td> <td>Disappearance of all lesions and pathological lymph nodes</td> <td>&#8805;30% decrease in the sum of the longest diameters</td> <td>Neither PR nor PD</td> <td>&#8805;20% increase in the sum of the longest diameters and &#8805;5 mm absolute increase in the sum of the longest diameters, or new lesions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Newer criteria<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">EASL</td> <td>Same as WHO</td> <td>Disappearance of all intratumoral arterial enhancement</td> <td>&#8805;50% decrease in the total tumor load of all measurable lesions (sum of the arterially enhancing areas, longest diameters multiplied by longest perpendicular diameters) determined by two observations, at least four weeks apart</td> <td>Neither PR nor PD</td> <td>&#8805;25% increase in the size of one or more arterially enhancing areas or development of a new lesion(s)</td> </tr> <tr> <td class=\"indent1\">mRECIST</td> <td>Same as RECIST 1.1</td> <td>Disappearance of any intratumoral arterial enhancement in all target lesions</td> <td>At least a 30% decrease in the sum of diameters of viable (enhancing) target lesions, taking as reference the baseline sum of the target lesions</td> <td>Neither PR nor PD</td> <td>&#8805;20% increase in the sum of the diameters of viable target lesions recorded since treatment initiation, or development of a new lesion(s)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Heath Organization; RECIST: Response Evaluation Criteria In Solid Tumor; EASL: European Association for the Study of the Liver; mRECIST: modified Response Evaluation Criteria in Solid Tumors for hepatocellular carcinoma; LD: longest diameter; NC: no change.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Yaghmai V, Besa C, Kim E, et al. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 2013; 201:80.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99517 Version 3.0</div></div></div>"},"99530":{"type":"graphic_diagnosticimage","displayName":"VFS showing laryngeal penetration and aspiration","title":"Laryngeal penetration and aspiration on VFS","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Laryngeal penetration and aspiration on VFS</div><div class=\"cntnt\"><img style=\"width:718px; height:296px;\" src=\"images/RADIOL/99530_VFS_shw_lryngl_pntrt_asprtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal reconstruction of a CT scan of the neck shows the normal structures involved in the swallowing mechanism, including the epiglottis (arrowhead), vestibule (v), esophagus (e), location of true and false cords (dashed arrow), and trachea (t). Image B is from a VFS study showing deep laryngeal penetration (arrow). The epiglottis is deflected (arrowhead), the vestibule (v) is closed, and the esophagus (e) is filled with contrast. Image C shows abnormal accumulation of contrast in the vestibule (arrow) as well as on the false cords (dashed arrow). The epiglottis (arrowhead) is relaxed. Image D shows aspiration into the trachea.</div><div class=\"graphic_footnotes\">CT: computed tomography; VFS: videofluoroscopic evaluation of swallowing.</div><div class=\"graphic_reference\">Image D courtesy of Tessa Goldsmith, MA, CCC-SLP.</div><div id=\"graphicVersion\">Graphic 99530 Version 1.0</div></div></div>"},"99531":{"type":"graphic_diagnosticimage","displayName":"VFS showing aspiration","title":"Aspiration on VFS","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Aspiration on VFS</div><div class=\"cntnt\"><img style=\"width:527px; height:371px;\" src=\"images/RADIOL/99531_VFS_showing_aspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal view of the pharynx and larynx (A) during VFS shows normal appearance of barium coating valleculae (v), pyriform sinuses (p), and arch of the superior border of the epiglottis (arrow). Image A also shows the region of the vocal cords (arrowhead) and the trachea (t). Image B demonstrates aspiration with barium coating the vestibule (large arrowheads), in the laryngeal ventricle (small arrowhead), and in the trachea (dashed arrow). There is normal contrast coating of the valleculae and pyriform sinuses (p).</div><div class=\"graphic_footnotes\">VFS: videofluoroscopic evaluation of swallowing.</div><div id=\"graphicVersion\">Graphic 99531 Version 1.0</div></div></div>"},"99532":{"type":"graphic_figure","displayName":"Genetic defects that impair lipid metabolism","title":"Sites of genetic defects that impair lipid metabolism in muscle","html":"<div class=\"graphic\"><div style=\"width: 832px\" class=\"figure\"><div class=\"ttl\">Sites of genetic defects that impair lipid metabolism in muscle</div><div class=\"cntnt\"><img style=\"width:812px; height:624px;\" src=\"images/NEURO/99532_Gen_def_impair_lipid_metab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overview of fat utilization in skeletal muscle indicating sites of genetic defects that impair fat metabolism.</div><div class=\"graphic_footnotes\">ATGL: adipose triglyceride lipase; Carn: carnitine; CoA: coenzyme A; CPT1: carnitine palmitoyl transferase 1; CPT2: carnitine palmitoyl transferase 2; Cyt <em>c</em>: cytochrome <em>c</em>; enolyl CoA, 3-hydroxy FA-CoA, 3 keto FA-CoA are intermediates in beta oxidation ultimately yielding acetyl-acyl-coenzyme A (for oxidation by the tricarboxylic acid cycle and a fatty acyl-coenzyme A (FA-CoA) shortened by two carbons for further beta oxidation; ETF: electron transfer flavoprotein (receives electrons from the dehydrogenase reaction catalyzed by VLCAD, MCAD and SCAD); ETFDH: electron transfer flavoprotein dehydrogenase (receives electrons from ETF, transfers them to coenzyme Q10 for oxidation via respiratory chain complexes III and IV); FFA: free fatty acid; GCI-58: protein involved in activation of ATGL; LCHAD: long chain hydroxy-acyl-coenzyme A dehydrogenase, one of the three enzymatic reactions (indicated by stars) catalyzed by mitochondrial trifunctional protein; LPIN1: protein involved in triglyceride synthesis; MCAD and SCAD: medium and short chain acyl-coenzyme A dehydrogenase; NADH: nicotinamide adenine dinucleotide; NADH produced in the reaction catalyzed by LCHAD is oxidized via complex I of the respiratory chain; OCTN2: carnitine transporter; Translocase: the carnitine, fatty acyl-coenzyme A transferase; VLCAD: very long chain acyl-coenzyme A dehydrogenase.</div><div class=\"graphic_reference\">Reproduced from: Sharp LJ, Haller RG. Metabolic and mitochondrial myopathies. Neurol Clin 2014; 32:777. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99532 Version 1.0</div></div></div>"},"99533":{"type":"graphic_algorithm","displayName":"Recommendations for ICDs in patients with Brugada syndrome","title":"Consensus recommendations for implantable cardioverter-defibrillators (ICDs) in patients diagnosed with Brugada syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Consensus recommendations for implantable cardioverter-defibrillators (ICDs) in patients diagnosed with Brugada syndrome</div><div class=\"cntnt\"><img style=\"width:350px; height:340px;\" src=\"images/CARD/99533_Recommend_ICDs_Brugada_synd.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; EP: electrophysiology; ICD: implantable cardioverter defibrillator; SCD: sudden cardiac death; VF: ventricular fibrillation; VT: ventricular tachycardia.</div><div class=\"graphic_reference\">Reproduced from: Priori S, Wilde A, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm 2013; 10:1932. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99533 Version 1.0</div></div></div>"},"99534":{"type":"graphic_figure","displayName":"Pyramid profile risk stratification for ICDs and SCD prevention","title":"Pyramid profile of risk stratification model currently used to identify patients at the highest sudden cardiac death (SCD) risk who may be candidates for an implantable cardioverter-defibrillator (ICD)","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">Pyramid profile of risk stratification model currently used to identify patients at the highest sudden cardiac death (SCD) risk who may be candidates for an implantable cardioverter-defibrillator (ICD)</div><div class=\"cntnt\"><img style=\"width:840px; height:396px;\" src=\"images/CARD/99534_Pyramid_profile_ICDs_SD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Major and minor risk markers appear in boxes at the left. At the right are the results of ICD therapy in 730 children, adolescents, and adults assembled from two registry studies.</div><div class=\"graphic_footnotes\">BP: blood pressure; CAD: coronary artery disease; EF: ejection fraction; ICD: implantable cardioverter-defibrillator; LV: left ventricular; LGE: late gadolinium enhancement; LVH: left ventricular hypertrophy; NSVT: nonsustained ventricular tachycardia; SD: sudden death; VT/VF: ventricular tachycardia/ventricular fibrillation.<br />* Extensive LGE is a novel primary risk marker that can also be used as an arbitrator when conventional risk assessment is ambiguous.<br />¶ SD events are uncommon after 60 years of age, even with conventional risk factors.</div><div class=\"graphic_reference\">Reproduced from: Maron B, Ommen S, Semsarian C. Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014; 64:83. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99534 Version 2.0</div></div></div>"},"99536":{"type":"graphic_table","displayName":"Patients requiring antibiotic prophylaxis for endoscopy","title":"Patients who require antibiotic prophylaxis for endoscopic procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patients who require antibiotic prophylaxis for endoscopic procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient group</td> <td class=\"subtitle1\">Procedures that require prophylaxis</td> <td class=\"subtitle1\">Comments*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Specific patient groups</td> </tr> <tr> <td class=\"indent1\">Patients with cirrhosis and acute GI bleeding</td> <td>All endoscopic procedures</td> <td>Patients with cirrhosis and acute GI bleeding require antibiotics as part of their routine treatment, even if they are not undergoing an endoscopic examination.</td> </tr> <tr> <td class=\"indent1\">Cirrhosis with ascites</td> <td>Procedures that are high risk for infection or bacteremia<sup>&#182;</sup></td> <td>Studies supporting using prophylactic antibiotics in patients with cirrhosis and ascites are lacking. We believe it is prudent to provide prophylaxis in this group of patients, given the risk of bacterial translocation.</td> </tr> <tr> <td class=\"indent1\"> <p>Severe neutropenia (ANC &#60;500 cells/mm<sup>3</sup>)</p> Advanced hematologic malignancy</td> <td>Procedures that are high risk for infection or bacteremia<sup>&#182;</sup></td> <td> <p>Studies supporting using prophylactic antibiotics in patients at increased risk for infection are lacking. We believe it is prudent to provide prophylaxis in this group of patients, given their increased risk for infection.</p> Prophylaxis is not recommended for patients who are immunocompromised for other reasons.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Synthetic vascular grafts within six months of graft placement</td> <td>Procedures that are high risk for infection or bacteremia<sup>&#182;</sup></td> <td> <p>When possible, elective procedures should be performed before a synthetic graft is placed or delayed for six months following graft placement.</p> <p>The AHA recommends antibiotic prophylaxis within six months of placement of a vascular graft for all endoscopic procedures. The ASGE does not recommend antibiotic prophylaxis following graft placement.</p> No prophylaxis is needed after six months.</td> </tr> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Patients/conditions that require prophylaxis</td> <td class=\"subtitle1\">Comments*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">For patients NOT falling into one of the above mentioned groups</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Upper endoscopy</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>With or without biopsy, polypectomy, esophageal stricture dilation, endoscopic sclerotherapy, or band ligation of varices </li> </ul> </td> <td>None</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>With PEG/PEJ tube insertion </li> </ul> </td> <td>All patients</td> <td>The ASGE guidelines recommend pre-procedural screening for MRSA in areas where MRSA is endemic and attempting decontamination before placing the feeding tube.</td> </tr> <tr> <td class=\"indent1\">Colonoscopy or flexible sigmoidoscopy, with or without biopsy or polypectomy</td> <td>None</td> <td>Patients undergoing peritoneal dialysis should have the procedure done with the peritoneum empty. However, this recommendation differs from that of the ASGE, which recommends antibiotic prophylaxis for patients undergoing peritoneal dialysis prior to lower GI endoscopy, and the ISPD, which recommends antibiotic prophylaxis for patients undergoing colonoscopy with polypectomy.</td> </tr> <tr> <td class=\"indent1\">ERCP</td> <td> <p>Cholangitis</p> <p>Biliary obstruction without cholangitis if complete drainage is unlikely (eg, in patients with malignant hilar carcinoma or primary sclerosing cholangitis)</p> Biliary complications following liver transplantation if drainage is unlikely</td> <td> <p>Patients with cholangitis should receive antibiotics as part of their routine treatment. Additional prophylaxis is not required.</p> If drainage is not successful, antibiotics should be started. Once drainage has been established, antibiotics can be discontinued if there is no cholangitis.</td> </tr> <tr> <td class=\"indent1\">EUS-FNA of cystic lesions</td> <td>Mediastinal cysts</td> <td> <p>The ASGE recommends antibiotic prophylaxis for all patients undergoing EUS-FNA of cystic lesions. However, we reserve it for patients with mediastinal cysts since they appear to be at increased risk of infection. We do not provide antibiotic prophylaxis for EUS-FNA of pancreatic cysts because there are insufficient data to support their use in this setting.</p> Antibiotics are typically continued for three to five days after the procedure.</td> </tr> <tr> <td class=\"indent1\">EUS-FNA of solid lesions along the GI tract</td> <td>None</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Interventional EUS procedures<sup>&#916;</sup>, natural orifice transluminal endoscopic surgery (NOTES)</td> <td>All patients</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Refer to other table on antibiotic prophylaxis for endoscopic procedures for specific regimens.</div><div class=\"graphic_footnotes\">GI: gastrointestinal; ANC: absolute neutrophil count; AHA: American Heart Association; ASGE: American Society for Gastrointestinal Endoscopy; PEG: percutaneous endoscopic gastrostomy; PEJ: percutaneous endoscopic jejunostomy; MRSA: methicillin-resistant <em>Staphylococcus aureus</em>; ISPD: the International Society for Peritoneal Dialysis; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; FNA: fine-needle aspiration.<br />* The recommendations in this table are generally consistent with guidelines from the ASGE and AHA except as noted here.<br />&para; Procedures that are high risk for bacteremia or infection include dilation of esophageal strictures, endoscopic sclerotherapy, ERCP, EUS-FNA, and PEG/PEJ tube placement.<br />&Delta; Interventional EUS procedures include drainage of walled-off pancreatic necrosis, biliary drainage, and fine-needle injection of cysts/tumors.</div><div class=\"graphic_reference\">Recommendations summarized from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>ASGE Standards of Practice Committee, Khashab MA, Chithadi KV, et al. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc 2015; 81:81.</li>&#xD;&#xA;    <li>Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.</li>&#xD;&#xA;    <li>Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:887.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99536 Version 4.0</div></div></div>"},"99540":{"type":"graphic_figure","displayName":"Uterine vessels, ureter, uterus after cesarean delivery","title":"Uterine vessels, ureter, uterus after cesarean delivery","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Uterine vessels, ureter, uterus after cesarean delivery</div><div class=\"cntnt\"><img style=\"width:511px; height:499px;\" src=\"images/OBGYN/99540_Uterine_vessels_after_cesarean.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99540 Version 4.0</div></div></div>"},"99545":{"type":"graphic_figure","displayName":"Pelvis anatomy","title":"Pelvis anatomy","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Pelvis anatomy</div><div class=\"cntnt\"><img style=\"width:483px; height:547px;\" src=\"images/EM/99545_Pelvis_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99545 Version 2.0</div></div></div>"},"99546":{"type":"graphic_figure","displayName":"Hip flexor muscles anatomy","title":"Hip flexor muscles anatomy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hip flexor muscles anatomy</div><div class=\"cntnt\"><img style=\"width:504px; height:712px;\" src=\"images/EM/99546_Flexor_muscles_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99546 Version 1.0</div></div></div>"},"99547":{"type":"graphic_figure","displayName":"Hip adductor muscle anatomy","title":"Hip adductor muscle anatomy","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Hip adductor muscle anatomy</div><div class=\"cntnt\"><img style=\"width:524px; height:621px;\" src=\"images/EM/99547_Adductor_muscle_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99547 Version 1.0</div></div></div>"},"99548":{"type":"graphic_figure","displayName":"Abdominal muscles anatomy","title":"Abdominal muscles anatomy","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Abdominal muscles anatomy</div><div class=\"cntnt\"><img style=\"width:480px; height:488px;\" src=\"images/EM/99548_Abdominal_muscles_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three layered muscles&nbsp;form the lateral abdominal wall. From superficial to deep, these include the external oblique, internal oblique, and the transversus abdominis. Located more centrally is the rectus abdominis. </div><div id=\"graphicVersion\">Graphic 99548 Version 2.0</div></div></div>"},"99549":{"type":"graphic_picture","displayName":"Polymorphous light eruption pinpoint papules","title":"Polymorphous light eruption","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Polymorphous light eruption</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99549_PMLE_pinpoint_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with darker skin tones, PMLE may present as pinpoint papules.</div><div class=\"graphic_footnotes\">PMLE: polymorphous light eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99549 Version 3.0</div></div></div>"},"99550":{"type":"graphic_picture","displayName":"Malignant pleural involvement by NSCLC","title":"Malignant pleural involvement by NSCLC","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Malignant pleural involvement by NSCLC</div><div class=\"cntnt\"><img style=\"width:577px; height:533px;\" src=\"images/ONC/99550_Mlgnnt_plrl_invlv_NSCLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pleuroscopy image showing extensive pleural studding by non-small cell lung cancer (NSCLC) in a patient with a cytologically negative pleural effusion. (Courtesy of Professor Philippe Astoul).</div><div id=\"graphicVersion\">Graphic 99550 Version 1.0</div></div></div>"},"99552":{"type":"graphic_figure","displayName":"Imaging response criteria in evaluation of HCC after treatment","title":"Imaging response criteria used in evaluation of HCC after treatment","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Imaging response criteria used in evaluation of HCC after treatment</div><div class=\"cntnt\"><img style=\"width:463px; height:427px;\" src=\"images/ONC/99552_Imaging_response_critieria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic representation of&nbsp;different imaging response&nbsp;assessment&nbsp;criteria used in evaluation of hepatocellular carcinoma (HCC) after treatment: World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), European Association for the Study of the Liver (EASL), and modified RECIST for HCC. A partially necrotic (<EM innerHtml>black) </EM>HCC with an arterially-enhancing (viable) component <EM innerHtml>(white) </EM>is shown. The arrows illustrate different measurements obtained for assessment of response&nbsp;according to&nbsp;the various criteria. WHO measures two perpendicular dimensions of the entire lesion;&nbsp;RECIST measures the single largest dimension of the entire&nbsp;lesion; EASL measures perpendicular dimensions of just the enhancing (viable) tumor; modified RECIST measures one single largest dimension of the enchancing tumor. Both EASL criteria and modified RECIST are based upon measurements obtained using cross sectional imaging (CT or MRI) and contrast-enhanced arterial phase images.</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva, 1979.</LI>&#xD;&#xA;<LI>Yaghmai V, Besa C, Kim E, et al. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 2013; 201:80.</LI></OL></div><div id=\"graphicVersion\">Graphic 99552 Version 1.0</div></div></div>"},"99558":{"type":"graphic_diagnosticimage","displayName":"Radiography and CT of a calcified pulmonary granuloma","title":"Radiography and CT of calcified pulmonary granuloma","html":"<div class=\"graphic\"><div style=\"width: 811px\" class=\"figure\"><div class=\"ttl\">Radiography and CT of calcified pulmonary granuloma</div><div class=\"cntnt\"><img style=\"width:791px; height:531px;\" src=\"images/RADIOL/99558_Imaging_calcifd_granulm_ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary granuloma. Chest radiograph AP view shows a well-circumscribed calcified nodule in the left upper lobe (arrow). Images from a chest CT without contrast viewed in lung (B) and soft tissue (C) windows shows the calcified granuloma (arrow) and ipsilateral calcified aortopulmonary lymph nodes (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 99558 Version 2.0</div></div></div>"},"99561":{"type":"graphic_diagnosticimage","displayName":"CT of a cavitating atypical mycobacterium pulmonary nodule","title":"CT of a cavitating atypical mycobacterium pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">CT of a cavitating atypical mycobacterium pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:751px; height:468px;\" src=\"images/RADIOL/99561_CT_atypcl_mycbctrm_edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical mycobacterium. Chest CT with contrast shows a 2.8 cm nodule (arrow) and punctate calcification (arrowhead). Central lucency within the nodule indicates cavitation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 99561 Version 2.0</div></div></div>"},"99563":{"type":"graphic_diagnosticimage","displayName":"Radiography and CT of a pulmonary hamartoma","title":"Radiography and CT of a pulmonary hamartoma","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Radiography and CT of a pulmonary hamartoma</div><div class=\"cntnt\"><img style=\"width:766px; height:236px;\" src=\"images/RADIOL/99563_Imaging_hamartoma_edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary hamartoma. A chest radiograph PA (A) and lateral (B) projections shows a 3 cm nodule with popcorn calcification (arrow) in the right lower lobe. Chest CT with contrast (C) performed two years later shows the nodule (arrow) unchanged in size and appearance.</div><div class=\"graphic_footnotes\">CT: computed tomography; PA: posteroanterior.</div><div id=\"graphicVersion\">Graphic 99563 Version 2.0</div></div></div>"},"99565":{"type":"graphic_diagnosticimage","displayName":"Radiography, CT and angiography of an arteriovenous malformation","title":"Radiography, CT and angiography of an arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Radiography, CT and angiography of an arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:723px; height:374px;\" src=\"images/RADIOL/99565_Imaging_AVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary arteriovenous malformation. Chest radiograph AP view (A) shows a right lung nodule (arrow). Chest CT coronal reconstruction (B) and axial (C) images shows the nodule (arrow) with a feeding artery (dashed arrow) and large draining vein (arrowhead).&nbsp;A pulmonary angiogram of another patient in the arterial phase (D) shows&nbsp;arteriovenous malformations of the&nbsp;right lower&nbsp;(arrow) and left upper (arrowhead) lobes.</div><div class=\"graphic_footnotes\">CT: computed tomography; AP: anteroposterior.</div><div class=\"graphic_reference\">Images A, B, and C courtesy of Scott Sequerra, MD.</div><div id=\"graphicVersion\">Graphic 99565 Version 3.0</div></div></div>"},"99566":{"type":"graphic_diagnosticimage","displayName":"Radiography and CT of a benign pulmonary nodule","title":"Radiography and CT of a benign pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Radiography and CT of a benign pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:725px; height:316px;\" src=\"images/RADIOL/99566_Imag_benign_lobulated_SPN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Benign pulmonary nodule.&nbsp;Chest&nbsp;radiograph&nbsp;PA&nbsp;view&nbsp;(A) and CT (B) shows a 30mm&nbsp;nodule&nbsp;in the left upper lobe (arrow) that was unchanged in size and appearance for over two years.</div><div class=\"graphic_footnotes\">CT: computed tomography; PA: posteroanterior.</div><div id=\"graphicVersion\">Graphic 99566 Version 3.0</div></div></div>"},"99567":{"type":"graphic_diagnosticimage","displayName":"Radiography and CT of a fat-containing benign pulmonary nodule","title":"Radiography and CT of a fat-containing benign pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">Radiography and CT of a fat-containing benign pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:780px; height:532px;\" src=\"images/RADIOL/99567_Imag_benign_ftty_lesion_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Benign pulmonary nodule. PA chest radiograph (A) shows&nbsp;a solid nodule&nbsp;(arrow) in the lingula (arrow).&nbsp;Images from a chest CT with contrast viewed in lung (C) and soft tissue (C)&nbsp;windows&nbsp;shows a solid nodule (arrow) measuring -30 HU, consistent with&nbsp;fat.&nbsp; The nodule was stable over two years.</div><div class=\"graphic_footnotes\">PA: posteroanterior; CT: computed tomography; HU: Hounsfield units.</div><div id=\"graphicVersion\">Graphic 99567 Version 2.0</div></div></div>"},"99574":{"type":"graphic_table","displayName":"Classification of shock","title":"Classification of shock","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of shock</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"12%\"></colgroup><colgroup width=\"76%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" rowspan=\"2\">Distributive</td> <td><strong>Septic</strong></td> <td> <ul> <li>Gram positive (<em>Pneumococcus</em>, <em>Staphylococcus</em>, <em>Streptococcus</em>, <em>Enterococcus</em>, <em>Legionella</em>, <em>Listeria</em>) </li> <li>Gram negative (<em>Klebsiella</em>, <em>Pseudomonas</em>, <em>Escherichia</em>, <em>Haemophilus</em>, <em>Neisseria</em>, <em>Moraxella</em>, <em>Rickettsia</em>, <em>Francisella</em> [<em>tularemia</em>]) </li> <li>Fungal (<em>Candida</em>, <em>Aspergillus</em>) </li> <li>Viral (influenza, cytomegalovirus, Ebola, varicella) </li> <li>Parasitic (<em>Plasmodium</em>, <em>Ascaris</em>, <em>Babesia</em>) </li> <li>Mycobacterium (<em>Mycobacterium tuberculosis</em>, <em>Mycobacterium abscessus</em>) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Non-septic</strong></td> <td> <ul> <li>Inflammatory shock (systemic inflammatory response syndrome) &ndash; Burns, trauma, pancreatitis, postmyocardial infarction, post coronary bypass, post cardiac arrest, viscus perforation, amniotic fluid embolism, fat embolism, idiopathic systemic capillary leak syndrome </li> <li>Neurogenic shock &ndash; Traumatic brain injury, spinal cord injury (quadriparesis with bradycardia or paraplegia with tachycardia), neuro-axial anesthesia </li> <li>Anaphylactic shock - IgE-mediated (eg, foods, medications, insect bites or stings), <span style=\"color: black;\">IgE-</span><span style=\"color: black;\">independent </span>(eg, iron dextran), nonimmumnologic (eg, exercise or heat-induced), idiopathic </li> <li>Other &ndash; Liver failure, transfusion reactions, vasoplegia (eg, vasodilatory agents, cardiopulmonary bypass), toxic shock syndrome, toxicologic (eg, heavy metals), beriberi </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" rowspan=\"3\">Cardiogenic</td> <td><strong>Cardiomyopathic</strong></td> <td> <ul> <li>Myocardial infarction (involving &#62;40% of the left ventricle or with extensive ischemia) </li> <li>Severe right ventricle infarction </li> <li>Acute exacerbation of severe heart failure from dilated cardiomyopathy </li> <li>Stunned myocardium from prolonged ischemia (eg, cardiac arrest, hypotension, cardiopulmonary bypass) </li> <li>Advanced septic shock </li> <li>Myocarditis </li> <li>Myocardial contusion </li> <li>Drug-induced (eg, beta blockers) </li> </ul> </td> </tr> <tr> <td><strong>Arrhythmogenic</strong></td> <td> <ul> <li>Tachyarrhythmia &ndash; Atrial tachycardias (fibrillation, flutter, reentrant tachycardia), ventricular tachycardia and fibrillation </li> <li>Bradyarrhythmia &ndash; Complete heart block, Mobitz type II second degree heart block </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mechanical</strong></td> <td> <ul> <li>Severe valvular insufficiency, acute valvular rupture (papillary or chordae tendineae rupture, valvular abscess), critical valvular stenosis, acute or severe ventricular septal wall defect, ruptured ventricular wall aneurysm, atrial myxoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" rowspan=\"2\">Hypovolemic</td> <td><strong>Hemorrhagic</strong></td> <td> <ul> <li>Trauma, gastrointestinal bleeding (eg, varices, peptic ulcer), intraoperative and postoperative bleeding, retroperitoneal bleeding (eg, ruptured aortic aneurysm), aortic-enteric fistula, hemorrhagic pancreatitis, iatrogenic (eg, inadvertent biopsy of arteriovenous malformation, or left ventricle), tumor or abscess erosion into major vessels, ruptured ectopic pregnancy, postpartum hemorrhage, uterine or vaginal hemorrhage (eg, infection, tumors, lacerations), spontaneous peritoneal hemorrhage from bleeding diathesis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Non-hemorrhagic</strong></td> <td> <ul> <li>Gastrointestinal losses (eg, diarrhea, vomiting, external drainage); skin losses (eg, heat stroke, burns, dermatologic conditions); renal losses (eg, excessive drug-induced or osmotic diuresis, salt-wasting nephropathies, hypoaldosteronism); third space losses into the extravascular space or body cavities (eg, postoperative and trauma, intestinal obstruction, crush injury, pancreatitis, cirrhosis) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" rowspan=\"2\">Obstructive</td> <td><strong>Pulmonary vascular</strong></td> <td> <ul> <li>Hemodynamically significant pulmonary embolus, severe pulmonary hypertension, severe or acute obstruction of the pulmonic or tricuspid valve, venous air embolus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mechanical</strong></td> <td> <ul> <li>Tension pneumothorax or hemothorax (eg, trauma, iatrogenic), pericardial tamponade, constrictive pericarditis, restrictive cardiomyopathy, severe dynamic hyperinflation (eg, elevated intrinsic PEEP), left or right ventricular outflow tract obstruction, abdominal compartment syndrome, aorto-caval compression (eg, positioning, surgical retraction) </li> </ul> </td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size: 1.2em; vertical-align: middle;\"><strong>Mixed/unknown</strong></td> <td>&nbsp;</td> <td> <ul> <li>Endocrine (eg, adrenal insufficiency, thyrotoxicosis, myxedema coma) </li> <li>Metabolic (eg, acidosis, hypothermia) </li> <li>Other - Polytrauma with more than one shock category, acute shock etiology with pre-existing cardiac disease, late under-resuscitated shock, miscellaneous poisonings </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Aortic dissection causes shock when retrograde dissection results in cardiac tamponade, acute aortic insufficiency, and myocardial infarction; please refer to the UpToDate topic text for details.</div><div class=\"graphic_footnotes\">PEEP: positive end-expiratory pressure.</div><div id=\"graphicVersion\">Graphic 99574 Version 4.0</div></div></div>"},"99575":{"type":"graphic_figure","displayName":"Face presentation","title":"Face presentation","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Face presentation</div><div class=\"cntnt\"><img style=\"width:530px; height:441px;\" src=\"images/OBGYN/99575_Face_presentation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99575 Version 2.0</div></div></div>"},"99600":{"type":"graphic_figure","displayName":"Stratification of sorafenib response mRECIST, AFP, and CP score","title":"Stratification of sorafenib response in advanced hepatocellular carcinoma by the combination of modified RECIST for hepatocellular carcinoma (mRECIST), serum alfa-fetoproteini (AFP), and Child-Pugh (CP) score","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Stratification of sorafenib response in advanced hepatocellular carcinoma by the combination of modified RECIST for hepatocellular carcinoma (mRECIST), serum alfa-fetoproteini (AFP), and Child-Pugh (CP) score</div><div class=\"cntnt\"><img style=\"width:481px; height:497px;\" src=\"images/ONC/99600_Strt_srfn_rs_mRECIST_AFP_CP.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RECIST: Response evaluation criteria in solid tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and alpha[1]-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib. Oncology 2012; 83:192. Copyright &copy; 2012 S. Karger AG Basel.</div><div id=\"graphicVersion\">Graphic 99600 Version 1.0</div></div></div>"},"99602":{"type":"graphic_diagnosticimage","displayName":"Subtraction MRI of large HCC before and after chemoembolization","title":"Dynamic (gadolinium-enhanced) subtraction magnetic resonance imaging (MRI) of large hepatocellular carcinoma before and after transarterial chemoembolization (TACE)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Dynamic (gadolinium-enhanced) subtraction magnetic resonance imaging (MRI) of large hepatocellular carcinoma before and after transarterial chemoembolization (TACE)</div><div class=\"cntnt\"><img style=\"width:720px; height:682px;\" src=\"images/ONC/99602_Sub_MRI_lrg_HCC_bfr_aft_chm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pre-treatment axial gadolinium-enhanced arterial phase MRI of a 60-year-old male showing a large enhancing lesion in segment 6 of liver (arrow).<br />(B) There is evidence of washout in the portal venous phase.<br />(C) Subtraction MRI showing enhancement (arrow). To obtain the subtracted image, pre-contrast T1 weighted image is subtracted from post-contrast T1 weighted image.<br />(D) Axial post-contrast MRI at the same level four weeks after chemoembolization showing no enhancement and minimal change in size. This is consistent with a complete response (CR) according to modified RECIST for hepatocellular carcinoma (mRECIST) but stable disease by standard RECIST criteria.</div><div id=\"graphicVersion\">Graphic 99602 Version 1.0</div></div></div>"},"99603":{"type":"graphic_diagnosticimage","displayName":"Recurrent HCC after RFA and SIRT","title":"Contrast-enhanced axial MRI following radiofrequency ablation (RFA) and selective internal radiation therapy (SIRT) demonstrating recurrent disease eight weeks posttreatment","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced axial MRI following radiofrequency ablation (RFA) and selective internal radiation therapy (SIRT) demonstrating recurrent disease eight weeks posttreatment</div><div class=\"cntnt\"><img style=\"width:580px; height:437px;\" src=\"images/ONC/99603_Recurrent_HCC_aft_RFA_SIRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the thick rind of enhancement (arrow), suspicious for recurrent/residual disease.</div><div id=\"graphicVersion\">Graphic 99603 Version 1.0</div></div></div>"},"99604":{"type":"graphic_diagnosticimage","displayName":"Contrast-enhanced MRI HCC after SIRT","title":"Arterial phase of a contrast-enhanced MRI prior to and following selective internal radiation therapy (SIRT)","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Arterial phase of a contrast-enhanced MRI prior to and following selective internal radiation therapy (SIRT)</div><div class=\"cntnt\"><img style=\"width:725px; height:312px;\" src=\"images/ONC/99604_Cntrst_enhnc_MRI_HCC_SIRT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Arterial phase MRI after gadolinium contrast showing enhancing lesion in right lobe of liver (arrow), consistent with HCC.<br />(B) Follow-up MRI after SIRT at the same level showing no evidence of enhancement of the lesion (arrow) with associated area of heterogeneous enhancement posteriorly (arrowheads) consistent enhancing fibrosis in the treated zone. This area of fibrosis will retract and atrophy over time.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 99604 Version 1.0</div></div></div>"},"99605":{"type":"graphic_picture","displayName":"Alopecia mucinosa on scalp","title":"Alopecia mucinosa (follicular mucinosis)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Alopecia mucinosa (follicular mucinosis)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99605_Alopecia_mucinosa_sclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, indurated plaques with alopecia on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99605 Version 3.0</div></div></div>"},"99606":{"type":"graphic_picture","displayName":"Juvenile xanthogranuloma on scalp","title":"Juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/99606_Jvnl_xanthogranuloma_sclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-orange papule on the scalp of an infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99606 Version 2.0</div></div></div>"},"99607":{"type":"graphic_picture","displayName":"Cylindroma on scalp","title":"Cylindroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cylindroma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99607_Cylindroma_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary, smooth papule on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99607 Version 2.0</div></div></div>"},"99608":{"type":"graphic_picture","displayName":"Angiolymphoid hyperplasia with eosinophilia","title":"Angiolymphoid hyperplasia with eosinophilia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Angiolymphoid hyperplasia with eosinophilia</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99608_Anglymphd_hyprpls_esnphl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple red-brown papules on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99608 Version 2.0</div></div></div>"},"99609":{"type":"graphic_picture","displayName":"Herpes zoster on scalp","title":"Herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Herpes zoster</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99609_Herpes_zoster_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unilateral eruption with erythema, vesicles, and crusts on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99609 Version 2.0</div></div></div>"},"99610":{"type":"graphic_picture","displayName":"Cutis verticis gyrata","title":"Cutis verticis gyrata","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cutis verticis gyrata</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99610_Cutis_verticis_gyrata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symmetric ridges and grooves arranged anteroposteriorly on the vertex of this patient with&nbsp;primary cutis verticis gyrata.&nbsp;&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99610 Version 3.0</div></div></div>"},"99624":{"type":"graphic_figure","displayName":"Prevention/treatment of cardiovascular events in cancer patients","title":"Prevention or treatment of cardiovascular events in cancer patients","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Prevention or treatment of cardiovascular events in cancer patients</div><div class=\"cntnt\"><img style=\"width:554px; height:338px;\" src=\"images/ONC/99624_Prvn_trt_crdv_evnt_cncr_ptn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The risk of cardiovascular events and the need for treatment increase gradually as cancer patients were denied primary and/or secondary prevention.</div><div class=\"graphic_reference\">Reproduced from: Salvatorelli E, Menna P, Cantalupo E, et al. The concomitant management of cancer therapy and cardiac therapy. Biochim Biophys Acta 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99624 Version 1.0</div></div></div>"},"99638":{"type":"graphic_picture","displayName":"Discoid lupus erythematosus plaques","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99638_Discoid_lupus_erythmts_plq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple well-demarcated, erythematous plaques with scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99638 Version 2.0</div></div></div>"},"99639":{"type":"graphic_picture","displayName":"Discoid lupus erythematosus scalp","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99639_Dscd_lp_erythmts_sclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated plaque on the scalp with erythema, scale, and peripheral hyperpigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99639 Version 2.0</div></div></div>"},"99644":{"type":"graphic_figure","displayName":"Alternative pathway cofactor activity","title":"Alternative pathway cofactor activity","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Alternative pathway cofactor activity</div><div class=\"cntnt\"><img style=\"width:706px; height:230px;\" src=\"images/ALLRG/99644_Altrntvpthwycfctractvty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cofactor, such as CD46 (shown) or&nbsp;factor H,&nbsp;binds to C3b attached to host cell membranes. This allows serine protease factor I to cleave C3b to prevent further C3 activation. In the classical pathway, C4b is inactivated by the same mechani<FONT color=red></FONT><FONT color=black>sm, with C4b binding protein&nbsp;serving as the cofactor protein.</FONT></div><div id=\"graphicVersion\">Graphic 99644 Version 3.0</div></div></div>"},"99680":{"type":"graphic_table","displayName":"Common childhood malignancies","title":"The most common malignancies in infants, children, and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The most common malignancies in infants, children, and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Cancer type</td> <td class=\"subtitle1\">Age &#60;1 year</td> <td class=\"subtitle1\">Age 1 to 4 years</td> <td class=\"subtitle1\">Age 5 to 9 years</td> <td class=\"subtitle1\">Age 10 to 14 years</td> <td class=\"subtitle1\">Age 15 to 19 years</td> <td class=\"subtitle1\">All pediatric ages</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"6\">Percentage of all cancers</td> </tr> <tr> <td>Leukemias</td> <td class=\"centered\">20</td> <td class=\"centered\">33</td> <td class=\"centered\">40</td> <td class=\"centered\">37</td> <td class=\"centered\">23</td> <td class=\"centered\">32</td> </tr> <tr> <td>CNS tumors</td> <td class=\"centered\">13</td> <td class=\"centered\">17</td> <td class=\"centered\">17</td> <td class=\"centered\">21</td> <td class=\"centered\">17</td> <td class=\"centered\">18</td> </tr> <tr> <td>Lymphoma</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">5</td> <td class=\"centered\">10</td> <td class=\"centered\">21</td> <td class=\"centered\">11</td> </tr> <tr> <td>Neuroblastoma</td> <td class=\"centered\">21</td> <td class=\"centered\">15</td> <td class=\"centered\">10</td> <td class=\"centered\">4</td> <td class=\"centered\">0.7</td> <td class=\"centered\">6</td> </tr> <tr> <td>Soft tissue sarcomas</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">5</td> <td class=\"centered\">8</td> <td class=\"centered\">6</td> </tr> <tr> <td>Wilms tumor</td> <td class=\"centered\">5</td> <td class=\"centered\">9</td> <td class=\"centered\">8</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">5</td> </tr> <tr> <td>Germ cell tumors</td> <td class=\"centered\">15</td> <td class=\"centered\">5</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">8</td> <td class=\"centered\">5</td> </tr> <tr> <td>Bone tumors</td> <td class=\"centered\">0.8</td> <td class=\"centered\">0.5</td> <td class=\"centered\">2</td> <td class=\"centered\">5</td> <td class=\"centered\">8</td> <td class=\"centered\">4</td> </tr> <tr> <td>Thyroid cancer</td> <td class=\"centered\">0.8</td> <td class=\"centered\">0</td> <td class=\"centered\">0.3</td> <td class=\"centered\">1.5</td> <td class=\"centered\">7</td> <td class=\"centered\">2.5</td> </tr> <tr> <td>Melanoma and skin cancers</td> <td class=\"centered\">0</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.4</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">1.6</td> </tr> <tr> <td>Other tumors</td> <td class=\"centered\">20</td> <td class=\"centered\">15</td> <td class=\"centered\">11</td> <td class=\"centered\">6.5</td> <td class=\"centered\">3</td> <td class=\"centered\">8</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The most common causes of cancer based upon age in the United States (2000 to 2011) from data obtained by the Surveillance, Epidemiology, and End Results program, National Cancer Institute.</div><div class=\"graphic_footnotes\">CNS: central nervous system; DCCPS: Division of Cancer Control and Population Sciences.</div><div class=\"graphic_reference\">Reproduced from: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (2000-2011) &lt;Katrina/Rita Population Adjustment&gt; - Linked To County Attributes - Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014 (updated 5/7/2014), based on the November 2013 submission.</div><div id=\"graphicVersion\">Graphic 99680 Version 2.0</div></div></div>"},"99681":{"type":"graphic_figure","displayName":"Muscle attachments of the distal upper limb - Anterior view","title":"Muscle attachments of the distal upper limb: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Muscle attachments of the distal upper limb: Anterior view</div><div class=\"cntnt\"><img style=\"width:568px; height:662px;\" src=\"images/EM/99681_Msclatchdstuprlmbantr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99681 Version 3.0</div></div></div>"},"99696":{"type":"graphic_figure","displayName":"Muscle attachments of the distal upper limb - Posterior view","title":"Muscle attachments of the distal upper limb: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Muscle attachments of the distal upper limb: Posterior view</div><div class=\"cntnt\"><img style=\"width:537px; height:663px;\" src=\"images/EM/99696_Msclatchdstluprlmbpstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99696 Version 3.0</div></div></div>"},"99697":{"type":"graphic_figure","displayName":"Muscles of the anterior forearm, superficial dissection","title":"Muscles of the anterior forearm, superficial dissection","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior forearm, superficial dissection</div><div class=\"cntnt\"><img style=\"width:569px; height:673px;\" src=\"images/EM/99697_Msclantrrfrmsprfcldssct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99697 Version 3.0</div></div></div>"},"99698":{"type":"graphic_figure","displayName":"Muscles of the anterior forearm, intermediate dissection","title":"Muscles of the anterior forearm, intermediate dissection","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior forearm, intermediate dissection</div><div class=\"cntnt\"><img style=\"width:622px; height:662px;\" src=\"images/EM/99698_Msclantrfrmintrmdtdsct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99698 Version 3.0</div></div></div>"},"99699":{"type":"graphic_figure","displayName":"Muscles of the anterior forearm, deep dissection","title":"Muscles of the anterior forearm, deep dissection","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior forearm, deep dissection</div><div class=\"cntnt\"><img style=\"width:629px; height:653px;\" src=\"images/EM/99699_Msclantrrfrrmdpdssct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99699 Version 3.0</div></div></div>"},"99701":{"type":"graphic_figure","displayName":"Arteries of the anterior forearm","title":"Arteries of the anterior forearm","html":"<div class=\"graphic\"><div style=\"width: 765px\" class=\"figure\"><div class=\"ttl\">Arteries of the anterior forearm</div><div class=\"cntnt\"><img style=\"width:745px; height:649px;\" src=\"images/EM/99701_Arteriesanteriorforearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99701 Version 3.0</div></div></div>"},"99702":{"type":"graphic_figure","displayName":"Nerves of the anterior forearm","title":"Nerves of the anterior forearm","html":"<div class=\"graphic\"><div style=\"width: 683px\" class=\"figure\"><div class=\"ttl\">Nerves of the anterior forearm</div><div class=\"cntnt\"><img style=\"width:663px; height:671px;\" src=\"images/EM/99702_Nervesanteriorforearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99702 Version 3.0</div></div></div>"},"99703":{"type":"graphic_figure","displayName":"Muscles of the posterior forearm - Superficial dissection","title":"Muscles of the posterior forearm: Superficial dissection","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Muscles of the posterior forearm: Superficial dissection</div><div class=\"cntnt\"><img style=\"width:571px; height:675px;\" src=\"images/EM/99703_Msclpstrrfrmsprfcldssct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99703 Version 3.0</div></div></div>"},"99704":{"type":"graphic_figure","displayName":"Muscles of the posterior forearm - Deep dissection","title":"Muscles of the posterior forearm: Deep dissection","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Muscles of the posterior forearm: Deep dissection</div><div class=\"cntnt\"><img style=\"width:595px; height:677px;\" src=\"images/EM/99704_Msclpstrrfrrmdeepdssct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99704 Version 3.0</div></div></div>"},"99715":{"type":"graphic_figure","displayName":"Elbow joint - Anterior, lateral, and medial views","title":"Elbow joint: Anterior, lateral, and medial views","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Elbow joint: Anterior, lateral, and medial views</div><div class=\"cntnt\"><img style=\"width:549px; height:628px;\" src=\"images/EM/99715_Elbwjntantrrltrlmdlvw.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99715 Version 3.0</div></div></div>"},"99716":{"type":"graphic_figure","displayName":"Median nerve","title":"Median nerve","html":"<div class=\"graphic\"><div style=\"width: 679px\" class=\"figure\"><div class=\"ttl\">Median nerve</div><div class=\"cntnt\"><img style=\"width:659px; height:690px;\" src=\"images/EM/99716_Mediannerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99716 Version 3.0</div></div></div>"},"99717":{"type":"graphic_figure","displayName":"Ulnar nerve","title":"Ulnar nerve","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Ulnar nerve</div><div class=\"cntnt\"><img style=\"width:655px; height:699px;\" src=\"images/EM/99717_Ulnarnerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99717 Version 3.0</div></div></div>"},"99718":{"type":"graphic_figure","displayName":"Radial nerve","title":"Radial nerve","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Radial nerve</div><div class=\"cntnt\"><img style=\"width:597px; height:687px;\" src=\"images/EM/99718_Radialnerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Upper limb. In: Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99718 Version 3.0</div></div></div>"},"99728":{"type":"graphic_figure","displayName":"Skin stapling PI","title":"Staples to close a cut","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Staples to close a cut</div><div class=\"cntnt\"><img style=\"width:508px; height:596px;\" src=\"images/PI/99728_Skin_stapling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sometimes, doctors use staples (instead of stitches) to close a cut. These staples are different from the staples used in paper. To put them in, doctors use a special stapler. Staples need to be taken out by a doctor or nurse after a certain amount of time.</div><div id=\"graphicVersion\">Graphic 99728 Version 1.0</div></div></div>"},"99729":{"type":"graphic_figure","displayName":"Timing of physeal closure in the lower extremity","title":"Timing of physeal closure (age, including range) in the lower extremity by sex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Timing of physeal closure (age, including range) in the lower extremity by sex</div><div class=\"cntnt\"><img style=\"width:300px; height:396px;\" src=\"images/EM/99729_Tmngphyslclsrlwextrmty.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Rathjen KE, Kim HKW. Physeal injuries and growth disturbance. In: Rockwood and Wilkins' Fractures in Children, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 99729 Version 4.0</div></div></div>"},"99732":{"type":"graphic_diagnosticimage","displayName":"CT of a pulmonary nodule with spiculated margins","title":"CT of a pulmonary nodule with spiculated margins","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">CT of a pulmonary nodule with spiculated margins</div><div class=\"cntnt\"><img style=\"width:785px; height:478px;\" src=\"images/RADIOL/99732_CT_scan_SPN_crn_rdt_sgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary nodule with spiculated margins. Chest CT images (A &amp; B)&nbsp;show a 27 mm&nbsp;right lung nodule (arrow) with&nbsp;spiculated margins, a finding usually associated with malignancy. </div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 99732 Version 2.0</div></div></div>"},"99733":{"type":"graphic_diagnosticimage","displayName":"Radiography, CT and FDG PET of an pulmonary amyloid nodule","title":"Radiography, CT and FDG PET of a pulmonary amyloid nodule","html":"<div class=\"graphic\"><div style=\"width: 799px\" class=\"figure\"><div class=\"ttl\">Radiography, CT and FDG PET of a pulmonary amyloid&nbsp;nodule</div><div class=\"cntnt\"><img style=\"width:779px; height:473px;\" src=\"images/RADIOL/99733_Imaging_amyloid_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary amyloid.&nbsp;Chest radiograph lateral view (A)&nbsp;shows&nbsp;a nodule (circle) in the&nbsp;retrocardiac region. CT (B) and FDG PET (C) images of the chest shows a 12 mm non-FDG avid&nbsp;nodule (arrow) in the left lower lobe confirmed to be&nbsp;amyloid on pathology.</div><div class=\"graphic_footnotes\">CT: computed tomography; FDG: fluorodeoxyglucose; PET: positron emission tomography.</div><div id=\"graphicVersion\">Graphic 99733 Version 2.0</div></div></div>"},"99734":{"type":"graphic_table","displayName":"Association CFTR genotype and PI","title":"Association between CFTR genotype and pancreatic insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Association between CFTR genotype and pancreatic insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Functional class</td> <td class=\"subtitle1\">\"Severe\" CFTR mutations </td> <td class=\"subtitle1\">\"Mild\" CFTR mutations</td> </tr> <tr> <td class=\"subtitle2\">If two of these mutations are present, there is a high likelihood of pancreatic insufficiency.<sup>[1,2]</sup></td> <td class=\"subtitle2\">If at least one of these is present, most patients have pancreatic sufficiency.<sup>[1,2]</sup></td> </tr> <tr> <td>Class I (Defective protein synthesis)</td> <td> <p>G542X</p> <p>W1282X</p> <p>R553X</p> <p>621+1G&#62;T</p> <p>1717&ndash;1G&#62;A</p> <p>3120+1G&#62;A&nbsp;</p> <p>R1162X</p> <p>3659delC</p> <p>1898+1G&#62;A</p> <p>2184delA</p> <p>711+1G&#62;T</p> </td> <td>&nbsp;</td> </tr> <tr> <td>Class II (Abnormal processing and trafficking)</td> <td> <p>F508del</p> I507del</td> <td>&nbsp;</td> </tr> <tr> <td>Class III (Defective channel regulation/gating)</td> <td> <p>G551D</p> <p>N1303K</p> <p>R560T</p> </td> <td>G85E*&nbsp;</td> </tr> <tr> <td>Class IV (Decreased channel conductance)</td> <td>&nbsp;</td> <td> <p>R117H</p> <p>R347P<sup>&#182;</sup></p> R334W<sup>&#916;</sup></td> </tr> <tr> <td>Class V (Reduced synthesis and/or trafficking)</td> <td>&nbsp;</td> <td> <p>3849+10kbC&#62;T<sup>&#916;</sup></p> <p>2789+5G&#62;A&nbsp;</p> <p>A445E</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the pancreatic phenotype for the 23 most common mutations of the cystic fibrosis transmembrane regulator (CFTR) gene. The presence of two class I, II, or III mutations is usually associated with pancreatic insufficiency, whereas the presence of at least one of the class IV or V mutations listed here usually is associated with pancreatic sufficiency. Information about the pancreatic phenotype for other less common mutations is available in the references.<SUP>[1,2]</SUP></div><div class=\"graphic_footnotes\">CFTR: cystic fibrosis transmembrane regulator.<br />* G85E is considered indeterminate for pancreatic insufficiency. In a study, one patient with F508del/G85E genotype had pancreatic sufficiency, and two patients&nbsp;had pancreatic insufficiency.<SUP>[1]</SUP><br />¶ Conflicting results were found in individual patients with an R347p mutation. In two studies that used fecal fat excretion to determine pancreatic insufficiency, all&nbsp;five patients with F508del/R347P genotype were pancreatic sufficient.<SUP>[1,3,4]</SUP> In a separate study, the one patient with this genotype appeared to have pancreatic insufficiency based on a low fecal elastase level.<SUP>[5]</SUP><br />Δ A study reported that these genotypes (R334W or 3849+10kbCT), combined with F508del or 1717–1GA, may be associated with either pancreatic insufficiency or pancreatic sufficiency (as measured by fecal elastase).<SUP>[5]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>​Ahmed N, Corey M, Forstner G et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 2003; 52:1159.</LI>&#xD;&#xA;<LI>The Clinical and Functional Translation of CFTR (CFTR2); available at http://cftr2.org (accessed 2/3/15)</LI>&#xD;&#xA;<LI>Santis G, Osborne L, Knight RA, Hodson ME. Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet 1990; 336:1081.</LI>&#xD;&#xA;<LI>Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992; 50:1178.</LI>&#xD;&#xA;<LI>Walkowiak J, Herzig KH, Witt M, et al. Analysis of exocrine pancreatic function in cystic fibrosis: one mild CFTR mutation does not exclude pancreatic insufficiency. Eur J Clin Invest 2001; 31:796.</LI></OL></div><div id=\"graphicVersion\">Graphic 99734 Version 1.0</div></div></div>"},"99736":{"type":"graphic_diagnosticimage","displayName":"CT and FDG PET of a pulmonary infarct from embolism","title":"CT and FDG PET of a pulmonary infarct from embolism","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">CT and FDG PET of a pulmonary infarct from embolism</div><div class=\"cntnt\"><img style=\"width:724px; height:287px;\" src=\"images/RADIOL/99736_Imag_cavitating_infarction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT without contrast (A) and FDG PET images (B) show&nbsp;a&nbsp;cavitating nodule (arrow) and&nbsp;subsegmental&nbsp;air space opacity&nbsp;(arrowhead) in the right lower lobe. Both are mildly FDG-avid with an indeterminate SUV of 2.1. Pathology of the nodule showed subacute infarction resulting from&nbsp;pulmonary embolism. The subsegmental&nbsp;air space opacity&nbsp;could represent another infarct or inflammation.</div><div class=\"graphic_footnotes\">CT: computed tomography; FDG: fluorodeoxyglucose (18F); PET: positron emission tomography; SUV: standardized uptake value.</div><div id=\"graphicVersion\">Graphic 99736 Version 2.0</div></div></div>"},"99739":{"type":"graphic_table","displayName":"Methemoglobin levels","title":"Toxicity in acute acquired methemoglobinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicity in acute acquired methemoglobinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Methemoglobin level</td> <td class=\"subtitle1\">Symptoms*</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">0 to&nbsp;3 percent</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Normal range for adults (mean: 1 percent)</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">3 to 12&nbsp;percent</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Minimal level associated with clinically detectable cyanosis or skin discoloration</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">3&nbsp;to 20 percent</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Usually asymptomatic unless pre-existing condition present</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">20 to 50 percent</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Mild to moderate symptoms of hypoxemia<sup>&#182;</sup></span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">50 to 70 percent</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Severe, life-threatening symptoms of hypoxemia<sup>&#916;</sup></span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">&#62;70 percent</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Usually fatal</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Pre-existing conditions such as anemia, heart, and lung disease may exacerbate toxicity. <br />¶ Symptoms of mild to moderate toxicity include lightheadedness, fatigue, tachycardia, dyspnea, and lethargy.<br />Δ Symptoms of severe toxicity include respiratory depression, altered sensorium, coma, shock, and seizures.</div><div id=\"graphicVersion\">Graphic 99739 Version 1.0</div></div></div>"},"99740":{"type":"graphic_table","displayName":"Testing guidelines for donors in a gestational carrier cycle","title":"Testing guidelines for donors in a gestational carrier cycle","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Testing guidelines for donors in a gestational carrier cycle</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Recommended US Food and Drug Administration testing guidelines per American Society of Reproductive Medicine for donors in a gestational carrier (GC) cycle and options for protecting the GC from infection:</td> </tr> <tr> <td class=\"subtitle1\">Male and female partners:</td> <td class=\"subtitle1\">Test</td> </tr> <tr> <td class=\"centered\">1</td> <td>HIV-1 antibody and nucleic acid testing (NAT)</td> </tr> <tr> <td class=\"centered\">2</td> <td>HIV-2 antibody</td> </tr> <tr> <td class=\"centered\">3</td> <td>HIV group O antibody. If US FDA-licensed test for HIV group O antibodies is unavailable then evaluation for genetic parents for risk associated with HIV group O infection</td> </tr> <tr> <td class=\"centered\">4</td> <td>Hepatitis C antibody and NAT</td> </tr> <tr> <td class=\"centered\">5</td> <td>Hepatitis B surface antigen</td> </tr> <tr> <td class=\"centered\">6</td> <td>Hepatitis B core antibody (IgG and IgM)</td> </tr> <tr> <td class=\"centered\">7</td> <td>Serologic test for syphilis</td> </tr> <tr> <td class=\"centered\">8</td> <td><em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em> NAT on urine or swab from cervix, urethral meatus or vagina</td> </tr> <tr> <td class=\"centered\">9</td> <td>Rh compatibility with the&nbsp;gestational carrier&nbsp;and appropriate counseling</td> </tr> <tr> <td class=\"subtitle1\">Additional testing for male partner:</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"centered\">1</td> <td>Human T-lymphotropic virus I (HTLV-I) and human T-lymphotropic virus II (HTLV-II)</td> </tr> <tr> <td class=\"centered\">2</td> <td>Cytomegalovirus (CMV) (IgG and IgM)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Any positive test results need to be responded to per standard Centers for Disease Control and Prevention guidelines and GCs offered the option of cryopreservation of embryos for 180 days until such test results are resolved and donors are retested.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">From the Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology.</div><div class=\"graphic_reference\">Data from: Practice Committee of the American Society for Reproductive Medicine. Recommendations for practices utilizing gestational carriers: a committee opinion. Fertil Steril 2015; 103:e1-e8.</div><div id=\"graphicVersion\">Graphic 99740 Version 1.0</div></div></div>"},"99749":{"type":"graphic_diagnosticimage","displayName":"Digital angiography of bilateral popliteal entrapment syndrome","title":"Digital angiography of bilateral popliteal entrapment syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Digital angiography of bilateral popliteal entrapment syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:479px;\" src=\"images/EM/99749_Dig_angio_bilat_popl_entrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital angiography in neutral position in an athlete with bilateral popliteal entrapment syndrome. Severe narrowing of right popliteal artery and complete obstruction of left are well demonstrated.</div><div class=\"graphic_reference\">From: Baltopoulos P, Filippou DK, Sigala F. Popliteal artery entrapment syndrome: anatomic or functional syndrome? Clin J Sports Med 2004; 14:8. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2004 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 99749 Version 1.0</div></div></div>"},"99750":{"type":"graphic_diagnosticimage","displayName":"Bony cortical irregularity on ultrasound adductor tendon origin","title":"Bony cortical irregularity on ultrasound at adductor tendon origin","html":"<div class=\"graphic\"><div style=\"width: 881px\" class=\"figure\"><div class=\"ttl\">Bony cortical irregularity on ultrasound at adductor tendon origin</div><div class=\"cntnt\"><img style=\"width:861px; height:381px;\" src=\"images/EM/99750_Artrgrm_dmnstrt_cncntrc_stn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inferior pubic ramus attachment of adductor muscles. On left is transverse view and on right is a longitudinal view.<br />(A) This shows bony irregularity at the origin of the tendon between the + signs on image.<br />(B) This demonstrates a spur sticking into soft tissue extending from the hyperechoic surface of the pubic ramus.</div><div class=\"graphic_reference\">Courtesy of Bev Roos.</div><div id=\"graphicVersion\">Graphic 99750 Version 5.0</div></div></div>"},"99762":{"type":"graphic_algorithm","displayName":"Hemodynamically unstable PE treatment algorithm","title":"Treatment algorithm for hemodynamically unstable patients with suspected pulmonary embolism (PE)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for hemodynamically unstable patients with suspected pulmonary embolism (PE)</div><div class=\"cntnt\"><img style=\"width:428px; height:646px;\" src=\"images/PULM/99762_Hmdynmc_unstbl_PE_trt_algrt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemodynamically unstable refers to the presence of overt shock from \"massive\" PE that is imminently life-threatening (please refer to the topic text for more details).</div><div class=\"graphic_footnotes\">RV: right ventricle.<br />* Resuscitation involves any combination of respiratory (oxygen, noninvasive or invasive mechanical ventilation) and hemodynamic support (intravenous fluids, vasopressors).<br />¶ The use of portable perfusion scanning is dependent upon institutional availability, but has a higher sensitivity for the diagnosis of PE than transthoracic echocardiography. Other alternative testing that may help the clinician make a presumptive diagnosis of PE and guide management decisions include transesophageal echocardiography and compressive ultrasound of the lower extremities, none of which are diagnostic of PE. Please refer to the UpToDate topic text for more details.<br />Δ Evidence of RV overload on echocardiography is supportive but not diagnostic of PE. Some experts may look for additional supportive evidence of PE (eg, deep venous thrombosis, thrombus in the right ventricle or main pulmonary artery). Please refer to the UpToDate topic text for more details.<br /><FONT class=lozenge>◊</FONT> The decision to empirically anticoagulate this population depends upon the clinical suspicion for PE.<br />§ In this population, it is assumed that the suspicion for PE remains high and that PE is the likely cause of hemodynamic instability.&nbsp;<br />¥ Patients not already on intravenous unfractionated heparin can proceed directly to thrombolysis, followed by anticoagulation. However, it is acceptable to proceed with thrombolytic therapy even while anticoagulated, particularly if the bleeding risk is deemed low and the patient is severely compromised.<br />‡ Combined catheter-directed embolectomy and thrombolysis is considered investigational and should be reserved for use in institutions with expertise.</div><div id=\"graphicVersion\">Graphic 99762 Version 2.0</div></div></div>"},"99763":{"type":"graphic_figure","displayName":"Total colectomy for cancer","title":"Total colectomy for cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Total colectomy for cancer</div><div class=\"cntnt\"><img style=\"width:426px; height:528px;\" src=\"images/SURG/99763_Total_colectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Total colon resection for cancer removes the entire colon, including the associated mesentery, with the mesenteric vessels&nbsp;ligated close to their origin to optimally resect lymphovascular tissue.</div><div id=\"graphicVersion\">Graphic 99763 Version 1.0</div></div></div>"},"99773":{"type":"graphic_picture","displayName":"Anterior segment in persistent fetal vasculature","title":"Persistent fetal vasculature: Anterior segment","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Persistent fetal vasculature: Anterior segment</div><div class=\"cntnt\"><img style=\"width:708px; height:527px;\" src=\"images/PEDS/99773_Antr_sgm_prsstnt_ftl_vscltr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior segment of an infant referred for retinoblastoma who was diagnosed with persistent fetal vasculature. The elongated ciliary body processes (arrowhead) are commonly seen in persistent fetal vasculature. The retrolental fibrous mass is shown with the arrow.</div><div id=\"graphicVersion\">Graphic 99773 Version 1.0</div></div></div>"},"99774":{"type":"graphic_figure","displayName":"Facets of the greater trochanter","title":"Facets of the greater trochanter","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Facets of the greater trochanter</div><div class=\"cntnt\"><img style=\"width:625px; height:328px;\" src=\"images/RHEUM/99774_Facetgreattrochanter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four facets of the greater trochanter. All but the posterior facet serve as direct insertion sites for the gluteus medius (superoposterior and lateral facets) and gluteus minimus (anterior facet) tendons.</div><div class=\"graphic_reference\">Reproduced with permission from: Poultsides LA, Kelly BT. Hip Arthroscopy&mdash;Disorders of the Trochanteric Space&mdash;Bursitis and Abductor Tears. In: The Adult Hip: Hip Preservation Surgery, Clohisy JC, Beaule PE, Della Valle CJ, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99774 Version 3.0</div></div></div>"},"99775":{"type":"graphic_picture","displayName":"FABER test (or Patrick test, \"figure of four\" test)","title":"FABER test (or Patrick test, \"figure of four\" test)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FABER test (or Patrick test, \"figure of four\" test)</div><div class=\"cntnt\"><img style=\"width:448px; height:712px;\" src=\"images/RHEUM/99775_FABERE_tst_Ptr_fig_four_tst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The FABER (flexion-abduction-external rotation) test, or Patrick test, consists of flexion of the hip, with abduction and external rotation of the hip. Force is applied down the bent knee and the opposite pelvis. In a patient with groin pain, reproduction of this pain is suggestive of underlying hip joint disease. In a patient with lateral hip pain, lateral pain will suggest GTPS. In a patient with buttock pain, a diagnosis of sacroiliac joint disease will be supported.</div><div class=\"graphic_footnotes\">GTPS: greater trochanteric pain syndrome.</div><div class=\"graphic_reference\">Courtesy of Margot Putukian, MD.</div><div id=\"graphicVersion\">Graphic 99775 Version 4.0</div></div></div>"},"99783":{"type":"graphic_picture","displayName":"Flexible fiberoptic intubation for supine patient","title":"Flexible fiberoptic intubation for supine patient","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Flexible fiberoptic intubation for supine patient</div><div class=\"cntnt\"><img style=\"width:712px; height:530px;\" src=\"images/ANEST/99783_Intubating_airways.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99783 Version 3.0</div></div></div>"},"99788":{"type":"graphic_figure","displayName":"Mechanism of pulsus paradoxus","title":"Mechanism of pulsus paradoxus","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">Mechanism of pulsus paradoxus</div><div class=\"cntnt\"><img style=\"width:854px; height:531px;\" src=\"images/CARD/99788_Mechanism_pulsus_paradoxus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracardiac pressure tracings from a patient who developed cardiac tamponade. During inspiration (thick yellow arrows), the pulmonary capillary wedge pressure (blue) drops below the left ventricle (LV) diastolic pressure (yellow), leading to underfilling of the LV and acute drop in LV stroke volume (thin yellow arrows) causing pulsus paradoxus.​</div><div id=\"graphicVersion\">Graphic 99788 Version 1.0</div></div></div>"},"99789":{"type":"graphic_figure","displayName":"Posterior staphylomatous outpouching ","title":"Posterior staphylomatous outpouching","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Posterior staphylomatous outpouching</div><div class=\"cntnt\"><img style=\"width:534px; height:441px;\" src=\"images/ANEST/99789_Posterior_staphylomatous_outpouching.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A posterior staphylomatous outpouching, such as illustrated above, elongates the globe and increases the risk of perforation by needle techniques.</div><div class=\"graphic_reference\">Modified from: Edge R, Navon S. Scleral perforation during retrobulbar and peribulbar anesthesia: risk factors and outcome in 50,000 consecutive injections. J Cataract Refract Surg 1999; 25:1237.</div><div id=\"graphicVersion\">Graphic 99789 Version 3.0</div></div></div>"},"99792":{"type":"graphic_table","displayName":"Equipment for office-based anesthesia","title":"Equipment for office-based anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equipment for office-based anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Monitors</td> </tr> <tr> <td class=\"indent1\">Noninvasive blood pressure with an assortment of cuff sizes</td> </tr> <tr> <td class=\"indent1\">Heart rate/ECG</td> </tr> <tr> <td class=\"indent1\">Pulse oximeter</td> </tr> <tr> <td class=\"indent1\">Temperature</td> </tr> <tr> <td class=\"indent1\">Capnography</td> </tr> <tr> <td class=\"subtitle1_single\">Airway supplies</td> </tr> <tr> <td class=\"indent1\">Nasal cannulae</td> </tr> <tr> <td class=\"indent1\">Oral airways</td> </tr> <tr> <td class=\"indent1\">Facemasks</td> </tr> <tr> <td class=\"indent1\">Self-inflating bag-mask ventilation device</td> </tr> <tr> <td class=\"indent1\">Laryngoscopes with blades&nbsp;in multiple sizes and styles (eg, Macintosh and Miller)</td> </tr> <tr> <td class=\"indent1\">Endotracheal tubes in&nbsp;multiple sizes</td> </tr> <tr> <td class=\"indent1\">Stylettes</td> </tr> <tr> <td class=\"indent1\">Supraglottic airway devices (eg, LMA) in multiple sizes</td> </tr> <tr> <td class=\"subtitle1_single\">Emergency airway equipment (supraglottic airway devices [eg, LMAs] in multiple sizes, videolaryngoscope [eg, Glidescope or CMAC], cricothyrotomy kit)</td> </tr> <tr> <td class=\"subtitle1_single\">Suction catheters and suction equipment</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac defibrillator</td> </tr> <tr> <td class=\"subtitle1_single\">Emergency drugs</td> </tr> <tr> <td class=\"indent1\">ACLS drugs (refer to UpToDate topics on ACLS)</td> </tr> <tr> <td class=\"indent1\">Dantrolene and malignant hyperthermia supplies (refer to UpToDate topics on malignant hyperthermia)</td> </tr> <tr> <td class=\"indent1\">20%&nbsp;lipid emulsion&nbsp;for local anesthetic systemic toxicity</td> </tr> <tr> <td class=\"subtitle1_single\">Anesthetic drugs</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular cannulation equipment</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Safe delivery of office-based anesthesia requires the availability of the listed equipment.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; LMA: laryngeal mask airway; ACLS: advanced cardiac life support.</div><div class=\"graphic_reference\">Modified&nbsp;with permission from: Hausman LM, Rosenblatt MA. Office-Based Anesthesia. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 99792 Version 5.0</div></div></div>"},"99793":{"type":"graphic_table","displayName":"Factors considered in accrediting an office for surgery","title":"Factors considered in accrediting an office for surgical procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors considered in accrediting an office for surgical procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Physical layout of the office</td> </tr> <tr> <td>2. Environmental safety/infection control</td> </tr> <tr> <td>3. Patient and personnel records</td> </tr> <tr> <td>4. Surgeon qualification </td> </tr> <tr> <td class=\"indent1\"> <p>a. Training</p> b. Local hospital privileges (surgical and admission)</td> </tr> <tr> <td>5. Office administration</td> </tr> <tr> <td>6. Anesthesiologist requirements</td> </tr> <tr> <td>7. Staffing intraoperatively and postoperatively</td> </tr> <tr> <td>8. Monitoring capabilities both intraoperatively and postoperatively</td> </tr> <tr> <td>9. Ancillary care</td> </tr> <tr> <td>10. Equipment</td> </tr> <tr> <td>11. Drugs (emergency, controlled substances, routine medications)</td> </tr> <tr> <td>12. BLS, ACLS/PALS certification</td> </tr> <tr> <td>13. Temperature</td> </tr> <tr> <td>14. Neuromuscular functioning</td> </tr> <tr> <td>15. Patient positioning</td> </tr> <tr> <td>16. Pre- and postanesthesia care/documentation</td> </tr> <tr> <td>17. Quality assurance/peer review</td> </tr> <tr> <td>18. Liability insurance</td> </tr> <tr> <td>19. PACU evaluation</td> </tr> <tr> <td>20. Discharge evaluation</td> </tr> <tr> <td>21. Emergency preparedness (fire/admission/transfer, etc.)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Hausman LM, Rosenblatt MA. Office-Based Anesthesia. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99793 Version 4.0</div></div></div>"},"99794":{"type":"graphic_form","displayName":"Safety checklist for office-based surgery","title":"Safety checklist for office-based surgery","html":"<div class=\"graphic\"><div style=\"width: 960px\" class=\"figure\"><div class=\"ttl\">Safety checklist for office-based surgery</div><div class=\"cntnt\"><img style=\"width:940px; height:674px;\" src=\"images/ANEST/99794_Safety_checklist_offc_srgry.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Institute for Safety in Office-Based Surgery constructed a 28-step perioperative checklist to identify and control safety risks during the different phases of an invasive office procedure. This checklist is not intended to be comprehensive. Additions and modifications to fit local practice are encouraged.</div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis; NPO: nil per os (nothing by mouth); AED: automated external defibrillator; MH: malignant hyperthermia; EBL: estimated blood loss.</div><div class=\"graphic_reference\">Credit: Richard Urman, Fred Shapiro, Copyright the Institute for Safety in Office-Based Surgery.</div><div id=\"graphicVersion\">Graphic 99794 Version 2.0</div></div></div>"},"99795":{"type":"graphic_table","displayName":"Continuum of depth of anesthesia","title":"American Society of Anesthesiologists (ASA) definitions of levels of sedation/anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Anesthesiologists (ASA) definitions of levels of sedation/anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Minimal sedation (anxiolysis)</td> </tr> <tr> <td class=\"indent1\"> <p>a. Drug-induced sedation</p> <p>b. Patient responds normally to verbal commands</p> <p>c. Cognitive and motor function may be impaired</p> d. Ventilatory and cardiovascular functions maintained normally</td> </tr> <tr> <td class=\"subtitle1_single\">2. Moderate sedation/analgesia (conscious sedation)</td> </tr> <tr> <td class=\"indent1\"> <p>a. Drug-induced sedation</p> <p>b. Patient responds purposefully to verbal commands either alone or with light tactile stimulation</p> <p>c. Patient maintains a patent airway and spontaneous ventilation</p> d. Cardiovascular function maintained</td> </tr> <tr> <td class=\"subtitle1_single\">3. Deep sedation/analgesia</td> </tr> <tr> <td class=\"indent1\"> <p>a. Drug-induced sedation</p> <p>b. Patient cannot be easily aroused but can respond purposefully to repeated or painful stimulation</p> <p>c. Ventilatory function may be impaired, requiring assistance in maintaining a patent airway, and spontaneous ventilation may be inadequate</p> <p>d. Cardiovascular function is usually maintained</p> </td> </tr> <tr> <td class=\"subtitle1_single\">4. General anesthesia</td> </tr> <tr> <td class=\"indent1\"> <p>a. Drug-induced loss of consciousness</p> <p>b. Patients are not aroused by painful stimulation</p> <p>c. Ventilatory function is often impaired; patient may require assistance in maintaining a patent airway</p> <p>d. Spontaneous ventilation may be impaired, as well as neuromuscular functioning</p> <p>e. Positive pressure ventilation is often required</p> f. Cardiovascular function may be impaired</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Definitions of levels of sedation/anesthesia by the American Society of Anesthesiologists (adopted October 13, 1999, by the House of Delegates).</div><div class=\"graphic_reference\">Reproduced with permission from: Hausman LM, Rosenblatt MA. Office-Based Anesthesia. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99795 Version 5.0</div></div></div>"},"99796":{"type":"graphic_figure","displayName":"Global HCV genotype distribution","title":"Proportion of HCV infections caused by the six major genotypes, by geographic region","html":"<div class=\"graphic\"><div style=\"width: 932px\" class=\"figure\"><div class=\"ttl\">Proportion of HCV infections caused by the six major genotypes, by geographic region</div><div class=\"cntnt\"><img style=\"width:912px; height:718px;\" src=\"images/ID/99796_Global_HCV_genotype_distrib.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCV: hepatitis C virus</div><div class=\"graphic_reference\">Data from: Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77.</div><div id=\"graphicVersion\">Graphic 99796 Version 1.0</div></div></div>"},"99797":{"type":"graphic_figure","displayName":"Regulation of phosphate homeostasis","title":"Regulation of phosphate homeostasis","html":"<div class=\"graphic\"><div style=\"width: 906px\" class=\"figure\"><div class=\"ttl\">Regulation of phosphate homeostasis</div><div class=\"cntnt\"><img style=\"width:886px; height:664px;\" src=\"images/NEPH/99797_Rgltn_phspht_hmsts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phosphate is absorbed from the diet in the gut, stored in the skeleton, and excreted by the kidneys. 1,25(OH)<SUB>2</SUB>D stimulates absorption of phosphate from the diet. FGF-23 increases renal phosphate clearance, suppresses synthesis of 1,25(OH)<SUB>2</SUB>D, and may decrease PTH (dashed line). PTH increases renal phosphate clearance and stimulates synthesis of 1,25(OH)<SUB>2</SUB>D.</div><div class=\"graphic_footnotes\">FGF-23: fibroblast growth factor 23; PTH: parathyroid hormone; Pit-2: type III sodium phosphate cotransporter; FGFR: fibroblast growth factor receptor; PTH1R: parathyroid hormone 1 receptor; NaPi-IIa/c: type IIa and type IIc sodium phosphate cotransporters;&nbsp;1,25(OH)<SUB>2</SUB>D:&nbsp;1,25-dihydroxyvitamin D.</div><div class=\"graphic_reference\">From: Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61:91. Reproduced with permission from the Annual Review of Medicine, Volume 61 © 2010 by Annual Reviews, <A spellcheck=true href=\"http://www.annualreviews.org/\" target=_blank>http://www.annualreviews.org</A>.</div><div id=\"graphicVersion\">Graphic 99797 Version 4.0</div></div></div>"},"99798":{"type":"graphic_picture","displayName":"Metastatic carcinoma","title":"Cutaneous metastasis from internal malignancy","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Cutaneous metastasis from internal malignancy</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/99798_Metastatic_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodule signifying metastasis of an internal malignancy to the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99798 Version 2.0</div></div></div>"},"99819":{"type":"graphic_figure","displayName":"Incidence of gonorrhea by age and gender (US, 2016)","title":"Incidence of gonorrhea in the United States in 2016, by age and gender","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">Incidence of gonorrhea in the United States in 2016, by age and gender</div><div class=\"cntnt\"><img style=\"width:820px; height:429px;\" src=\"images/ID/99819_GonorrheaagegendrUS2016.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Sexually Transmitted Disease Surveillance 2016. Centers for Disease Control and Prevention. Available at: <A href=\"https://www.cdc.gov/std/stats16/Gonorrhea.htm\" target=_blank>https://www.cdc.gov/std/stats16/Gonorrhea.htm</A> (Accessed on October 26, 2017).</div><div id=\"graphicVersion\">Graphic 99819 Version 3.0</div></div></div>"},"99820":{"type":"graphic_figure","displayName":"Incidence of gonorrhea by state (US, 2016)","title":"Incidence of gonorrhea in the United States in 2016, by state","html":"<div class=\"graphic\"><div style=\"width: 870px\" class=\"figure\"><div class=\"ttl\">Incidence of gonorrhea in the United States in 2016, by state</div><div class=\"cntnt\"><img style=\"width:850px; height:500px;\" src=\"images/ID/99820_GonorrheastateUS2016.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VT: Vermont; NH: New Hampshire; MA: Massachusetts; RI: Rhode Island; CT: Connecticut; NJ: New Jersey; DE: Delaware; MD: Maryland; DC: Washington, DC.</div><div class=\"graphic_reference\">Reproduced from: Sexually Transmitted Disease Surveillance 2016. Centers for Disease Control and Prevention. Available at: <A href=\"https://www.cdc.gov/std/stats16/Gonorrhea.htm\" target=_blank>https://www.cdc.gov/std/stats16/Gonorrhea.htm</A> (Accessed on October 26, 2017).</div><div id=\"graphicVersion\">Graphic 99820 Version 3.0</div></div></div>"},"99832":{"type":"graphic_figure","displayName":"Closure of physes (growth plates) by age and sex","title":"Closure of physes (growth plates) by age and sex in the upper and lower extremity","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Closure of physes (growth plates) by age and sex in the upper and lower extremity</div><div class=\"cntnt\"><img style=\"width:612px; height:408px;\" src=\"images/EM/99832_Clsrphysgrwthpltagesex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical age (and range) of closure of physes in the (A) upper extremity and (B) lower extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: Rathjen KE, Kim HKW. Physeal injuries and growth disturbance. In: Rockwood and Wilkins' Fractures in Children, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 99832 Version 3.0</div></div></div>"},"99833":{"type":"graphic_figure","displayName":"Longitudinal bone growth of extremities by physis","title":"Longitudinal bone growth of the upper and lower extremities by physis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal bone growth of the upper and lower extremities by physis</div><div class=\"cntnt\"><img style=\"width:417px; height:405px;\" src=\"images/EM/99833_Lngtdbngrwthextrmtphys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Approximate percentage of longitudinal growth provided by the proximal and distal physes for each long bone in the upper (A) and lower (B) extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: Rathjen KE, Kim HKW. Physeal injuries and growth disturbance. In: Rockwood and Wilkins' Fractures in Children, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 99833 Version 3.0</div></div></div>"},"99837":{"type":"graphic_algorithm","displayName":"Algorithm evaluation hypoglycemia children","title":"Algorithm for evaluation of an infant or child with hypoglycemia","html":"<div class=\"graphic\"><div style=\"width: 1136px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of an infant or child with hypoglycemia</div><div class=\"cntnt\"><img style=\"width:1116px; height:800px;\" src=\"images/PEDS/99837_Alorthm_evlt_hypglycm_chld.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; FFA: free fatty acids; PG: plasma glucose; &uarr;: elevated; &darr;: decreased; ACTH: adrenocorticotropic hormone; NH3: ammonia; IGF-I: insulin-like growth factor I; IGFBP3: insulin-like growth factor binding protein 3; T4: thyroxine; TSH: thyroid stimulating hormone (thyrotropin).<br />* Plasma insulin levels may be either low or high if exogenous insulin has been given (eg, in Munchausen syndrome by proxy). This is because recombinant modified human insulins may not be detected in the monoclonal \"sandwich\" assays used by many commercial laboratories to measure unmodified human insulin. Thus, if the glucagon challenge test is positive (rise in BG), but measured plasma insulin concentrations are low (and the C-peptide level is also low), polyclonal insulin assays must be sought to detect exogenous insulin.<br />&para; Acylcarnitine elevations will be for a specific fatty acid oxidation disorder.<br />&Delta; When the lactate is elevated without hepatomegaly, consider organic acidemia, ketolysis defect, or mitochondrial respiratory chain disorder. If the lactate is present with isolated hepatomegaly, glycogen storage disease or gluconeogenesis defects are suspected.<br /><span class=\"lozenge\">&loz;</span> Defects of ketolysis may cause markedly elevated ketones in the setting of mild hypoglycemia. These disorders are rare, and include SCOT deficiency (MIM #245050), alpha-methylacetoacetic aciduria (MIM #203750), and monocarboxylase transporter 1 deficiency (MIM #616095).<br />&sect; Thyroid function tests are measured as part of the evaluation for panhypopituitarism. It is unlikely that isolated hypothyroidism causes hypoglycemia.</div><div id=\"graphicVersion\">Graphic 99837 Version 3.0</div></div></div>"},"99856":{"type":"graphic_algorithm","displayName":"Approach to device reimplantation","title":"Approach to timing of reimplantation following removal of an infected cardiac electronic device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to timing of reimplantation following removal of an infected cardiac electronic device</div><div class=\"cntnt\"><img style=\"width:434px; height:320px;\" src=\"images/ID/99856_Appr_device_reimplantation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the setting of generator pocket infection or erosion of the generator or lead(s) and high-grade bacteremia, follow guidelines for antibiotic therapy of endocarditis; a new device may be implanted following debridement of the generator pocket, once blood cultures are negative for 72 hours. The duration of antibiotics should be counted from the day of device removal.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography.</div><div class=\"graphic_reference\">Original figure modified for this publication. Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007; 49:1851. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99856 Version 2.0</div></div></div>"},"99857":{"type":"graphic_table","displayName":"Common triggers of elevated BNP and NT-proBNP","title":"Common triggers of elevated BNP and NT-proBNP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common triggers of elevated BNP and NT-proBNP</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Cardiac conditions</strong> <ul class=\"decimal_heading\"> <li>Heart failure&nbsp;with reduced ejection fraction</li> <li>Heart failure with preserved ejection fraction</li> <li>Right ventricular failure </li> <li>Valvular heart disease </li> <li>Diseases of myocardium (left ventricular hypertrophy, myocarditis) </li> <li>Coronary artery disease </li> <li>Myocardial trauma (contusion, cardiac surgery, cardioversion) </li> <li>Arrhythmias (atrial fibrillation) </li> <li>Pericardial disease (associated with normal or elevated levels) </li> </ul> </td> </tr> <tr> <td><strong>Pulmonary disease</strong> <ul class=\"decimal_heading\"> <li>Acute pulmonary embolism (see right ventricular failure above) </li> <li>Pulmonary hypertension </li> <li>Obstructive sleep apnea </li> <li>Infection </li> <li>Chronic obstructive lung disease </li> </ul> </td> </tr> <tr> <td><strong>Neurologic disorders</strong> <ul class=\"decimal_heading\"> <li>Ischemic stroke </li> <li>Hemorrhagic stroke </li> </ul> </td> </tr> <tr> <td><strong>Critical illness</strong> <ul class=\"decimal_heading\"> <li>Sepsis </li> <li>Burns </li> <li>Transfusion associated circulatory overload (TACO) </li> </ul> </td> </tr> <tr> <td><strong>Toxins</strong> <ul class=\"decimal_heading\"> <li>Cancer chemotherapy </li> <li>Snake bites </li> </ul> </td> </tr> <tr> <td><strong>Other</strong> <ul class=\"decimal_heading\"> <li>Renal insufficiency </li> <li>Anemia </li> <li>Cirrhosis </li> <li>Hyperaldosteronism </li> <li>Hypertension </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In many of the listed non-cardiac conditions, the BNP or NT-proBNP elevation is mediated by a cardiac condition.</div><div id=\"graphicVersion\">Graphic 99857 Version 2.0</div></div></div>"},"99863":{"type":"graphic_diagnosticimage","displayName":"Misplaced Foley catheter on CT","title":"Misplaced Foley catheter on CT","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Misplaced Foley catheter on CT</div><div class=\"cntnt\"><img style=\"width:518px; height:328px;\" src=\"images/RADIOL/99863_CT_misplaced_Foley_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan reformatted in the sagittal plane (A) shows a Foley catheter (arrow) with balloon (delta) impacted into the base of the penile urethra. The prostate gland (asterisk) is cranial to the Foley catheter. The urinary bladder (bl) is significantly distended. Image B is an axial image through the base of the penis and the distended balloon of the Foley catheter (delta) is located at the base of the penis. Image C is a coronal view of the pelvis and shows the Foley balloon (delta) below the prostate (asterisk).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin Tomera, MD.</div><div id=\"graphicVersion\">Graphic 99863 Version 3.0</div></div></div>"},"99864":{"type":"graphic_diagnosticimage","displayName":"Imaging tuberculoma of the brain","title":"Tuberculoma of the brain on CT and MRI","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Tuberculoma of the brain on CT and MRI</div><div class=\"cntnt\"><img style=\"width:520px; height:380px;\" src=\"images/RADIOL/99864_Imaging_tuberculoma_brain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A noncontrast CT scan (A) of a six-year-old male presenting with left-sided hemiplegia and seizures shows a large soft tissue density mass (asterisk) containing central calcification (arrowhead) involving almost the entire visualized frontoparietal region. Image B is a contrast-enhanced CT scan reformatted in the coronal plane and shows the large mass (asterisk) with central calcification (arrowhead) and an enhancing border (arrows). Image C is a T1-weighted sagittal sequence showing an iso- to hypointense lesion (asterisk). Image D is a contrast-enhanced T1-weighted MRI in the axial plane and shows the mass (asterisk) with an enhancing rim (arrows). Image E is a T2-weighted MRI and shows the characteristic low intensity mass (asterisk), surrounding edema (delta), midline shift (arrowhead), and a dilated, partially obstructed left lateral ventricle (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Fourie Bezuidenhout, MD.</div><div id=\"graphicVersion\">Graphic 99864 Version 2.0</div></div></div>"},"99865":{"type":"graphic_picture","displayName":"Dilated RCA in infant with PA/IVS","title":"Severely dilated right coronary artery in an infant with PA/IVS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severely dilated right coronary artery in an infant with PA/IVS</div><div class=\"cntnt\"><img style=\"width:413px; height:377px;\" src=\"images/PEDS/99865_Dilated_RCA_infant_PAIVS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A severely dilated right coronary artery was observed in a one-week-old infant with pulmonary atresia with intact ventricular septum (PA/IVS) undergoing modified Blalock-Taussig shunt. In patients with PA/IVS and a small tricuspid valve, coronary-cameral fistulae may develop. If the normal origins of these coronary arteries are stenotic or atretic, the heart is dependent on right ventricular coronary filling. This patient had a tortuous and severely dilated right coronary artery, which was noted to have ostial stenosis, and an intact left coronary artery.</div><div class=\"graphic_reference\">Courtesy of David M Kwiatkowski, MD.</div><div id=\"graphicVersion\">Graphic 99865 Version 1.0</div></div></div>"},"99866":{"type":"graphic_diagnosticimage","displayName":"Radiograph of a comminuted fracture of the fibula","title":"Comminuted fracture of the fibula with butterfly fragment on radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted fracture of the fibula with butterfly fragment on radiography</div><div class=\"cntnt\"><img style=\"width:413px; height:347px;\" src=\"images/RADIOL/99866_Rdgrph_cmmnt_frctr_fbl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frontal radiograph of the left fibula (A) shows a comminuted spiral fracture of the distal shaft. Image B shows the fracture outlined with black overlay, while image C reveals three fragments with the lightest turquoise green overlaying the triangular or butterfly fragment. The mechanism of this injury is usually a twisting or torsional injury (thick arrow). The interosseous membrane acts as a resisting force (thin arrows)accounting for the butterfly fragment.</div><div id=\"graphicVersion\">Graphic 99866 Version 1.0</div></div></div>"},"99867":{"type":"graphic_diagnosticimage","displayName":"Radiograph of an oblique fracture of the fibula with dislocation","title":"Oblique fracture of the fibula with dislocation of the tibia on radiography","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the fibula with dislocation of the tibia on radiography</div><div class=\"cntnt\"><img style=\"width:600px; height:340px;\" src=\"images/RADIOL/99867_Rdgrph_oblq_frctr_fbl_dslct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are close-up images taken from radiographs of the lower leg. The frontal of the distal left tibia and fibula (A) shows a displaced oblique fracture of the distal shaft of the fibula (arrow) and a dislocated tibia (arrowhead). In image B the ankle is overlaid in purple and the area of interest is highlighted in gray scale. There is significant, lateral displacement of the distal fragment (arrow) resulting in the absence of bone on bone alignment. In image C the ankle is overlaid in teal blue and the dislocated tibia is highlighted in gray scale (arrowhead).</div><div id=\"graphicVersion\">Graphic 99867 Version 2.0</div></div></div>"},"99868":{"type":"graphic_diagnosticimage","displayName":"Radiograph of Maisonneuve fracture","title":"Maisonneuve fracture on radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maisonneuve fracture on radiography</div><div class=\"cntnt\"><img style=\"width:214px; height:396px;\" src=\"images/RADIOL/99868_Rdgrph_Maisonneuve_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal radiograph of the right tibia and fibula (A) shows an oblique comminuted fracture through the proximal fibula (arrow) and a comminuted oblique fracture through the distal tibia (arrowheads). Image B is a magnified view of the proximal fibula highlighting the fracture (arrow), and image C is a magnified view of the distal tibia showing the comminuted fracture (arrowheads).</div><div id=\"graphicVersion\">Graphic 99868 Version 1.0</div></div></div>"},"99871":{"type":"graphic_table","displayName":"Early-onset dementia neurologic features","title":"Early-onset dementia neurologic features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Early-onset dementia neurologic features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neurologic features</td> <td class=\"subtitle1\">Range of diseases</td> </tr> <tr> <td> <p>Visual or ocular involvement</p> <p class=\"indent1\">Optic atrophy</p> <p class=\"indent1\">Retinal degeneration</p> <p class=\"indent1\">Cataracts</p> <p class=\"indent1\">Argyll Robertson pupil</p> <p class=\"indent1\">Kayser-Fleischer rings</p> </td> <td> <p>&nbsp;</p> <p>Neurometabolic (MLD, Krabbe, PMD, CTX, HDLAS, mitochondrial disease)</p> <p>Neurometabolic (Krabbe, Cockayne syndrome, mitochondrial disease)</p> <p>Neurometabolic (CTX, mitochondrial disease)</p> <p>Neurosyphillis</p> Wilson disease</td> </tr> <tr> <td>Psychiatric or behavioral symptoms</td> <td>FTD, DLB, neurometabolic (MLD, ALD, VWM, APBD, HDLAS)</td> </tr> <tr> <td>Myoclonus or early seizures</td> <td>Prion disease, AD, DLB, DRPLA, neurometabolic (mitochondrial disease, Gaucher disease, Tay-Sachs, ANCL, Lafora body disease, sialidosis), SSPE</td> </tr> <tr> <td>Gaze palsy/ophthalmoplegia</td> <td>PSP, SCA2, neurometabolic (Gaucher disease, Neiman Pick type C, mitochondrial disease), Whipple disease, alcohol</td> </tr> <tr> <td>Deafness</td> <td>Superficial siderosis, mitochondrial disease</td> </tr> <tr> <td>Dysautonomia</td> <td>DLB, MSA, prion disease, anti-NMDAR encephalitis, AADL</td> </tr> <tr> <td>Pyramidal signs</td> <td>MS, FTD with MND, AD (PSEN1), SCA, neurometabolic (ALD, VWM, Krabbe, APBD, CTX, HDLAS)</td> </tr> <tr> <td>Tremor</td> <td>PDD, PSP, MSA, HIV, Wilson disease</td> </tr> <tr> <td>Dystonia/chorea</td> <td>HD, ANCL, CBD, Wilson disease, neuroacanthocytosis, Lesch-Nyhan, DRPLA, anti-NMDAR encephalitis, variant CJD</td> </tr> <tr> <td>Peripheral neuropathy</td> <td>HIV, alcohol, neurometabolic (CTX, ALD, MLD, Krabbe, APBD, mitochondrial disease, Fabry disease), SCA2</td> </tr> <tr> <td>Abnormal gait and station</td> <td>NPH, PDD, PSP, vascular dementia, neurosyphillis, Tay-Sachs</td> </tr> <tr> <td>Ataxia</td> <td>SCA, paraneoplastic encephalopathy, prion disease, DPRLA, fragile X, MSA, MS, neurometabolic (CTX, Alexander disease, APBD, VWM, mitochondrial disease, ANCL)</td> </tr> <tr> <td>Migraine and stroke</td> <td>CADASIL</td> </tr> <tr> <td>Sleep disturbance</td> <td>Neurodegenerative dementias, prion disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MLD: metachromatic leukodystrophy; PMD: Pelizaeus-Merzbacher disease; CTX: cerebrotendinous xanthomatosis; HDLAS: hereditary diffuse leukoencephalopathy with axonal spheroids; FTD: frontotemporal dementia; DLB: dementia with Lewy bodies; ALD: X-linked adrenoleukodystrophy; VWM: vanishing white matter disease; APBD: adult polyglucosan body disease; AD: Alzheimer dementia; DRPLA: dentatorubral pallidoluysian atrophy; ANCL: adult-onset neuronal ceroid lipofuscinosis; SSPE: subacute sclerosing panencephalitis; MSA: multiple systems atrophy; AADL: adult-onset autosomal dominant leukodystrophy; MS: multiple sclerosis; FTD: frontotemporal dementia; MND: motor neuron disease; PSEN1: presenilin 1; SCA: spinocerebellar atrophy; PDD: Parkinson disease dementia; PSP: progressive supranuclear palsy; HIV: human immunodeficiency virus; HD: Huntington disease; CBD: corticobasal degeneration; CJD: Creutzfeldt-Jacob disease; NPH: normal pressure hydrocephalus; CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.</div><div class=\"graphic_reference\">Adapted from Rossor MN et al. The diagnosis of young-onset dementia. Lancet Neurol 2010; 9:793 and Ahmed RM et al. A practical approach to diagnosing adult onset leukodystrophies. J Neurol Neurosurg Psychiatry&nbsp;2014; 85:770.</div><div id=\"graphicVersion\">Graphic 99871 Version 3.0</div></div></div>"},"99875":{"type":"graphic_table","displayName":"2015 IOM diagnostic criteria for CFS/SEID","title":"2015 IOM diagnostic criteria for CFS/SEID","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2015 IOM diagnostic criteria for CFS/SEID</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Diagnosis requires that the patient have the following three symptoms:</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>A substantial reduction or impairment in the ability to engage in pre-illness levels of occupational, educational, social, or personal activities that persists for more than&nbsp;six months and is accompanied by fatigue, which is often profound, is of new or definite onset (not lifelong), is not the result of ongoing excessive exertion, and is not substantially alleviated by rest; </li> <li>Post-exertional malaise;* and </li> <li>Unrefreshing sleep* </li> </ol> </td> </tr> <tr> <td>At least one of the two following manifestations is also required:</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Cognitive impairment*; or </li> <li>Orthostatic intolerance&#177; </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFS/SEID: chronic fatigue syndrome/systemic exertion intolerance disease.<br />* Frequency and severity of symptoms should be assessed. The diagnosis of CFS/SEID should be questioned if patients do not have these symptoms at least half of the time with moderate, substantial, or severe intensity.<br />± Onset of symptoms when standing upright that are improved by lying back down.</div><div class=\"graphic_reference\">From: Institute of Medicine of the National Academies. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an illness. Report Brief, February 2015. Reprinted with permission from the National Academies Press, Copyright © 2015 National Academy of Sciences.</div><div id=\"graphicVersion\">Graphic 99875 Version 7.0</div></div></div>"},"99876":{"type":"graphic_picture","displayName":"Chronic vitreous hemorrhage","title":"Chronic vitreous hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Chronic vitreous hemorrhage</div><div class=\"cntnt\"><img style=\"width:714px; height:525px;\" src=\"images/PEDS/99876_Chronic_vitreous_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic vitreous hemorrhage causing whitish deposits (arrow), which mimic vitreous seeding from retinoblastoma. There was no significant intraocular mass on ultrasonography and vitrectomy confirmed the diagnosis of vitreous hemorrhage.</div><div id=\"graphicVersion\">Graphic 99876 Version 1.0</div></div></div>"},"99878":{"type":"graphic_picture","displayName":"Retinoblastoma mimicking pars planitis","title":"Retinoblastoma mimicking pars planitis","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Retinoblastoma mimicking pars planitis</div><div class=\"cntnt\"><img style=\"width:634px; height:474px;\" src=\"images/PEDS/99878_Rtnblstm_mmck_par_plnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An eight-year-old child referred for evaluation of pars planitis (a subset of uveitis) who was diagnosed with retinoblastoma. Note the clumps of tumor seeds in the vitreous (arrow), which mimic \"snow balls\" of pars planitis. A clue to the diagnosis of retinoblastoma is the preretinal invasion by tumor cells (arrowhead), which would not occur in uveitis. Retinoblastoma was confirmed by histopathology after enucleation.</div><div id=\"graphicVersion\">Graphic 99878 Version 1.0</div></div></div>"},"99882":{"type":"graphic_table","displayName":"Anti-clotting medicines PI","title":"Common questions about the different anti-clotting medicines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common questions about the different anti-clotting medicines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Warfarin</td> <td class=\"subtitle1\">Newer anti-clotting medicines<br /> (dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>How often do I need to take it?</strong></td> <td>Once a day</td> <td>Once or twice a day, depending on the medicine and the reason for taking it.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Are regular blood tests required?</strong></td> <td>Yes</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Will I take the same dose each day?</strong></td> <td>Maybe, but it might need to be adjusted a few times to get the right dose. Also, the dose could change if you start another new medicine or if you get sick.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>If I have bleeding, is there an antidote to control it?</strong></td> <td>Yes</td> <td>Yes for dabigatran, under development for the others</td> </tr> <tr class=\"divider_bottom\"> <td><strong>How many other medicines change the way it works?</strong></td> <td>Many</td> <td>Few</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Do I need to be careful about my diet while taking it?</strong></td> <td> <p>Yes &ndash; you need to pay attention to how much vitamin K you're getting.</p> <p><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">You also need to be aware of foods that might interact with warfarin. Many doctors suggest limiting cranberry juice, grapefruit juice, and alcohol to 1 or 2 servings a day or less.</span></p> </td> <td>A little &ndash; you should avoid grapefruit and grapefruit juice, which can change the way these medicines work.</td> </tr> <tr> <td><strong>How does the price compare?</strong></td> <td>Less expensive</td> <td>More expensive</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 99882 Version 4.0</div></div></div>"},"99883":{"type":"graphic_table","displayName":"Risk factors for perioperative respiratory adverse events","title":"Factors that have been associated with an increased risk for perioperative respiratory adverse events in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that have been associated with an increased risk for perioperative respiratory adverse events in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient factors</td> </tr> <tr> <td class=\"indent1\">Age; younger higher risk than older</td> </tr> <tr> <td class=\"indent1\">Premature birth</td> </tr> <tr> <td class=\"indent1\">Upper respiratory tract infection (&#8804;2 weeks)</td> </tr> <tr> <td class=\"indent1\">Recurrent wheezing</td> </tr> <tr> <td class=\"indent1\">Current/past asthma</td> </tr> <tr> <td class=\"indent1\">Nocturnal dry cough</td> </tr> <tr> <td class=\"indent1\">Wheezing during exercise</td> </tr> <tr> <td class=\"indent1\">Hayfever</td> </tr> <tr> <td class=\"indent1\">Current/past eczema</td> </tr> <tr> <td class=\"indent1\">Family history of asthma, eczema, hayfever</td> </tr> <tr> <td class=\"indent1\">Passive/active smoker</td> </tr> <tr> <td class=\"indent1\">Other respiratory illnesses (eg, bronchopulmonary dysplasia, cystic fibrosis)</td> </tr> <tr> <td class=\"indent1\">Previous history of apnea</td> </tr> <tr> <td class=\"indent1\">Obstructive sleep apnea</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Syndromes associated with airway obstruction (eg, Down Syndrome)</td> </tr> <tr> <td class=\"indent1\">Anemia, hematocrit level less than 30%</td> </tr> <tr> <td class=\"indent1\">Unfasted patient</td> </tr> <tr> <td class=\"subtitle1_single\">Surgical factors</td> </tr> <tr> <td class=\"indent1\">Shared airway procedures (eg, ear, nose, and throat; dental; respiratory)</td> </tr> <tr> <td class=\"indent1\">Blood, secretions in upper airway</td> </tr> <tr> <td class=\"indent1\">Sudden surgical stimulation</td> </tr> <tr> <td class=\"indent1\">Emergency procedure</td> </tr> <tr> <td class=\"subtitle1_single\">Anesthesia-related factors</td> </tr> <tr> <td class=\"indent1\">Premedication with midazolam</td> </tr> <tr> <td class=\"indent1\">Topical airway lidocaine</td> </tr> <tr> <td class=\"indent1\">Inhalational induction of anesthesia</td> </tr> <tr> <td class=\"indent1\">Invasive airway management (endotracheal tube &#62; laryngeal mask airway &#62; facemask)</td> </tr> <tr> <td class=\"indent1\">Less experience with airway management</td> </tr> <tr> <td class=\"indent1\">Insufficient supervision ratio for trainees (eg, supervisor absent for critical periods during anesthesia)</td> </tr> <tr> <td class=\"indent1\">Desflurane administration</td> </tr> <tr> <td class=\"indent1\">High-dose opioid administration, intraoperative or postoperative</td> </tr> <tr> <td class=\"indent1\">Administration of neuromuscular blocking agents</td> </tr> <tr> <td class=\"indent1\">Nurse-to-patient ratio in the recovery area (&#60;1:1)</td> </tr> <tr> <td class=\"indent1\">Mixed anesthetic clinical practice (adult/pediatric &#62; solely pediatric)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. von Ungern-Sternberg B. Respiratory complications in the pediatric post-anesthesia care unit. Anesthesiol Clin 2014; 32:45. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99883 Version 7.0</div></div></div>"},"99884":{"type":"graphic_table","displayName":"HLA-haploidentical donor selection criteria","title":"HLA-haploidentical donor selection criteria (in decreasing order of priority)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HLA-haploidentical donor selection criteria (in decreasing order of priority)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Donor must be medically, socially, and psychologically fit to donate</strong></td> </tr> <tr> <td><strong>The patient must lack clinically significant antibodies against donor HLA molecules</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Specifically, complement dependent cytotoxicity and flow cytometric crossmatch assays must be negative, and the mean fluorescence intensity (MFI) of any anti-donor HLA antibody by solid phase immunoassay should be &#60;3000 </li> </ul> </td> </tr> <tr> <td><strong>Donor</strong> <strong>age &#60;40 years preferred over donor age &#8805;40 years</strong></td> </tr> <tr> <td><strong>No major ABO incompatibility between donor and recipient</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Major ABO incompatibilities include: <ul> <li>Recipient blood type O: Donor type A, B, or AB </li> <li>Recipient blood type A: Donor blood type B or AB </li> <li>Recipient blood type B: Donor blood type A or AB </li> <li>Recipient blood type AB: No major ABO incompatibilities </li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>Matched CMV IgG serologic status between donor and recipient</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>For a recipient who is CMV IgG negative, use a CMV IgG negative donor </li> <li>For a recipient who is CMV IgG positive, use a CMV IgG positive donor </li> </ul> </td> </tr> <tr> <td><strong>Use an ABO compatible donor over a minor ABO incompatible donor</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>ABO compatible transplants are O&#8594;O, A&#8594;A, B&#8594;B, or AB&#8594;AB </li> </ul> </td> </tr> <tr> <td><strong>Other donor characteristics (in no order of priority)</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Donor age &#8805;18 preferred over donor &#60;18 </li> <li>Among donors &#8805;18 years, prefer younger and lighter donors </li> <li>For male recipients, male donors are preferred over nulliparous female donors who are preferred over multiparous female donors </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 99884 Version 2.0</div></div></div>"},"99885":{"type":"graphic_table","displayName":"Early-onset dementia systemic features","title":"Early-onset dementia systemic features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Early-onset dementia systemic features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Systemic features</td> <td class=\"subtitle1\">Range of diseases</td> </tr> <tr> <td>Splenomegaly</td> <td>Niemann-Pick type C, Gaucher</td> </tr> <tr> <td>Tendon xanthomas</td> <td>CTX</td> </tr> <tr> <td>Paget disease of bone</td> <td>FTD</td> </tr> <tr> <td>Renal impairment</td> <td>Fabry disease, Lesch-Nyhan, mitochondrial disease</td> </tr> <tr> <td>Liver dysfunction</td> <td>Wilson disease, Gaucher disease, mitochondrial disease</td> </tr> <tr> <td>Respiratory failure</td> <td>FTD with MND, mitochondrial disease, anti-NMDAR encephalitis</td> </tr> <tr> <td>Gastrointestinal dysfunction</td> <td>Whipple disease</td> </tr> <tr> <td>Anemia</td> <td>Vitamin B12 deficiency, neuroacanthocytosis, Wilson disease, alcohol</td> </tr> <tr> <td>Urinary incontinence</td> <td>NPH</td> </tr> <tr> <td>Skin lesions</td> <td>Systemic vasculitides, Fabry disease</td> </tr> <tr> <td>Hyponatremia</td> <td>Limbic encephalitis</td> </tr> <tr> <td>Amenorrhea</td> <td>VWM</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTX: cerebrotendinous xanthomatosis; FTD: frontotemporal dementia; MND: motor neuron disease; NMDAR: n-methyl-D-aspartate receptor; NPH: normal pressure hydrocephalus; VWM: vanishing white matter disease.</div><div class=\"graphic_reference\">Adapted from: Rossor MN1, Fox NC, Mummery CJ, et al. The diagnosis of young-onset dementia. Lancet Neurol 2010; 9:793.</div><div id=\"graphicVersion\">Graphic 99885 Version 1.0</div></div></div>"},"99887":{"type":"graphic_diagnosticimage","displayName":"Acquired cystic disease of the kidney ultrasound","title":"Ultrasound of acquired cystic disease of the kidney","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Ultrasound of acquired cystic disease of the kidney</div><div class=\"cntnt\"><img style=\"width:720px; height:510px;\" src=\"images/NEPH/99887_Acquired_cystic_kidney_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A longitudinal view of the right kidney in a 71-year-old male with chronic kidney disease stage 5 and acquired cystic kidney disease. The kidney presents with a thin and echogenic cortex and loss of corticomedullary differentiation. There are several round-shaped hypoechoic lesions, with posterior enhancement throughout the cortex (mostly peripheral) representing simple cysts. The cysts are less than 1.5 cm in their large diameter.</div><div class=\"graphic_reference\">Courtesy of Frederic F Rahbari-Oskoui, MD, MSCR.</div><div id=\"graphicVersion\">Graphic 99887 Version 1.0</div></div></div>"},"99888":{"type":"graphic_diagnosticimage","displayName":"Acquired cystic disease of the kidney MRI","title":"Magnetic resonance image of acquired cystic disease of the kidney","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of acquired cystic disease of the kidney</div><div class=\"cntnt\"><img style=\"width:474px; height:318px;\" src=\"images/NEPH/99888_Acquired_cystic_kidney_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal T2-weighted magnetic resonance imaging (MRI) of both kidneys and the liver, without injection of gadolinium, in a 71-year-old male with CKD stage 5 and acquired cystic kidney disease. The kidneys are relatively small (measuring approximately 9 cm in the longitudinal axis). There are several lesions with high T2 signal throughout the cortex on both kidneys, consistent with simple cysts.</div><div class=\"graphic_reference\">Courtesy of Frederic F Rahbari-Oskoui, MD, MSCR.</div><div id=\"graphicVersion\">Graphic 99888 Version 1.0</div></div></div>"},"99889":{"type":"graphic_table","displayName":"Drugs associated with psoriasiform drug eruptions","title":"Reported causes of psoriasiform drug eruptions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reported causes of psoriasiform drug eruptions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\">Psychoactive drugs (lithium)</td> </tr> <tr> <td class=\"indent1\">Antihypertensives (beta-blockers)</td> </tr> <tr> <td class=\"indent1\">Antimalarials (chloroquine, hydroxychloroquine, quinidine)</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal anti-inflammatory drugs, antibiotics (tetracycline)</td> </tr> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\">Tumor necrosis factor inhibitors (infliximab, adalimumab, etanercept, certolizumab pegol)<sup>[1,2]</sup></td> </tr> <tr> <td class=\"indent1\">Antifungals (terbinafine)<sup>[3]</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\">Antihypertensives (clonidine)</td> </tr> <tr> <td class=\"indent1\">Antiarrhythmics (digoxin, amiodarone)</td> </tr> <tr> <td class=\"indent1\">Antiepileptics (carbamazepine, valproic acid)</td> </tr> <tr> <td class=\"indent1\">Psychoactives (fluoxetine)</td> </tr> <tr> <td class=\"indent1\">Antihypertensives/diuretics (captopril, chlorthalidone, diltiazem, nifedipine, nicardipine,<sup>[4]</sup> acetazolamide)</td> </tr> <tr> <td class=\"indent1\">Antibiotics (penicillin, amoxicillin, ampicillin)</td> </tr> <tr> <td class=\"indent1\">Opioids (morphine)</td> </tr> <tr> <td class=\"indent1\">Anesthetics (procaine)</td> </tr> <tr> <td class=\"indent1\">Antihistamines (cimetidine, ranitidine)</td> </tr> <tr> <td class=\"indent1\">Heavy metals (gold, mercury)</td> </tr> <tr> <td class=\"indent1\">Hormonal agents (oxandrolone, progesterone)</td> </tr> <tr> <td class=\"indent1\">Fibrates (gemfibrozil)</td> </tr> <tr> <td class=\"indent1\">Antithyroid (potassium iodide)</td> </tr> <tr> <td class=\"indent1\">Cytokines/cytokine inducers (GM-CSF, imiquimod)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GM-CSF: granulocyte macrophage colony-stimulating factor.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9:1.</li>&#xD;&#xA;    <li>Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34:1318. doi:10.1111/j.1365-2036.2011.04866.x.</li>&#xD;&#xA;    <li>Gupta AK, Sibbald RG, Knowles SR, et al. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997; 36:858.</li>&#xD;&#xA;    <li>Kitamura K, Kanasashi M, Suga C, et al. Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions. J Dermatol 1993; 20:279.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Ahronowitz I, Fox L. Severe drug-induced dermatoses. Semin Cutan Med Surg 2014; 33:49. Copyright &copy; 2014 Frontline Medical Communications.</div><div id=\"graphicVersion\">Graphic 99889 Version 2.0</div></div></div>"},"99890":{"type":"graphic_waveform","displayName":"EEG Temporal intermittent rhythmic delta activity","title":"Temporal intermittent rhythmic delta activity","html":"<div class=\"graphic\"><div style=\"width: 982px\" class=\"figure\"><div class=\"ttl\">Temporal intermittent rhythmic delta activity</div><div class=\"cntnt\"><img style=\"width:962px; height:601px;\" src=\"images/NEURO/99890_Tmpr_intrmt_rhthmc_dlt_actv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporal intermittent rhythmic delta activity (TIRDA; see boxes) in the left temporal region in a patient with epilepsy and left mesial temporal sclerosis on MRI.</div><div id=\"graphicVersion\">Graphic 99890 Version 2.0</div></div></div>"},"99892":{"type":"graphic_picture","displayName":"Tinea corporis on extremity","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99892_Tinea_corporis_extremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular plaque with scale on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99892 Version 1.0</div></div></div>"},"99893":{"type":"graphic_waveform","displayName":"EEG Lateralized rhythmic delta activity","title":"Lateralized rhythmic delta activity (LRDA)","html":"<div class=\"graphic\"><div style=\"width: 972px\" class=\"figure\"><div class=\"ttl\">Lateralized rhythmic delta activity (LRDA)</div><div class=\"cntnt\"><img style=\"width:952px; height:601px;\" src=\"images/NEURO/99893_Ltrlz_rhthmc_dlt_actv_LRDA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateralized rhythmic delta activity (LRDA; see boxes) in the left hemisphere, most pronounced in the left temporal region.</div><div id=\"graphicVersion\">Graphic 99893 Version 2.0</div></div></div>"},"99894":{"type":"graphic_picture","displayName":"Candidal intertrigo","title":"Candidal intertrigo","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Candidal intertrigo</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/99894_Candidal_intertrigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaque with satellite papules and pustules.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99894 Version 2.0</div></div></div>"},"99895":{"type":"graphic_waveform","displayName":"EEG 14- and 6-Hertz positive bursts","title":"14 and 6-Hertz positive bursts","html":"<div class=\"graphic\"><div style=\"width: 978px\" class=\"figure\"><div class=\"ttl\">14 and 6-Hertz positive bursts</div><div class=\"cntnt\"><img style=\"width:958px; height:589px;\" src=\"images/NEURO/99895_14_6_Hertz_pstv_brst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">14- and 6-Hertz positive bursts (arrows). This is a normal variant, generally seen during drowsiness or light sleep, maximal in the posterior temporal region. The bursts are usually 14 Hz, although can occur at a rate of 6 to 7 Hz, and have a positive spiky component with a smooth negative phase.</div><div id=\"graphicVersion\">Graphic 99895 Version 2.0</div></div></div>"},"99896":{"type":"graphic_table","displayName":"Component blood type for HCT recipients","title":"Blood component transfusion in hematopoietic cell transplant recipients in the immediate post-transplant period","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood component transfusion in hematopoietic cell transplant recipients in the immediate post-transplant period</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Recipient ABO type</td> <td class=\"subtitle1\" colspan=\"2\">Donor type&nbsp;O</td> <td class=\"subtitle1\" colspan=\"2\">Donor type A</td> <td class=\"subtitle1\" colspan=\"2\">Donor type B</td> <td class=\"subtitle1\" colspan=\"2\">Donor type AB</td> </tr> <tr> <td class=\"subtitle2\">RBC type</td> <td class=\"subtitle2\">FFP/PLT type</td> <td class=\"subtitle2\">RBC type</td> <td class=\"subtitle2\">FFP/PLT type</td> <td class=\"subtitle2\">RBC type</td> <td class=\"subtitle2\">FFP/PLT type</td> <td class=\"subtitle2\">RBC type</td> <td class=\"subtitle2\">FFP/PLT type</td> </tr> <tr> <td>O</td> <td>O</td> <td>Any type</td> <td>O</td> <td>A or AB</td> <td>O</td> <td>B or AB</td> <td>O</td> <td>AB</td> </tr> <tr> <td>A</td> <td>O</td> <td>A or AB</td> <td>A or O</td> <td>A or AB</td> <td>O</td> <td>AB</td> <td>A or O</td> <td>AB</td> </tr> <tr> <td>B</td> <td>O</td> <td>B or AB</td> <td>O</td> <td>AB</td> <td>B or O</td> <td>B or AB</td> <td>B or O</td> <td>AB</td> </tr> <tr> <td>AB</td> <td>O</td> <td>AB</td> <td>A or O</td> <td>AB</td> <td>B or O</td> <td>AB</td> <td>AB, A, B, or O</td> <td>AB</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Recipient Rh</td> <td class=\"subtitle1\" colspan=\"2\">Donor Rh-negative</td> <td class=\"subtitle1\" colspan=\"2\">Donor Rh-positive</td> </tr> <tr> <td class=\"subtitle2\">RBC Rh</td> <td class=\"subtitle2\">PLT Rh</td> <td class=\"subtitle2\">RBC Rh</td> <td class=\"subtitle2\">PLT Rh</td> </tr> <tr> <td>Rh positive</td> <td>Negative</td> <td>See note</td> <td>Positive</td> <td>See note</td> </tr> <tr> <td>Rh negative</td> <td>Negative</td> <td>See note</td> <td>Negative</td> <td>See note</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HCT recipients who receive HSCs of a different blood type may have chimerism in the immediate post-transplant period. The goals of component selection are to minimize risks of RBC hemolysis and to optimize hematopoiesis from donor cells. Rh(D)-positive recipients with Rh(D)-negative donors receive Rh(D)-negative RBCs and granulocytes. Rh(D)-negative recipients with Rh(D)-positive donors receive Rh(D)-negative RBCs and granulocytes. Platelets should be of the ABO type listed if available. Refer to UpToDate topics on pretransfusion testing, transfusion, and management in the immediate post-HCT period for additional details.</div><div class=\"graphic_footnotes\">RBC: red blood cell; FFP: fresh frozen plasma; PLT: platelets; Rh: Rh(D); HCT: hematopoietic cell transplant; HSCs: hematopoietic stem cells.</div><div id=\"graphicVersion\">Graphic 99896 Version 3.0</div></div></div>"},"99897":{"type":"graphic_table","displayName":"GI disorders in patients with different types of PID","title":"Gastrointestinal disorders in patients with different types of primary immunodeficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gastrointestinal disorders in patients with different types of primary immunodeficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Gastrointestinal presentation</td> <td class=\"subtitle1\">&nbsp;Epidemiology and common extraintestinal features</td> <td class=\"subtitle1\">&nbsp;Key diagnostic tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Predominantly antibody deficiencies</td> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Common variable immunodeficiency</td> <td>Chronic diarrhea, malabsorption, weight loss, giardiasis, atrophic gastritis, pernicious anemia, NLH, IBD-like disease, sprue-like disease, hepatitis, liver dysfunction, primary biliary cirrhosis, granulomatous liver disease, and gastric carcinoma</td> <td>Patients of any age, both males and females. Sinopulmonary&nbsp;bacterial infections, autoimmune hematologic disorders (eg, autoimmune hemolytic anemia, ITP), splenomegaly.</td> <td>IgG&nbsp;AND either IgA or IgM below the lower limit of normal for age, poor or absent responses to protein and polysaccharide vaccines.</td> </tr> <tr> <td class=\"indent1\">X-linked agammaglobulinemia</td> <td>Chronic diarrhea, malabsorption, viral and bacterial gastrointestinal infections, enteropathy resembling Crohn disease, gastric adenocarcinoma, and colorectal cancer</td> <td> <p>Boys, usually 6 months to 5 years of age.</p> <p>Sinopulmonary bacterial infections, chronic enteroviral infections (echovirus, coxsackie) presenting as meningoencephalitis or chronic hepatitis.</p> <p>Vaccine-related polio after live vaccination.</p> <p>Hypoplastic tonsils, adenoids.</p> </td> <td> <p>Low to absent IgG, IgA, IgM.</p> <p>Low to absent CD19+ B&nbsp;cells.</p> <p>Absent antibody responses to vaccines and microbial antigens.</p> </td> </tr> <tr> <td class=\"indent1\">X-linked hyperimmunoglobulin M syndrome</td> <td>Protracted and recurrent infectious diarrhea, FTT, oral ulcers, gingivitis, rectal ulcer, progressive liver disease, sclerosing cholangitis, carcinomas of the liver, pancreas, biliary tract</td> <td>Recurrent sinopulmonary bacterial infections, opportunistic infections, lymphadenopathy, and hepatosplenomegaly.</td> <td> <p>Normal or elevated IgM with low IgG, IgA, and IgE.</p> <p>Lack of response to polysaccharide and protein vaccines.</p> </td> </tr> <tr> <td class=\"indent1\">Selective IgA deficiency&nbsp;&nbsp;</td> <td>Diarrhea, celiac disease, IBD, NLH, and giardiasis</td> <td>Patients of any age, both males and females.&nbsp;Often are asymptomatic. Symptomatic patients may have sinopulmonary infections, autoimmune disorders, and/or allergic disorders.</td> <td> <p>Serum IgA low or absent, with normal&nbsp;IgG and IgM. Occasional impaired responses to polysaccharide vaccines and&nbsp;less commonly&nbsp;protein vaccines.</p> <p>Some have associated IgG subclass deficiency.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Combined immunodeficiencies</td> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Severe combined immunodeficiency</td> <td>Diarrhea, FTT, bacterial and viral gastrointestinal infections, candidiasis of oral cavity, esophagus and anus, villous atrophy in small intestine, GVHD and GVHD-like process in small intestine and colon</td> <td>Both males and females, usually presents within the first 3 months of life, early-onset severe and/or recurrent bacterial, viral, and fungal infections, and FTT.</td> <td> <p>Absent or decreased circulatory T cells. Normal, increased or decreased B cells. Normal, absent, or decreased NK cells. Lack of functional antibodies.</p> <p>Low or absent TRECs on newborn screening.</p> </td> </tr> <tr> <td class=\"indent1\">DiGeorge syndrome</td> <td>Diarrhea, feeding difficulties, FTT, and candidiasis</td> <td>Both male and females, structural abnormalities may present at birth, recurrent infections present in those older than 3 to 6 months, conotruncal cardiac anomalies, hypoplastic thymus, hypocalcemia, and abnormal facies. Slow cognitive development.</td> <td>Normal or decreased T cells. Normal B cells. Normal or decreased NK cells.</td> </tr> <tr> <td class=\"indent1\">MHC class II deficiency</td> <td>Diarrhea and FTT</td> <td>Similar to SCID even though milder forms also exist.</td> <td>Normal number of T cells, decreased number of CD4+ T cells. Normal number of B cells. Lack of functional antibodies. Normal in vitro response of T cell to PHA. Absence of MHC II expression and slight decrease in MHC I expression on B cells.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Well-defined syndromes with immunodeficiency</td> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Wiskott-Aldrich syndrome</td> <td>Early-onset gastrointestinal bleeding and early-onset IBD-like colitis</td> <td>Young males within the first 2 years of life, thrombocytopenia with small platelets, eczema, autoimmunity, lymphoma, and recurrent bacterial and viral infections.</td> <td>Decreased number and function of T cells, normal number of B cells, normal or increased number of NK cells, but their function may be impaired.<br /> Impaired response to polysaccharide vaccines. <br /> Decreased IgM, normal or decreased IgG, increased IgA, and IgE. Decreased function of regulatory T (Treg) cells. Impaired chemotaxis of phagocytic cells.<br /> </td> </tr> <tr> <td class=\"indent1\">Hyperimmunoglobulin E syndrome</td> <td>Disseminated gastrointestinal infection caused by Cryptococcus and Histoplasma, colon diverticulitis and perforation, and severe food allergy</td> <td>Patients of any age.<br /> Both male and females.<br /> Facial abnormalities, eczema, skeletal abnormalities, delay of shedding primary teeth, recurrent and/ or severe cutaneous and pulmonary bacterial infections mainly due to Staphylococcus aureus and Candidiasis.</td> <td>Markedly increased IgE. Impaired specific antibody production. Decreased memory B cells. Increased B cell-activating factor. Decreased Th17 and T follicular helper cells.</td> </tr> <tr> <td class=\"indent1\">Ataxia-telangiectasia</td> <td>Adenocarcinomas and lymphoreticular malignancies of gastrointestinal tract</td> <td>Both males and females. Commonly presents in early childhood.<br /> Ataxic gait, telangiectasia, recurrent sinopulmonary infections, and tendency to malignancies.</td> <td>Decreased or normal IgG, IgA, and IgE subclasses. Increased or normal IgM. Progressive decrease of T cells. Elevated levels of alpha-1-fetoprotein, radiosensitivity.</td> </tr> <tr> <td class=\"indent1\">Immunodeﬁciency with multiple intestinal atresias</td> <td>Multiple intestinal atresias involving stomach to rectum, gastrointestinal obstruction, and gastrointestinal infections</td> <td>Both boys and girls.<br /> Presents early after birth.<br /> Multiple intestinal atresias which is frequently accompanied by intrauterine polyhydramnios and death at an early age, and SCID-like phenotype in some cases.</td> <td>Hypogammaglobulinemia. T cells may be absent.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Phagocytic defects</td> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Chronic granulomatous disease</td> <td>Diarrhea with or without blood, steatorrhea, malabsorption, FTT, abdominal pain, constipation, gastrointestinal infections, hepatic abscess, perirectal abscess, cholecystitis noncaseating granulomatous colitis resembling Crohn disease, granulomata formation, dysphagia, esophageal dysmotility, and gastrointestinal obstruction</td> <td>Majority of patients are males.<br /> At any age but most commonly before 5 years of age.<br /> Granuloma formation, and severe and/ or recurrent bacterial and fungal infections.</td> <td>Hypogammaglobulinemia. Anemia of chronic disease. Impaired neutrophil function tests.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Defects in innate immunity</td> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Chronic mucocutaneous candidiasis</td> <td>Chronic and recurrent candidiasis in oral cavity, esophagus and gastrointestinal tract, dental abnormalities, chronic diarrhea, and constipation</td> <td>Both males and females.<br /> Usually presents before 5 years of age.<br /> Candidiasis of skin, mucous membranes, and nails, autoimmunity.</td> <td>Impaired in vivo and in vitro response to Candida.&nbsp;Some have&nbsp;impaired response to polysaccharide vaccines. Hypogammaglobulinemia is rare. Anemia of iron deficiency or Vitamin B12 deficiency. Impaired thyroid, liver, and blood sugar tests due to an underlying autoimmune cause.</td> </tr> <tr> <td class=\"indent1\">NEMO deficiency</td> <td>Diarrhea, abdominal pain, malabsorption, mycobacterial and CMV infection, bloody stool, weight loss, atypical enterocolitis, vomiting, and giardiasis</td> <td>Almost all patients are male.<br /> Presents in the first year of life in most of cases.<br /> Recurrent and/ or severe infections by bacteria, Mycobacteria, viruses and fungal organisms,<br /> ectodermal dysplasia, and colitis.</td> <td>Hypogammaglobulinemia with impaired response to polysaccharide vaccines. Normal or increased IgM and IgA. Impaired function of NK cells and lymphocytosis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Diseases of immune dysregulation</td> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Immune dysfunction, polyendocrinopathy, enteropathy, X-linked (IPEX)</td> <td>Watery diarrhea, which can also be mucoid or bloody, malabsorption, FTT, and severe enteropathy resembling food allergy</td> <td>Typically a male infant. <br /> Autoimmune endocrinopathy such as type I diabetes mellitus and thyroiditis. Dermatitis most commonly in the form of eczema.</td> <td>Typically eosinophilia. Neutropenia, anemia, or thrombocytopenia are also present. <br /> Increased total and antigen-specific IgE. Increased IgA in one-half of patients. IgG and IgM may be normal or low.<br /> Impaired thyroid and blood sugar tests.</td> </tr> <tr> <td class=\"indent1\">CD25 deﬁciency</td> <td>Similar to IPEX</td> <td>Severe infections. <br /> Other features similar to IPEX.</td> <td>Similar to IPEX. Impaired response to antigen specific vaccines.</td> </tr> <tr> <td class=\"indent1\">STAT5b deﬁciency</td> <td>Similar to IPEX</td> <td>Growth hormone resistance.<br /> Other features similar to IPEX.</td> <td>Similar to IPEX.</td> </tr> <tr> <td class=\"indent1\">Hermansky-Pudlak syndrome</td> <td>Granulomatous colitis which may resemble IBD, enamel hypoplasia, lactase deficiency, and bacterial overgrowth</td> <td>Both males and females.<br /> Presents in infancy or early childhood.<br /> Recurrent infections, partial albinism, pulmonary fibrosis, and bleeding tendency.</td> <td>Normal number but with absent function of cytotoxic T and NK cells.</td> </tr> <tr> <td class=\"indent1\">Chediak-Higashi syndrome</td> <td>Gingivitis, periodontal disease, oral ulcers, and enterocolitis</td> <td>Both males and females.<br /> Presents in infancy or early childhood.<br /> Recurrent pyogenic infections, partial oculocutaneous albinism, progressive neurologic dysfunction, bleeding tendency, and a lymphoma-like accelerated phase.</td> <td>Neutropenia. Decreased chemotactic response of neutrophils and monocytes. Normal number but with absent function of NK cells. Increased number of activated T cells but absent fun cytotoxic T cell cells. Hypergammaglobulinemia. Abnormal coagulation tests.</td> </tr> <tr> <td class=\"indent1\">IL-10, IL-10 R1 deficiency, and IL-10 R2 deficiency</td> <td>Early-onset IBD accompanied by folliculitis and arthritis</td> <td>Both males and females.<br /> Usually presents before 3 months of age.<br /> Folliculitis and arthritis.</td> <td>Absence of functional IL-10 secretion.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NLH: nodular lymphoid hyperplasia; IBD: inflammatory bowel diseases<FONT color=black>; </FONT><FONT color=red><FONT color=black>ITP: immune thrombocytopenia; IgG</FONT><FONT color=black><FONT color=black>: immunoglobulin G; IgA: </FONT>immunoglobulin A; IgM: immunoglobulin M;</FONT> </FONT>FTT: failure to thrive;&nbsp;<FONT color=black>EBV: Epstein-Barr virus; </FONT><FONT color=black>GVHD: graft-versus-host disease; NK: natural killer cell; TRECs: T cell receptor excision circles; MHC: major histocompatibility complex; SCID: severe combined immunodeficiency; PHA: phytohemagglutinin; IgE</FONT>: immunoglobulin E; Treg: regulatory T cell; NEMO: NF-kappa-B essential modifier; CMV: cytomegalovirus; STAT5b: signal transducer and activator of transcription 5b; IL-10: interleukin-10; IL-10 R1: interleukin-10 receptor 1; IL-10 R2: interleukin-10 receptor 2.</div><div id=\"graphicVersion\">Graphic 99897 Version 4.0</div></div></div>"},"99898":{"type":"graphic_table","displayName":"GI infections among patients with different types of PID","title":"Common organisms responsible for gastrointestinal infections among patients with different types of primary immunodeficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common organisms responsible for gastrointestinal infections among patients with different types of primary immunodeficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Organism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Predominantly antibody deficiencies</td> </tr> <tr> <td class=\"indent1\">Common variable immunodeficiency</td> <td> <p>Bacteria: <em>Campylobacter jejuni</em>, Salmonella, <em>Helicobacter pylori</em></p> <p>Viruses: CMV, norovirus</p> <p>Fungal: Candida</p> Parasites: Cryptosporidium,&nbsp;<em>Giardia lamblia</em></td> </tr> <tr> <td class=\"indent1\">X-linked agammaglobulinemia</td> <td> <p>Bacteria: Salmonella, Campylobacter</p> <p>Parasites: Cryptosporidium,&nbsp;<em>Giardia lamblia</em></p> Viruses: Rotavirus</td> </tr> <tr> <td class=\"indent1\">X-linked hyperimmunoglobulin M syndrome</td> <td> <p>Bacteria: Salmonella</p> Parasites: Cryptosporidium,&nbsp;<em>Giardia lamblia</em>, <em>Entamoeba histolytica</em></td> </tr> <tr> <td class=\"indent1\">Selective IgA deficiency</td> <td>Parasites: <em>Giardia lamblia</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Combined immunodeficiencies</td> </tr> <tr> <td class=\"indent1\">Severe combined immunodeficiency</td> <td> <p>Bacteria: Salmonella, <em>Escherichia coli</em></p> <p>Viruses: Rotavirus, picornavirus, parvovirus, adenovirus, CMV</p> <p>Fungal: Candida</p> Parasites: Cryptosporidium,&nbsp;<em>Giardia lamblia</em></td> </tr> <tr> <td class=\"indent1\">DiGeorge syndrome</td> <td>Fungal: Candida</td> </tr> <tr> <td class=\"indent1\">MHC class II deficiency</td> <td> <p>Bacteria: Shigella, Salmonella, <em>Staphylococcus aureus</em>, <em>Escherichia coli</em>, Campylobacter</p> Viruses: Adenovirus, enterovirus</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Well-defined syndromes with immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Hyperimmunoglobulin E syndrome</td> <td>Fungal: Candida</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Phagocytic defects</td> </tr> <tr> <td class=\"indent1\">Chronic granulomatous disease</td> <td> <p>Bacteria: <em>Staphylococcus aureus</em>, <em>Pseudomonas aeruginosa</em>, <em>Burkholderia cepacia</em>, Serratia, Mycobacteria, <em>Escherichia coli</em></p> Fungal: Candida, Aspergillus</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Defects in innate immunity</td> </tr> <tr> <td class=\"indent1\">Chronic mucocutaneous candidiasis</td> <td>Fungal: Candida</td> </tr> <tr> <td class=\"indent1\">NEMO deficiency</td> <td> <p>Bacteria: Mycobacteria</p> Viruses: CMV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; IgA: immunoglobulin A; MHC: major histocompatibility complex; NEMO: NF-kappa-B essential modifier.</div><div id=\"graphicVersion\">Graphic 99898 Version 2.0</div></div></div>"},"99900":{"type":"graphic_table","displayName":"Glucocorticoid nasal sprays: Adult dosing","title":"Glucocorticoid nasal sprays: Adult dosing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glucocorticoid nasal sprays: Adult dosing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">United States trade name</td> <td class=\"subtitle1\">Generic available in United States</td> <td class=\"subtitle1\">Available without a prescription in United States</td> <td class=\"subtitle1\">Usual adult dose<br /> (per nostril)</td> <td class=\"subtitle1\">Type of preparation<br /> (alcohol content*)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Second-generation (systemic bioavailability &#60;1% or undetectable)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Ciclesonide</td> <td>Omnaris</td> <td>No</td> <td>No</td> <td>Two sprays once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td>Zetonna</td> <td>No</td> <td>No</td> <td>One spray once daily</td> <td>Pressurized aerosol spray (3.4% alcohol)</td> </tr> <tr> <td class=\"indent1\">Fluticasone furoate</td> <td>Flonase Sensimist (OTC)</td> <td>No</td> <td>Yes</td> <td>Two sprays once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td class=\"indent1\">Fluticasone propionate</td> <td>Flonase Allergy Relief (OTC), GoodSense Nasoflow (OTC), Ticaspray</td> <td>Yes</td> <td>Yes</td> <td>Two sprays once daily or one spray twice daily</td> <td>Aqueous suspension pump spray (0.25% alcohol)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mometasone</td> <td>Nasonex</td> <td>Yes</td> <td>No</td> <td>Two sprays once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">First-generation (systemic bioavailability 10 to 50%)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Beclomethasone</td> <td>Beconase AQ</td> <td>No</td> <td>No</td> <td>One or two sprays twice daily</td> <td>Aqueous suspension pump spray (0.25% alcohol)</td> </tr> <tr> <td>Qnasl</td> <td>No</td> <td>No</td> <td>Two sprays once daily</td> <td>Pressurized aerosol spray (8% alcohol)</td> </tr> <tr> <td class=\"indent1\">Budesonide</td> <td>Rhinocort Allergy (OTC)</td> <td>Yes</td> <td>Yes</td> <td>One spray once daily</td> <td>Aqueous suspension pump spray</td> </tr> <tr> <td class=\"indent1\">Flunisolide</td> <td>Generic (former United States brand: Nasarel)</td> <td>Yes</td> <td>No</td> <td>Two sprays twice daily</td> <td>Aqueous suspension pump spray (contains propylene glycol, a possible irritant)</td> </tr> <tr> <td class=\"indent1\">Triamcinolone</td> <td> <p>GoodSense Nasal Allergy (OTC), Nasacort Allergy 24 Hr (OTC), Nasal Allergy 24 Hour (OTC), generic (former United States brand: Nasacort&nbsp;AQ)</p> </td> <td>Yes</td> <td>Yes</td> <td>Two sprays once daily</td> <td>Aqueous suspension pump spray</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Nasal sprays work best when they are administered properly and the medication remains in the nose rather than draining down the back of the throat. Note that the recommended techniques for the aqueous and aerosol sprays are different. If the nose is crusted or contains mucus, it should first be cleaned with a saline nasal spray prior to use of intranasal sprays. Some people find that holding the other nostril closed with a finger improves their ability to draw the spray into the upper nose.<br />Once symptoms are controlled, the daily dose can be reduced to the lowest dose that maintains control.</div><div class=\"graphic_footnotes\">OTC: over-the-counter (available without a prescription in United States).<br />* Alcohol may contribute to dryness or irritation.</div><div id=\"graphicVersion\">Graphic 99900 Version 10.0</div></div></div>"},"99902":{"type":"graphic_picture","displayName":"Corynebacterium minutissimum","title":"<em>Corynebacterium minutissimum</em>","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\"><em>Corynebacterium minutissimum</em></div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99902_Corynebacterium_minutissim.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram-positive, rod-shaped bacteria.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99902 Version 3.0</div></div></div>"},"99903":{"type":"graphic_picture","displayName":"Erythrasma interdigital","title":"Erythrasma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythrasma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99903_Erythrasma_interdigital.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Interdigital scale and maceration on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99903 Version 2.0</div></div></div>"},"99904":{"type":"graphic_picture","displayName":"Erythrasma intertriginous","title":"Erythrasma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythrasma</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/99904_Erythrasmaintertriginous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous patches with fine scale in the groin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank'\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99904 Version 3.0</div></div></div>"},"99905":{"type":"graphic_picture","displayName":"Erythrasma in the axilla","title":"Erythrasma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Erythrasma</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/99905_Erythrasma_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented patch with fine scale in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99905 Version 1.0</div></div></div>"},"99927":{"type":"graphic_table","displayName":"Agents with potential adverse effects on fetal growth","title":"Agents with potential adverse effects on fetal growth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents with potential adverse effects on fetal growth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle2\" colspan=\"3\">Selected agents with potential adverse effects on fetal growth or gestational age, by strength of evidence*</td> </tr> <tr> <td class=\"subtitle1\">Limited</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Strong</td> </tr> <tr> <td>Carbon tetrachloride</td> <td>Air pollution</td> <td>Carbon monoxide</td> </tr> <tr> <td>Dioxins/TCDD</td> <td>Herbicides</td> <td>Cocaine</td> </tr> <tr> <td>PCE/TCE (in water)<sup>&#182;</sup></td> <td>Metals (Pb, Hg, As)<sup>&#182;</sup></td> <td>Ethanol</td> </tr> <tr> <td>Perfluorinated acids</td> <td>Nicotine</td> <td>Tobacco smoke<sup>&#916;</sup></td> </tr> <tr> <td>Phenoxyacetic</td> <td>OC pesticides<sup>&#182;</sup><sup>&#916;</sup></td> <td rowspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Herbicides</td> <td>OP pesticides<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td>Phthalates</td> <td>Pentachlorophenol</td> </tr> <tr> <td rowspan=\"4\">&nbsp;</td> <td class=\"indent1\">Biphenyls (PCBs)</td> </tr> <tr> <td>Solvents</td> </tr> <tr> <td>Water disinfection</td> </tr> <tr> <td>Byproducts<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Compiled primarily from CHE Summery of Evidence Website (6) and LaDou, 2007 (5) - see for details of specific endpoint associations. Bolded compounds are discussed in the text.<br />&para; PCE = perchlorethylene; TCE = trichloroethylene; metals include lead (Pb), mercury (Hg), and arsenic (As); OC = organo-chlorinated; OP = organophosphate.<br />&Delta; The evidence for these is discussed in details in results.</div><div class=\"graphic_reference\">Reproduced from: Windham G, Fenster L. Environmental contaminants and pregnancy outcomes. Fertil Steril 2008; 89:e111. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 99927 Version 1.0</div></div></div>"},"99929":{"type":"graphic_algorithm","displayName":"Constrictive pericarditis versus restrictive cardiomyopathy","title":"Algorithmic approach to the differentiation of constrictive pericarditis versus restrictive cardiomyopathy.","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to the differentiation of constrictive pericarditis versus restrictive cardiomyopathy.</div><div class=\"cntnt\"><img style=\"width:587px; height:488px;\" src=\"images/CARD/99929_Cnstr_prcrd_vrs_rstrc_crdmy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BNP: brain natriuretic peptide; CMR: cardiovascular magnetic resonance; CP: constrictive pericarditis; CT: computed tomography; ECG: electrocardiogram; RCM: restrictive cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 99929 Version 1.0</div></div></div>"},"99934":{"type":"graphic_diagnosticimage","displayName":"Normal SPECT radionuclide MPI study","title":"Normal single-photon emission computed tomography (SPECT) radionuclide myocardial perfusion imaging (MPI) study","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Normal single-photon emission computed tomography (SPECT) radionuclide myocardial perfusion imaging (MPI) study</div><div class=\"cntnt\"><img style=\"width:710px; height:656px;\" src=\"images/CARD/99934_Nrml_SPECT_rdncld_MPI_stdy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single-photon emission computed tomography (SPECT) radionuclide myocardial perfusion imaging (rMPI) showing normal perfusion both at rest and following stress.</div><div class=\"graphic_reference\">Courtesy of James Udelson, MD.</div><div id=\"graphicVersion\">Graphic 99934 Version 1.0</div></div></div>"},"99935":{"type":"graphic_picture","displayName":"Angiosarcoma","title":"Angiosarcoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Angiosarcoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/99935_Angiosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric patch with nodules and ulceration on the forehead and scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99935 Version 2.0</div></div></div>"},"99937":{"type":"graphic_table","displayName":"BRCA mutation cancer risks","title":"Estimated risks for cancer with BRCA mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated risks for cancer with BRCA mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cancer type</td> <td class=\"subtitle1\">Risk in carriers to age 70 years*</td> <td class=\"subtitle1\">Lifetime risk in general population</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Breast</td> <td> <p><em>BRCA1:</em> 55 to 70%</p> <em>BRCA2:</em> 45 to 70%</td> <td>~12%<sup>&#182;</sup><sup>[1]</sup></td> <td> <p>In most studies, risk in <em>BRCA1</em> carriers is higher than that observed in <em>BRCA2</em> carriers.</p> The incidence of breast cancer diagnosed younger than 50 years of age is higher in <em>BRCA1</em> carriers compared with <em>BRCA2</em> carriers, but both groups have an increased risk of premenopausal breast cancer, as well as increased lifetime risks.</td> </tr> <tr class=\"divider_bottom\"> <td>Contralateral (opposite) breast</td> <td>Up to 63% at 25 years post-diagnosis but highly age-dependent</td> <td>7% at 25 years post-diagnosis<sup>[2]</sup></td> <td> <p>Risk is affected by other factors such as tamoxifen use and oophorectomy.</p> Mutation carriers who have had lumpectomy have increased ipsilateral risks over long follow-up periods.</td> </tr> <tr class=\"divider_bottom\"> <td>Ovarian</td> <td> <p><em>BRCA1:</em> Approximately 40%</p> <em>BRCA2:</em> Approximately 15%</td> <td>~1%<sup>[1]</sup></td> <td> <p>The incidence of ovarian cancer diagnosed younger than 50 years of age is higher in <em>BRCA1</em> carriers, and overall rare in all carriers younger than 40 years old.</p> Risk of fallopian tube cancer is also substantially elevated.</td> </tr> <tr class=\"divider_bottom\"> <td>Colon</td> <td>Unclear</td> <td>~5%<sup>[1]</sup></td> <td>Studies have not been consistent about whether risk is elevated. If elevated, risk is likely to be small.</td> </tr> <tr class=\"divider_bottom\"> <td>Prostate</td> <td>Elevated; absolute risk not well defined</td> <td> <p>~14% Whites</p> ~19% African Americans</td> <td>Risk appears to be higher in <em>BRCA2</em> carriers and in men younger than 65 years old.</td> </tr> <tr class=\"divider_bottom\"> <td>Male breast</td> <td> <p><em>BRCA1:</em> 1%</p> <em>BRCA2:</em> 8%</td> <td>0.1%<sup>[3]</sup></td> <td>Risk before age 50 is very low.</td> </tr> <tr class=\"divider_bottom\"> <td>Pancreatic</td> <td> <p><em>BRCA1:</em> Unclear</p> <em>BRCA2:</em> 5%</td> <td>1.5%<sup>[1]</sup></td> <td>Risk in <em>BRCA2</em> carriers is higher versus <em>BRCA1</em> carriers.</td> </tr> <tr> <td>Other sites</td> <td>To be determined</td> <td>Varied</td> <td>These sites may include cancer of the stomach and skin (melanoma), and uterine papillary serous carcinoma.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These risks are estimates based upon review of the literature. Specific studies have reported risks that are lower or higher than the ranges or estimates quoted; however, the estimates reported here are representative of findings from high quality studies. Risks will also vary based on an individual's current age and other risk factors. (Refer to UpToDate topics on BRCA mutation-associated hereditary breast and ovarian cancer syndrome.)</div><div class=\"graphic_footnotes\">* Risk to individuals over age 70 is higher, but data are generally unavailable.<br />&para; Lifetime risk at birth for all races unless otherwise specified.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li><a href=\"http://seer.cancer.gov/csr/1975_2011/\" target=\"_blank\">http://seer.cancer.gov/csr/1975_2011/</a> (Accessed on February 17, 2015).</li>&#xD;&#xA;    <li><a href=\"http://seer.cancer.gov/archive/publications/mpmono/\" target=\"_blank\">http://seer.cancer.gov/archive/publications/mpmono/</a> (Accessed on February 17, 2015). </li>&#xD;&#xA;    <li><a href=\"http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-key-statistics\" target=\"_blank\">http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-key-statistics</a> (Accessed on February 17, 2015).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99937 Version 1.0</div></div></div>"},"99938":{"type":"graphic_picture","displayName":"Neonatal cholestasis in CF","title":"Neonatal cholestasis in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Neonatal cholestasis in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:725px; height:275px;\" src=\"images/PEDS/99938_Neonatal_cholestasis_CF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bile ductular proliferation with inspissated hypereosinophilic concretions and acute cholangitis (magnification 200x).<br />(B) Hypereosinophilic inspissated material within ducts and ductules, with focal atrophy of the ductular epithelium, and with acute cholangitis and bile ductule proliferation (magnification 400x).</div><div class=\"graphic_reference\">Courtesy of Deborah Schady, MD, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 99938 Version 2.0</div></div></div>"},"99939":{"type":"graphic_picture","displayName":"Hepatic steatosis in CF","title":"Hepatic steatosis in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Hepatic steatosis in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:628px; height:473px;\" src=\"images/PEDS/99939_Hepatic_steatosis_CF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver parenchyma with diffuse macrovesicular steatosis with microvesicular steatosis (magnification 200x).</div><div class=\"graphic_reference\">Courtesy of Deborah Schady, MD, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 99939 Version 2.0</div></div></div>"},"99940":{"type":"graphic_picture","displayName":"Focal biliary cirrhosis in CF","title":"Focal biliary cirrhosis in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Focal biliary cirrhosis in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:629px; height:473px;\" src=\"images/PEDS/99940_Focal_biliary_cirrhosis_CF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Focal biliary fibrosis with bile ductular proliferation, eosinophilic concretions, and bile plugs, with increased portal fibrosis adjacent to relatively unremarkable hepatic parenchyma. </div><div class=\"graphic_reference\">Courtesy of Deborah Schady, MD, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 99940 Version 2.0</div></div></div>"},"99941":{"type":"graphic_picture","displayName":"Multilobular cirrhosis in CF","title":"Multilobular cirrhosis in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Multilobular cirrhosis in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:629px; height:473px;\" src=\"images/PEDS/99941_Multilobular_cirrhosis_CF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Multilobular cirrhosis\" with entrapped lobules of hepatic parenchyma surrounded by bands of fibrosis.</div><div class=\"graphic_reference\">Courtesy of Deborah Schady, MD, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 99941 Version 2.0</div></div></div>"},"99947":{"type":"graphic_algorithm","displayName":"Natural history of hepatitis C virus infection","title":"Natural history of hepatitis C virus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natural history of hepatitis C virus</div><div class=\"cntnt\"><img style=\"width:396px; height:399px;\" src=\"images/ID/99947_Natural_history_hep_C_virus.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">The likelihood of chronic infection following acquisition of HCV and the rate of fibrosis progression depend on various host and viral factors. As examples, young women and children are more likely to spontaneously clear HCV infection, and if chronically infected, have relatively slow fibrosis progression rates. Refer to the UpToDate topic on the natural history of HCV infection for further details. </div><div id=\"graphicVersion\">Graphic 99947 Version 1.0</div></div></div>"},"99949":{"type":"graphic_picture","displayName":"Pityriasis rosea on back 2","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/99949_Pityriasis_rosea_bck_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple oval macules and patches in a \"Christmas tree\" pattern on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 99949 Version 1.0</div></div></div>"},"99955":{"type":"graphic_figure","displayName":"External cephalic version backwards somersault","title":"External cephalic version backwards somersault","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">External cephalic version backwards somersault</div><div class=\"cntnt\"><img style=\"width:511px; height:585px;\" src=\"images/OBGYN/99955_External_cephalic_version_backwards_somersault.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Beckmann C, Ling FW, et al. Obstetrics and Gynecology, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006.</div><div id=\"graphicVersion\">Graphic 99955 Version 1.0</div></div></div>"},"99957":{"type":"graphic_diagnosticimage","displayName":"Shoulder radiograph using West Point axillary view","title":"Shoulder radiograph using West Point axillary view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder radiograph using West Point axillary view</div><div class=\"cntnt\"><img style=\"width:391px; height:524px;\" src=\"images/RADIOL/99957_Radiogrph_wst_pnt_axllry_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph demonstrates a normal shoulder using the West Point axillary view technique.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 99957 Version 1.0</div></div></div>"},"99958":{"type":"graphic_diagnosticimage","displayName":"CT splenic artery aneurysms","title":"Calcified splenic artery aneurysms on CT","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Calcified splenic artery aneurysms on CT</div><div class=\"cntnt\"><img style=\"width:726px; height:236px;\" src=\"images/RADIOL/99958_CT_splenic_artery_aneurysms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper abdomen (left image) shows two splenic artery aneurysms with calcified walls (arrows). The image on the right from the same patient shows a third 4 cm aneurysm (asterisk) with a calcified wall (arrow). The aneurysms were an incidental finding.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 99958 Version 1.0</div></div></div>"},"99963":{"type":"graphic_table","displayName":"Vasopressors and inotropes","title":"Vasopressors and inotropes in treatment of acute hypotensive states and shock: Adult dose and selected characteristics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vasopressors and inotropes in treatment of acute hypotensive states and shock: Adult dose and selected characteristics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">US trade name</td> <td class=\"subtitle1\">Initial dose</td> <td class=\"subtitle1\">Usual maintenance dose range</td> <td class=\"subtitle1\">Range of maximum doses used in refractory shock</td> <td class=\"subtitle1\">Role in therapy and selected characteristics</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Vasopressors (alpha-1 adrenergic)</td> </tr> <tr> <td class=\"indent1\">Norepinephrine (noradrenaline)</td> <td>Levophed</td> <td> <p>8 to 12 mcg/minute (0.1 to 0.15 mcg/kg/minute)</p> A lower initial dose of 5 mcg/minute may be used, eg, in older adults</td> <td>2 to 4 mcg/minute (0.025 to 0.05 mcg/kg/minute)</td> <td>35 to 100 mcg/minute (0.5 to 0.75 mcg/kg/minute; up to 3.3 mcg/kg/minute has been needed rarely)</td> <td> <ul> <li>Initial vasopressor of choice in septic, cardiogenic, and hypovolemic shock. </li> <li>Wide range of doses utilized clinically. </li> <li>Must be diluted; eg, a usual concentration is 4 mg in 250 mL of D5W or NS (16 micrograms/mL). </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Epinephrine (adrenaline)</td> <td>Adrenalin</td> <td>1 mcg/minute (0.014 mcg/kg/minute)</td> <td>1 to 10 mcg/minute (0.014 to 0.14 mcg/kg/minute)</td> <td>10 to 35 mcg/minute (0.14 to 0.5 mcg/kg/minute)</td> <td> <ul> <li>Initial vasopressor of choice in anaphylactic shock. </li> <li>Typically an add-on agent to norepinephrine in septic shock when an additional agent is required to raise MAP to target and occasionally an alternative first-line agent if norepinephrine is contraindicated. </li> <li>Increases heart rate; may induce tachyarrhythmias and ischemia. </li> <li>Elevates lactate concentrations during initial administration (ie, may preclude use of lactate clearance goal); may decrease mesenteric perfusion. </li> <li>Must be diluted; eg, a usual concentration is 1 mg in 250 mL D5W (4 micrograms/mL). </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Phenylephrine</td> <td>Neo-Synephrine, Vazculep</td> <td>100 to 180 mcg/minute until stabilized (alternatively, 0.5 to 2 mcg/kg/minute)</td> <td>20 to 80 mcg/minute (0.25 to 1.1 mcg/kg/minute)</td> <td> <p>80 to 360 mcg/minute (1.1 to 6 mcg/kg/minute);</p> Doses &#62;6 mcg/kg/minute do not increase efficacy according to product information in the United States</td> <td> <ul> <li>Pure alpha-adrenergic vasoconstrictor. </li> <li>Initial vasopressor when tachyarrhythmias preclude use of norepinephrine. </li> <li>Alternative vasopressor for patients with septic shock who: (1) develop tachyarrhythmias on norepinephrine, epinephrine, or dopamine, (2) have persistent shock despite use of two or more vasopressor/inotropic agents including vasopressin (salvage therapy), or (3) high cardiac output with persistent hypotension. </li> <li>May decrease stroke volume and cardiac output in patients with cardiac dysfunction. </li> <li>May be given as bolus dose of 50 to100 micrograms to support blood pressure during rapid sequence intubation. </li> <li>Must be diluted; eg, a usual concentration is 10 mg in 250 mL D5W or NS (40 micrograms/mL). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dopamine</td> <td>Inotropin</td> <td>2 to 5 mcg/kg/minute</td> <td>5 to 20 mcg/kg/minute</td> <td>20 to &#62;50 mcg/kg/minute</td> <td> <ul> <li>An alternative&nbsp;to norepinephrine in septic shock in highly selected patients (eg, with compromised systolic function or absolute or relative bradycardia and a low risk of tachyarrhythmias). </li> <li>More adverse effects (eg, tachycardia, arrhythmias particularly at doses &#8805;20 mcg/kg/minute) and less effective than norepinephrine for reversing hypotension in septic shock.</li> <li>Lower doses (eg, 1 to 3 mcg/kg/minute) should not be used for renal protective effect and can cause hypotension during weaning. </li> <li>Must be diluted; eg, a usual concentration is 400 mg in 250 mL D5W (1.6 mg/mL); use of a commercially available pre-diluted solution is preferred. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Antidiuretic hormone</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vasopressin (arginine-vasopressin)</td> <td>Pitressin, Vasostrict</td> <td>0.03 units per minute (alternatively 0.01 to 0.03 units/minute initially)</td> <td>0.03 to 0.04 units per minute (not titrated)</td> <td> <p>0.04 to 0.07 units/minute;</p> Doses &#62;0.04 units/minute can cause cardiac ischemia and should be reserved for salvage therapy</td> <td> <ul> <li>Add-on to&nbsp;norepinephrine to raise blood pressure to target MAP or decrease&nbsp;norepinephrine requirement. Not recommended as a replacement for a first-line vasopressor. </li> <li>Pure vasoconstrictor; may decrease stroke volume and cardiac output in myocardial dysfunction or precipitate ischemia in coronary artery disease. </li> <li>Must be diluted; eg, a usual concentration is 25 units in 250 mL D5W or NS (0.1 units/mL). </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Inotrope (beta<sub>1</sub> adrenergic)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dobutamine</td> <td>Dobutrex</td> <td> <p>0.5 to 1 mcg/kg/minute</p> (alternatively, 2.5 mcg/kg/minute in more severe cardiac decompensation)</td> <td>2 to 20 mcg/kg/minute</td> <td> <p>20 to 40 mcg/kg/minute;</p> Doses &#62;20 mcg/kg/minute are not recommended in heart failure and should be reserved for salvage therapy</td> <td> <ul> <li>Initial agent of choice in cardiogenic shock with low cardiac output and maintained blood pressure. </li> <li>Add-on to norepinephrine for cardiac output augmentation in septic shock with myocardial dysfunction (eg, in elevated left ventricular filling pressures and adequate MAP) or ongoing hypoperfusion despite adequate intravascular volume and use of vasopressor agents. </li> <li>Increases cardiac contractility and rate; may cause hypotension and tachyarrhythmias. </li> <li>Must be diluted; a usual concentration is 250 mg in 500 mL D5W or NS (0.5 mg/mL); use of a commercially available pre-diluted solution is preferred. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Inotrope (nonadrenergic, PDE<sub>3</sub> inhibitor)</td> </tr> <tr> <td class=\"indent1\">Milrinone</td> <td>Primacor</td> <td>Optional loading dose: 50 mcg/kg over 10 minutes (usually not given)</td> <td>0.125 to 0.75 mcg/kg/minute</td> <td>&nbsp;</td> <td> <ul> <li>Alternative for short-term cardiac output augmentation to maintain organ perfusion in cardiogenic shock refractory to other agents. </li> <li>Increases cardiac contractility and modestly increases heart rate at high doses; may cause peripheral vasodilation, hypotension, and/or ventricular arrhythmia. </li> <li>Renally cleared; dose adjustment in renal impairment needed. </li> <li>Must be diluted; eg, a usual concentration is 40 mg in 200 mL D5W (200 micrograms/mL); use of a commercially available pre-diluted solution is preferred. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>All doses shown are for intravenous (IV) administration in adult patients. The initial doses shown in this table may differ from those recommended in immediate post-cardiac arrest management (ie, advanced cardiac life support). For details, refer to the UpToDate topic review of post-cardiac arrest management in adults, section on hemodynamic considerations.</LI>&#xD;&#xA;<LI>Vasopressors can cause life-threatening hypotension and hypertension, dysrhythmias, and myocardial ischemia. They should be administered by use of an infusion pump adjusted by clinicians trained and experienced in dose titration of intravenous vasopressors using continuous noninvasive electronic monitoring of blood pressure, heart rate, rhythm, and function. Hypovolemia should be corrected prior to the institution of vasopressor therapy. Reduce infusion rate gradually; avoid sudden discontinuation.</LI>&#xD;&#xA;<LI>Vasopressors can cause severe local tissue ischemia; central line administration is preferred. When a patient does not have a central venous catheter, vasopressors can be temporarily administered in a low concentration through an appropriately positioned peripheral venous catheter (ie, in a large vein) until a central venous catheter is inserted. The examples of concentrations shown in this table are useful for peripheral (short-term) or central line administration. Closely monitor catheter site throughout infusion to avoid extravasation injury. In event of extravasation, prompt local infiltration of an antidote (eg, phentolamine) may be useful for limiting tissue ischemia. Stop infusion and refer to extravasation management protocol.</LI>&#xD;&#xA;<LI>Vasopressor infusions are high-risk medications requiring caution to prevent a medication error and patient harm. To reduce the risk of making a medication error, we suggest that centers have available protocols that include steps on how to prepare and administer vasopressor infusions using a limited number of standardized concentrations. Examples of concentrations and other detail are based on recommendations used at experienced centers; protocols can vary by institution.</LI></UL></div><div class=\"graphic_footnotes\">D5W: 5% dextrose water; MAP: mean arterial pressure; NS: 0.9% saline.</div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45:486. </LI>&#xD;&#xA;<LI>Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 2011; 183:847.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 99963 Version 8.0</div></div></div>"},"99966":{"type":"graphic_table","displayName":"Causes of and risk factors for FGR","title":"Causes of and risk factors for fetal growth restriction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of and risk factors for fetal growth restriction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Causes of and risk factors for fetal growth restriction (FGR)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Fetal genetic abnormalities</td> <td>Account for 5 to 20% of FGR. Genetic abnormalities include: aneuploidy (including triploidy), uniparental disomy, single gene mutations (eg, <em>IGF1, <em>IGF2, </em></em><em>IGF1R</em>), partial deletions or duplications, ring chromosome, and aberrant genomic imprinting. The finding of symmetric FGR prior to 20 weeks of gestation suggests aneuploidy as the cause, most commonly trisomy 18. Syndromes to consider include Russell-Silver, which is characterized by asymmetric growth impairment (head&nbsp;size is normal) and Smith-Lemli-Opitz, which is characterized by small head size and multiple extracranial anomalies.</td> </tr> <tr> <td>Fetal infection</td> <td>Account for 5 to 10% of FGR. Cytomegalovirus (CMV) and toxoplasmosis are the most common infectious etiologies of FGR in developed countries. Other viruses and parasites that may cause FGR include rubella, varicella-zoster, malaria, syphilis, and herpes simplex. Malaria is a common infectious cause of FGR where the infection is endemic.</td> </tr> <tr> <td>Fetal structural anomaly</td> <td>Fetuses with congenital anomalies can have impaired growth, which is often related to coexistent cytogenetic disorders. The frequency of FGR is related to both the type and number of anomalies.</td> </tr> <tr> <td>Multiple gestation</td> <td>Fetal growth in multiple gestations is directly related to the number of fetuses. The lower weight of fetuses from multiple gestations is thought to be due to an inability of the environment to meet the nutritional needs of multiple fetuses and to pregnancy complications more common in multiple gestations (eg, preeclampsia, twin-to-twin transfusion). Placental and umbilical cord anomalies potentially associated with underperfusion are also more common in multiple gestations (eg, velamentous cord insertion). Loss of one fetus of a&nbsp;twin gestation increases the risk for FGR in the surviving twin.</td> </tr> <tr> <td>Confined placental mosaicism</td> <td> <p>Confined placental mosaicism (CPM) refers to chromosomal mosaicism in the placenta, but not in the fetus. It usually involves a trisomy and is strongly associated with FGR. CPM has been identified after birth in approximately 10% of otherwise idiopathic FGR and in one-third of FGR associated with placental infarction and decidual vasculopathy. By comparison, the rate of CPM in placentas of women undergoing chorionic villus sampling (CVS) is about 1%.</p> The severity of FGR associated with CPM depends upon the chromosomes involved, the proportion of mosaic cells, and the presence of uniparental disomy.</td> </tr> <tr> <td>Ischemic placental disease</td> <td>Ischemic placental disease can manifest clinically as FGR, preeclampsia, abruptio placenta, or a combination of these disorders, and is often recurrent.</td> </tr> <tr> <td>Gross cord and placental abnormalities</td> <td> <p>Gross cord and placental structural anomalies possibly associated with FGR include single umbilical artery, velamentous umbilical cord insertion, marginal cord insertion, bilobate placenta, circumvallate placenta, and placental hemangioma. If an association between these entities and FGR exists, it is at most weak.</p> <p><span style=\"white-space: normal; word-spacing: 0px; text-transform: none; float: none; color: #000000; text-align: left; font: 13px/19px arial, helvetica, clean, sans-serif; widows: 1; display: inline !important; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px;\">Placental mesenchymal dysplasia is a rare placental abnormality characterised by placentomegaly and grape-like vesicles resembling a partial mole. The euploid fetus is at increased risk for intrauterine growth restriction, perinatal death, and Beckwith-Wiedemann syndrome.</span></p> </td> </tr> <tr> <td>Maternal genetic factors</td> <td>In epidemiologic studies, women who were growth-restricted at birth have a twofold increase in risk of FGR in their offspring. In addition, women who give birth to a growth restricted fetus are at high risk of recurrence, and the risk increases with increasing numbers of FGR deliveries.</td> </tr> <tr> <td>Maternal medical and obstetrical conditions</td> <td> <p>Maternal conditions that can be associated with diminished utero-placental-fetal blood flow and/or oxygen delivery have been associated with FGR. These conditions include, but are not limited to:</p> <ul class=\"decimal_heading\"> <li>Preeclampsia </li> <li>Abruptio placenta </li> <li>Chronic hypertension </li> <li>Chronic kidney disease </li> <li>Pregestational diabetes mellitus </li> <li>Systemic lupus erythematosus and antiphospholipid syndrome </li> <li>Cyanotic heart disease </li> <li>Chronic pulmonary disease </li> <li>Severe chronic anemia </li> <li>Sickle cell disease </li> <li>Uterine malformations </li> <li>Misuse of alcohol, cigarettes, and/or drugs (eg, heroin, cocaine) </li> <li>Prepregnancy radiation therapy to the pelvis</li> <li>Heavy first trimester antepartum bleeding</li> </ul> </td> </tr> <tr> <td>Teratogens and other environmental factors</td> <td>Exposures to various teratogens, including medications such as warfarin, anticonvulsants (eg, valproic acid), antineoplastic agents, and folic acid antagonists, can cause FGR with specific dysmorphic features.&nbsp;Exposure to alcohol, tobacco, and air pollution can also impair fetal growth. Exposure to therapeutic, but not diagnostic, doses of radiation can cause permanent restriction of growth.</td> </tr> <tr> <td>Assisted reproductive technologies</td> <td>Singleton pregnancies conceived via assisted reproductive technologies have a higher prevalence of small for gestational age infants compared with naturally conceived pregnancies.</td> </tr> <tr> <td>Low prepregnancy weight, poor gestational weight gain, malabsorption, poor nutritional status</td> <td>Maternal weight at birth, prepregnancy weight, and gestational weight gain can affect the risk of FGR as these factors are responsible for about 10% of the variance in fetal weight. Macro- and micronutrients in the maternal diet also appear to play a role.</td> </tr> <tr> <td>Residing at high altitude</td> <td>A direct relationship between increasing altitude and lower birth weight has been demonstrated in studies performed in Denver and Leadville, Colorado (altitude 1600 and 3100 m, respectively), Tibet (altitude 3658 m), and Peru. Birth weight data from 15 areas in Peru located between sea level and 4575 m showed birth weight declined an average of 65 g for every additional 500 m in altitude above 2000 m.</td> </tr> <tr> <td>Short interpregnancy interval</td> <td>&nbsp;</td> </tr> <tr> <td>Extremes of maternal age</td> <td>&nbsp;</td> </tr> <tr> <td>Abnormal maternal biochemical markers for Down syndrome screening</td> <td>Examples include Low pregnancy-associated plasma protein A&nbsp;(PAPP-A), low beta-human chorionic gonadotropin (HCG), high alpha-fetoprotein (AFP)</td> </tr> <tr> <td>Discrepancy between crown-rump length measurements and accurate menstrual history by&nbsp;two to six days&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 99966 Version 5.0</div></div></div>"},"99977":{"type":"graphic_figure","displayName":"Compartmental model for lead","title":"Compartmental model for lead","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Compartmental model for lead</div><div class=\"cntnt\"><img style=\"width:584px; height:426px;\" src=\"images/PC/99977_Compartmental_model_lead.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compartmental model for lead (modified from O'Flaherty 1993). The percentages shown represent the fractions of lead found in different tissue compartments. Used with permission of Brian Schwartz, Johns Hopkins Bloomberg School of Public Health.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">From: Committee on Potential Health Risks from Recurrent Lead Exposure of DOD Firing-Range Personnel, Committee on Toxicology, Board on Environmental Studies and Toxicology, et al. Potential Health Risks to DOD Firing-Range Personnel from Recurrent Lead Exposure, The National Academies Press, Washington, DC, 2013; 49. Copyright &copy; 2013 Brian S. Schwartz, MD, MS. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 99977 Version 2.0</div></div></div>"},"99978":{"type":"graphic_picture","displayName":"Paraglossal straight blade approach","title":"Paraglossal straight blade approach","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Paraglossal straight blade approach</div><div class=\"cntnt\"><img style=\"width:586px; height:262px;\" src=\"images/EM/99978_Prglsslstrghtbldapprch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paraglossal straight blade approach. Tongue control and gutter entry&nbsp;can be&nbsp;initiated from the centerline or (as pictured above) by crossing from the left to enter the right gutter (B, C, D), then advancing only to the right anterior pillar. Pharyngeal landmarks are sought by rotating the blade tip to the left (E). The blade tip is advanced under the epiglottis and lifted to expose the glottis, then the blade is moved toward the midline to displace the tongue and make room for the ET (F).</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 99978 Version 3.0</div></div></div>"},"99985":{"type":"graphic_table","displayName":"NCI CTCAE v5 left ventricular systolic dysfunction","title":"NCI CTCAE v5.0 left ventricular systolic dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 left ventricular systolic dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Left ventricular systolic dysfunction</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Symptomatic due to drop in ejection fraction responsive to intervention</td> <td>Refractory or poorly controlled heart failure due to drop in ejection fraction; intervention such as ventricular assist device, intravenous vasopressor support, or heart transplant indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Left ventricular systolic dysfunction is a disorder characterized by failure of the left ventricle to produce adequate output despite an increase in distending pressure and in end-diastolic volume. Clinical manifestations may include dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 99985 Version 5.0</div></div></div>"},"99987":{"type":"graphic_table","displayName":"NCI CTCAE v5 right ventricular dysfunction","title":"NCI CTCAE v5.0 right ventricular dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 right ventricular dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Right ventricular dysfunction</td> <td>Asymptomatic with laboratory (eg, BNP [B-natriuretic peptide]) or cardiac imaging abnormalities</td> <td>Symptoms with mild to moderate activity or exertion</td> <td>Severe symptoms, associated with hypoxemia, right heart failure; oxygen indicated</td> <td>Life-threatening consequences; urgent intervention indicated (eg, ventricular assist device); heart transplant indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Right ventricular dysfunction is characterized by impairment of right ventricular function associated with low ejection fraction and a decrease in motility of the right ventricular wall.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 99987 Version 6.0</div></div></div>"},"99992":{"type":"graphic_picture","displayName":"Ovassapian, Berman, and Williams airways","title":"Ovassapian, Berman, and Williams airways","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Ovassapian, Berman, and Williams airways</div><div class=\"cntnt\"><img style=\"width:708px; height:528px;\" src=\"images/ANEST/99992_Ovassapian_berman_wllm_arwy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 99992 Version 2.0</div></div></div>"},"99993":{"type":"graphic_figure","displayName":"Classification extracranial carotid artery aneurysm","title":"Classification extracranial carotid artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Classification extracranial carotid artery aneurysm</div><div class=\"cntnt\"><img style=\"width:538px; height:289px;\" src=\"images/SURG/99993_Classification_extracranial_carotid_artery_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Morphological classification of the extracranial carotid artery aneurysm:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Type I: Aneurysm of the internal carotid artery above the carotid bulb</li>&#xD;&#xA;    <li>Type II: Aneurysm of the internal carotid artery</li>&#xD;&#xA;    <li>Type III: Aneurysm of the carotid bifurcation</li>&#xD;&#xA;    <li>Type IV: Aneurysm of the internal carotid artery and the common carotid artery</li>&#xD;&#xA;    <li>Type V: Aneurysm of the common carotid artery</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Modified from: Attigah N, K&uuml;lkens S, Zausig N, et al. Surgical therapy of extracranial carotid artery aneurysms: long-term results over a 24-year period. Eur J Vasc Endovasc Surg 2009; 37:127.</div><div id=\"graphicVersion\">Graphic 99993 Version 2.0</div></div></div>"},"99995":{"type":"graphic_table","displayName":"Antimuscarinic medications for treatment of UI","title":"Antimuscarinic medications for treatment of women with urge incontinence or overactive bladder (OAB) with incontinence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimuscarinic medications for treatment of women with urge incontinence or overactive bladder (OAB) with incontinence</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Maximum dose</td> <td class=\"subtitle1\">Selected characteristics</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Darifenacin extended-release</p> 7.5 and 15 mg tablets</td> <td>7.5 mg orally once daily</td> <td>15 mg orally once daily</td> <td> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Dry mouth (19 to 35%) and constipation (15 to 21%) are common </li> <li>Metabolized in liver by CYP3A4; maximum 7.5 mg daily with strong CYP3A4 inhibitors* </li> <li>Reduced dose for moderate hepatic impairment </li> <li>Not recommended for severe hepatic impairment </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Fesoterodine extended-release</p> 4 and 8 mg tablets</td> <td>4 mg orally once daily</td> <td>8 mg orally once daily</td> <td> <ul> <li>See&nbsp;legend (\"General antimuscarinic issues\") below this table </li> <li>Dry mouth (19 to 35%) and constipation (4 to 6%) are common </li> <li>Metabolized in liver by CYP3A4; maximum 4 mg daily with strong CYP3A4 inhibitors* </li> <li>Reduced dose for severe renal impairment </li> <li>Not recommended for severe hepatic impairment </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Oxybutynin immediate-release</p> 5 mg tablet</td> <td>5 mg orally&nbsp;two or three&nbsp;times daily</td> <td>5 mg orally&nbsp;four times daily</td> <td> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Dry mouth (71%) and constipation (9%) are common </li> <li>Dizziness (17%) and somnolence (14%) can occur </li> <li>Often not tolerated by older adults and medically ill patients due to anticholinergic (including CNS) side effects </li> <li>Reduced dose in older adults </li> <li>Short effect may be useful when continence is desired at specific times </li> <li>Compliance is difficult with frequent dosing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Oxybutynin extended-release</p> 5, 10, and 15 mg tablets</td> <td>5 to 10 mg orally once daily</td> <td>30 mg orally once daily</td> <td> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Dry mouth (35%) and constipation (9%) are common </li> <li>Somnolence (6%) can occur </li> <li>Compliance is improved with daily dosing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Oxybutynin transdermal 3% gel (pump)</td> <td>Apply&nbsp;three pumps (84 mg) daily</td> <td>Same as starting dose</td> <td rowspan=\"2\"> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Associated with low rates of dry mouth (2 to 12%) and constipation (1%) </li> <li>Apply to clean, dry, intact skin on abdomen, thighs, or upper arms/shoulders </li> <li>Keep area dry for at least&nbsp;one hour after application </li> <li>Do not use same application site more than once in&nbsp;seven days </li> <li>Application site reaction including irritation and dermatitis (up to 14%) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Oxybutynin transdermal 10% gel sachet (packet)</td> <td>Apply&nbsp;one sachet (packet) daily</td> <td>Same as starting dose</td> </tr> <tr class=\"divider_bottom\"> <td>Oxybutynin transdermal 3.9 mg patch</td> <td>Apply&nbsp;one patch twice per week (ie, once every&nbsp;three to four&nbsp;days)</td> <td>Do not exceed starting dose</td> <td> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Available without a prescription (OTC) in the United States and some other countries </li> <li>Associated with low rates of dry mouth (10%) and constipation (3%) </li> <li>Apply under clothing to abdomen, hip, or buttock </li> <li>Do not use same application site more than once in&nbsp;seven days </li> <li>Application site pruritus (14 to 17%); local erythema (8%), rash (3%) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Solifenacin</p> 5 and 10 mg tablets</td> <td>5 mg orally once daily</td> <td>10 mg orally once daily</td> <td> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Dry mouth (11 to 28%) and constipation (5 to 13%) are common </li> <li>Reduce dose for severe renal impairment or moderate hepatic impairment </li> <li>Not recommended for severe hepatic impairment </li> <li>Metabolized in liver by CYP3A4; maximum 5 mg daily with CYP3A4 inhibitors* </li> <li>Modestly prolongs QTc interval; caution with other QTc prolonging drugs* and in patients with congenital prolonged QT </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Tolterodine extended-release</p> 2 and 4 mg tablets</td> <td>2 mg orally once per day</td> <td>4 mg orally once per day</td> <td rowspan=\"2\"> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Dry mouth (23 to 35%) and constipation (6 to 7%) are common </li> <li>Reduced dose for renal and/or hepatic impairment, not recommended for severe renal or hepatic impairment </li> <li>Metabolized in liver by CYPs 3A4 and 2D6; maximum 2 mg daily with strong CYP3A4 inhibitors* </li> <li>Modestly prolongs QTc interval; caution with other QTc prolonging drugs* and in patients with congenital prolonged QT </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Tolterodine immediate-release</p> 1 and 2 mg tablets</td> <td>1 mg orally twice per day</td> <td>2 mg orally twice per day</td> </tr> <tr> <td class=\"divider_bottom\"> <p>Trospium extended-release</p> 60 mg tablet</td> <td class=\"divider_bottom\">60 mg orally once per day</td> <td class=\"divider_bottom\">Same as starting dose</td> <td rowspan=\"2\"> <ul> <li>See&nbsp;\"General antimuscarinic issues\" below this table </li> <li>Need to take on empty stomach or&nbsp;one hour before meal </li> <li>Dry mouth (9 to 22%) and constipation (9 to 10%) are common </li> <li>Reduce dose for renal impairment, not recommended for severe renal impairment </li> <li>Not metabolized by CYP and therefore has a low risk of drug-drug interactions </li> <li>Avoid alcohol consumption within&nbsp;two hours of using extended-release preparation </li> </ul> </td> </tr> <tr> <td> <p>Trospium immediate-release</p> 20 mg tablet</td> <td>20 mg orally once daily</td> <td>20 mg twice daily</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><FONT color=black><STRONG>General antimuscarinic issues</STRONG>:<br />All antimuscarinics&nbsp;are contraindicated in gastric retention, untreated narrow angle closure glaucoma, and supraventricular tachycardia.<br />Evidence suggests that cumulative exposure to potent antimuscarinics is associated with increased rates of dementia and Alzheimer disease [1].<br />All antimuscarinics exert peripheral anticholinergic effects (eg, dry mouth, constipation, tachycardia, palpitations).<br />All antimuscarinics may have additive side effects with other medications that have strong anticholinergic effects (eg, first-generation H1 antihistamines, muscle relaxants, tricyclic antidepressants, antipsychotics, inhaled anticholinergic bronchodilators).* <br />Approach to agent selection and dose titration is reviewed in the topic section on pharmacologic therapy of urge incontinence.</FONT></div><div class=\"graphic_footnotes\">CNS: central nervous system; OTC: over-the-counter; CYP: cytochrome P-450 metabolism.<br />* To check for specific interactions, use the Lexi-Interact program included with UpToDate.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: S prospective cohort study. JAMA 2015; 175:401.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99995 Version 3.0</div></div></div>"},"99999":{"type":"graphic_table","displayName":"Framework models for communicating serious news","title":"Framework models for communicating serious news to patients and their families","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Framework models for communicating serious news to patients and their families</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">SPIKES<sup>[1]</sup></td> <td class=\"subtitle1\">ABCDE<sup>[2]</sup></td> <td class=\"subtitle1\">GUIDE<sup>[3]</sup></td> <td class=\"subtitle1\">BREAKS<sup>[4]</sup></td> <td class=\"subtitle1\">Serious illness conversation guide<sup>[5]</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>S: Setting</strong> up the interview&#8212;arrange for privacy, sit down, manage interruptions.</td> <td><strong>A: Advance</strong> preparation&#8212;arrange a time, ask about a support person being present, ask what the patient knows.</td> <td><strong>G: Get</strong> ready&#8212;gather info, set up privacy and a quiet location, find out who needs to be there.</td> <td><strong>B: Background,</strong> knowing the background of the patient/family and the clinical problem.</td> <td><strong>1. Set up the conversation</strong> <ul class=\"decimal_heading\"> <li>Introduce purpose </li> <li>Prepare for future decisions </li> <li>Ask permission </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>P:</strong> Assessing the patient's <strong>Perception</strong>&#8212;ask open-ended questions about how the patient perceives the medical situation.</td> <td><strong>B: Build</strong> a therapeutic environment/relationship&#8212;arrange a private, quiet place, reassure about suffering and non-abandonment.</td> <td><strong>U: Understand</strong>&#8212;ask the patient what they already know, then listen.</td> <td><strong>R: Rapport,</strong> build rapport, provide ample space and time.</td> <td><strong>2. Assess understanding and preferences</strong> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>I:</strong> Obtaining the patient's <strong>Invitation</strong>&#8212;how would the patient like the information disclosed.</td> <td><strong>C: Communicate</strong> well&#8212;be direct, avoid jargon, allow for silence.</td> <td><strong>I: Inform</strong>&#8212;deliver the news in a single sentence, then listen.</td> <td><strong>E: Explore,</strong> start with what the patient knows. Involve other family or support as per the patient's preference.</td> <td><strong>3. Share prognosis</strong> <ul class=\"decimal_heading\"> <li>Share prognosis </li> <li>Frame as a \"wish&hellip;worry,\" \"hope&hellip;worry\" statement </li> <li>Allow silence, explore emotion </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>K:</strong> Giving <strong>Knowledge</strong> and information to the patient&#8212;use nontechnical words and give information in small chunks.</td> <td><strong>D: Deal</strong> with patient and family reactions&#8212;assess patient reactions, listen actively, explore feelings, express empathy.</td> <td><strong>D: Deepen</strong>&#8212;observe and respond to emotions by acknowledging them; can give silence if the patient has turned away.</td> <td><strong>A: Announce,</strong> give a warning shot, then deliver the news using straightforward language.</td> <td><strong>4. Explore key topics</strong> <ul class=\"decimal_heading\"> <li>Goals </li> <li>Fears and worries </li> <li>Sources of strength </li> <li>Critical abilities </li> <li>Tradeoffs </li> <li>Family </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>E:</strong> Addressing the patient's <strong>Emotions</strong> with empathic responses&#8212;observe for emotion, identify it and its reason, let the patient know you've made this connection.</td> <td><strong>E: Encourage</strong> and validate emotions&#8212;correct distortions, evaluate the effect of the news, address further needs, arrange follow-up.</td> <td><strong>E: Equip</strong>&#8212;map out the next steps. Describe treatment options if you can.</td> <td><strong>K: Kindling,</strong> address emotions as they arise.</td> <td><strong>5. Close the conversation</strong> <ul class=\"decimal_heading\"> <li>Summarize </li> <li>Make a recommendation </li> <li>Check in with patient </li> <li>Affirm commitment </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>S: Strategy</strong> and <strong>Summary</strong>&#8212;discuss the plan going forward and summarize the discussion.</td> <td>&nbsp;</td> <td>&nbsp;</td> <td><strong>S: Summarize,</strong> give a summary of the session and set up treatment/care plans.</td> <td><strong>6. Document your conversation</strong> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td><strong>7. Communicate with key clinicians</strong> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Baile WF, Buckman R, Lenzi R, et al. SPIKES&mdash;a six-step protocol for deliver bad news: application to the patient with cancer. Oncologist 2000; 5:302.</li>&#xD;&#xA;    <li>Rabow MW, McPhee SJ. Beyond breaking bad news: how to help patients who suffer. West J Med 1999; 171:260.</li>&#xD;&#xA;    <li>Back AL. (2013) Vital Talk (1.0) [Mobile Application Software] Retrieved from <a href=\"http://vitaltalk.org/\" target=\"_blank\">http://vitaltalk.org</a>.</li>&#xD;&#xA;    <li>Narayanan V, Bista B, Koshy C. \"BREAKS\" protocol for breaking bad news. Indian J Palliat Care 2010; 16:61.</li>&#xD;&#xA;    <li>Serious Illness Conversation Guide (Accessed on October 16, 2017). This material has been modified by UpToDate. The original content can be found at <a href=\"https://portal.ariadnelabs.org/\" target=\"_blank\">https://portal.ariadnelabs.org</a> and is licensed by Ariadne Labs under the <a href=\"https://creativecommons.org/licenses/by-nc-sa/4.0/\" target=\"_blank\">Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License</a>. Ariadne Labs licenses the original content as-is and as-available, and makes no representations or warranties of any kind concerning the original content or concerning this material, which Ariadne Labs has not reviewed or endorsed.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 99999 Version 2.0</div></div></div>"}};